var title_f25_14_25824="Moderate physical activities";
var content_f25_14_25824=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Examples of moderate physical activity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 553px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A moderate amount of physical activity is roughly equivalent to physical activity that uses approximately 150 calories (kcal) of energy per day, or 1000 calories per week. Some activities can be performed at various intensities; the suggested durations correspond to the expected intensity of effort.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_14_25824=[""].join("\n");
var outline_f25_14_25824=null;
var title_f25_14_25825="Gray patch tinea kerion";
var content_f25_14_25825=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Kerion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 253px; height: 327px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFHAP0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5YoqXyT/e/Sjyf9r9KdgsRUVL5P8AtfpR5P8AtfpRYCKipfK/2v0o8n/a/SiwWIqKl8r/AGv0o8rn736UWCxFRUvlc/e/SjyveiwWIqKl8r3o8r/aosFiKipfK96PK96LBYioqXyuetHle/6UWCxFRUnl+9L5XvRYLEVFS+V7/pR5XvRYLEVFS+V70eV7/pRZhYioqXyvejyvf9KLDsRUVL5Xv+lHlf7X6UWCxFRUvlf7X6UeUPU/lRYLEVFS+V7n8qPK9z+VFgsRV9UfsN/8zr/25f8AtxXy55Xufyr6l/YeXb/wmvP/AD5f+16LCPmDjJGRkdqXAzXW+NPBUnhW+NtcalbXEyj5tkbKM+gz1rl/Il8oyiNjGCAWA4BPQGtJU5RdmhRnGSumQ8fnRT9h3FehHXPak9PepsyxtGKk8s+T5hZQudoGeT+HpRGitIFd9ik/e2k4/AU7MVyPFGKcAcDPAP8AP0qx9kkZ4o4yrySFVC5AO5s4AGefc9AeKVmF0iqelJirU1uIG2zu0Mgfa0bxkMBj73oRnj1qSHTL2bzjFazMsALSvt+WMDGST0GMjP1p2YXRRIFGOK0bHTWudTt7F3aOWaUJ8kZlwCcE4XO7AycDPQipbzS4INWWzt7+O6iMhVpo4yu1QfvEH/ZGcfr3o5WLmRk8dqKt3VqkBcC6hkdZTGEQ7iQBw+4ZXBz2J6VDHC0gJ3KoAJ3McDp6+/Qe9HK9h3W5FikwPepY1DSBZH8pe7MpOPwpnfg0rANwKXAq1DbLJ5IaeGMy5K7jgKBnO49unHrTnsnjjuZJCY1hKgpKNsh3DKnYece/uKdmLmRTFHFXbfTribdlRGFi89t5wdm4DIHUnnp3qtIgEpRXyB3I2/oafKwUk9CPig461I0bLGrsCFbO3Ixn3FMqWrDQlHb1pe+BSspUlWGGBwQeoosMbgUuKKWgBMUlKDSj60AJgUUtFADQOa+o/wBiL/mdP+3L/wBr18uivqL9iL/mdP8Aty/9r0nsJnlvxwlV/FMxPOG+9Xm6/cdCpYvgqdxGD9O9egfFSVZ9dvnO3aH+X2rz6Vldt0amNR2JzzXXWfvtmNFe4kRnIJ9almZ553aQgzM2cD+In9KYis5IADM3HPUe9KyjzFVQzZA4x1P+Fc62NhA4jjlj4O7GSOMEdv5irDRwQ7Q0pmd4xhQhBiYnvnqR1GMg57VHcGIsFgUBIwQW5y5znJB6enHpUYjfy94VvK3bdxHGcZ61QrFqCJBcT25Ky3ABWErnY7dPY5x90evXir+kzrEws5dMt7iXzd9x9oh8wxomc7QCGXGTlQecD6VViWKKzE8sck8W/a0exoyGKHa4kwRjPRc84PHepNKks/sN9DNEjX8u1obuTIWELktg7gAW4HIPtg0vIkrTERXRW1uJLiJE8lHPO9cEEDI+UYJOOoz+NXdNuWYnTba7uUsprlZI7YsCjtgqAxyu3IbBPAweajs7VbuKNRc2rE/uzE7+W/C7yR2OcMN2evpkUQPtlgjjtJGhkdjaPEgEksgOFJyDuGeCn+0cU/MUuyJL3yoJntI5d0apsWSRijIwCmXb8xH3gyjkhj0AzUt9HPcQLd3sN01xBtuJL2SUMZLdiqRjB7ghsHnOccYp15cXWr6yl5qxNrah5PLEZ8qGEg+Y8UOflTBYkIOhYDGTUn9owpaxzPbyzvNCRNNcEKASVT92CcsoVfvA5yeQACCbi2Rk3t6Lq6ubm7EU9xOXZ5PufOTkMFUAdP4QMdanv5tSFnHZanNLFbWsYMdvKm0ornzFwuAcNuLA9MHPQirFhC39lPazXP8Aotw/m3RCopR1QlPmcBj1JIBweOpFJd6Zd289tLru+aWeKNlEd3HJLs4UDJ3chVICnBXCnpwXruGi0MgM0TsbhXYMuCpfaWB5H4dDUytafZv31s4dowscqMcCRW+YkHrkYHtTLid31B54GlZzIfKL4ZwASACAMZwR2q4s7DRorSaytpEYP5Mm/bJE7MBlscn7pADdjQtRvoSaZqDLfW01pbWNveW/mSiVlAQjaeCpyCRnIHOcAVNb6hZnwzqUNx5Kais8Mts/2feZdvDgyEkjjBxjB56dKz7eUCxurFbRLlzJvjnRDvXHHX+7/s+pqizsy5J+XATgelF7BypsmvGna5LTq6TBVLbiSxwOD+WKgYEg7g3zcnPet2CC1t7CxuZbi8i1YMZUI2TRiMY8v5eqncDnJx04qtqMzXbTXLReQdjMyLGWRSWAwGJ74Jz603FvVgpdEUZ7me4nSW4fzpFVUAYfwqMBcD2AplukT3CrNL5URzl9uccZ6fpUeeQBwfWlOMtjPsai9y7dEOgVZZI43dIgxwZH6L9aRk2xxvuDb859iD/k08mIyERowVuBvbJXpzx+NbTQXtzaWMMNtBNaR3AjUsoBaaQdHbr0APoKajcTlY58nAPGaDUwt5GvBaxDzJTJ5ShDnc2cDB+tRyKY3dHBDISrD0I4NQ0ykxtFLSCkMWiko9aAAV9RfsRf8zp/25f+16+Xa+ov2Iv+Z0/7cv8A2vSYmeNeMZ1knu5XjDvJIQGPb0rjkCswjAJBHc9/Wuv1VZZplCIrjkkMOK5m9tpFkLgBCecAVtKaQoU29ij5cgid1B8sHazY4qZba4YKUheQqm7CjJVBznH0yah8+ZUMfmNs/unp+VPjllE5a2LRZBGIzjjHI+lRoyru5NNe3F0kEbyqkcUbRRtjGE5O0kde/XnmoJjIiJbybcREnCYOM4PUdf8AIqbcyWZUiMFGLMNgycj19B6VJqluljJHBDPFcF0juPNjiaM5cA7MEDOPbj0zTTugcbMrOEFz5ZlMlurBQVJAZR6Z6d/pVpGjSdhPJcR2EzBZltyA7p1AycAkEDg8cZ9KNsMtvLO1uxkeRgwQERx5HyKvBwxIPBzlR2qFJIizi8cSNsCI4ckx7QCOO4I+XHGMe1Fib3RdtrX7RMLmexeWGJ2FzHAwTkDop5G37uffI7ipra8WTT3me88jUHnLebGhaQoFBVcg5I3KMZHy4+92MQi1KeybZve1CKjB3WFF3EshIyASdjHnnIHfFQadBDepGXuoIFjdA5dgr7D94oDgNjGSCwPTHWmZl2zecavbafqMLX7M/lyWpkwZBIwYhXOQjN97eB9e9VNQn8y1FncsZVt2ZYW3ljbhmBZcgkMg5xjHLE055oQ6WttGkpV/3c0a7ZZc9U4JwOePStL/AI99PaKKOMzG0Mt4bkeXLGyqR5IJwGRhtcLgk4Hpim+wLuaNrJpeo6fHMIvt/iFYxJFaW0TeUShUKJBn5m2qzZXJJOGx1GLrd5pt7NfTJYXK3V0fMgYrHCI5iw80bEHzLwVVeMZ71JrOq3Sa7e3lzNcPrBjEH2giW3lLFcGbqCG2jYVPBBNQaxerJdnUkRNPuboBltLeLZFEQqqD83UMNx4GM/oeolq7mdZ2plEv7xI50XeigMZGIbBHy5xt5Y5xgDIz0qwbUX1w81tZ3DWkjmOMoN2G6KM9Cc9ee9WrLTLvy7S6kspZzcvIkbY3CRdnzN8pyxG4HjsO9bGmWcpgv01Cym1WwgQW0MEF4FMcj/cc7Sd5wrEAAgk8kYFCXQbfUqf8IvPNo1lcWEVysE032e4vWObaRjgqB3XbkjBHPWqmraeuiiC3aBzqTFo5GlXMMiOBtK5+6w/+vmtRLi9kh0yHVtTvINP02aQTQ22WFnGrEx7gowGZ3ZQzEn5vTr2N9cWHibQNPvDc315fOs4dNScOySQpvdAzEKu5c4Od3yHAyQDaSZDk1ueUXqstzcCcRW8qlYmgTJyAMbgRwRwO/OeK6bQtIvYbKze506SCG582azvp7cvDKQAjI4ORtU7uexOafrFjpf8AZ5v4NPW1S/uJXiDSecyW5TMZCD7oBzlic+1VdVlurTStL8y7u7uKO1jeRRKViVXZsRjbnqAPQ8HOaLWdx3urIzriwS0uLzTxcWs23an2xFzFGpILHcRnOcAfjW3ceEoT4n1TTrLWLCaCwto5TKkmVlYqBtTP3jubHFcxHOt2EgnuPsqGSSaWWQlwzY+XIHfjH41C1zcTxWsiIy/YUVFdcnZ8xIJ9OTSuirSJb+0bStYktZ22TW5IYqN3zAdD9a0r250+bwlYQROFvrdzJOACC5dj8vp8o5z74rAlllnmeaWRnlc7mdzkk+pph68Co57XsXy3tcespR42j+R4z8pHbByPxpjHdkk5J5OaPrig5wAT07VDKQYx1FA+lB6Dkc9qBSGJ1paUszBQTkKMKPSkoASvqL9iL/mdP+3L/wBr18u/hX1H+xF/zOn/AG5f+16TEzyjTl8y7u8sTsXI+lVvEFnBPbRvbr5buPug/KpBwMk9M8mp7dGWR9p25IyQasadHLcytFE23dlSxTeVz14+npRJ9Dammlc4DVtOlspPnxkjPHQj1FZ4rsPFFq0ErR+YZtnBYqRg+hzXH4weex5FTB3KrQ5WmupdsEdwfKwQD8yt6VcmMfkNAGSEohLyNlvNYcqBgcHt7VSsZYonLuW8xhtQg/6s5HJ9RjirNyYyJRLgnJUBBjdxkN9KppqWgk04akQZXEaASLbMwMwj+YAf3tpPLAZ5/lT55PtM/wDo8bmEAxKkCs6RKecLk5PcgE+tRpDLcGERxLNcSJv/AHeVd12nIA4HGwkkfrVrS4pts5OoG3gTZ50iPtY7lIGIyQX6kE9gSenXS1kYXux0ukifV47MTSGWRA7PguiptLdVJPAAHsQQcYrTaIatrc8ekedqy7jeCA26WqssafNIVQ7VwqkkD075NVtPS2nvo01KRp8gK8SuEJXaCrlx8qqGA3ZweTVPUTphtnht/PQQpvUuisJZC5wrFWxgR459Qw6EUzN72JLqG5snN/A5S3u3aOFpAPMMa4ySq52lTtzjn04zWza6tZtZyRPYabH5qPBNcSmecyOFOSIxjazFhgjABx070Iby6002sthbT2qeWITcLbFHkkEbCWMSnkEiRlbBxtxxgAVq+G7m38MeIIru7jn06MsCotokmkmt5Mq6xtJuUZRiAWBBx1zyF5h5GVe6O13qF2cy2175STQWl2Wkln3ADZ8q4VvvN8xHAAxk87jaM2m6RNcPeR3tj5iWYuBucfPFHI3kO2ELIy7GB4XJGCSDT/F9tdQ63qF0LqxgV43ndbiB7XzXU42BR8pkByygcZznnileC0n0fRJ7zWZomvriZr+yDPEYzsH79GZdh3cbwOBgY9qWj1IburIxVv5BpJ1OS4uykSfYo9zGIwSgR/NCYyF3mJcHcOcHOTgjOfTL+0lFpbwLC9yIXjKyqNwP3TvzgNycjIx+FamneHpdci0rTdCLzSZZZ5Zzi3EzjckSHb8kj7CoBPzkDGBmt1NX0TQjr2nC1MlisAtmiMxbEjR4YqTkErJ838JGGAOCRTSFfscfZ20kVrcOtzJb3eVZQJSRhQSS6gHPT5T68+9ZE1xLcR4k+YvK0rSYJZ2OM5Pf/wCvXoDzPp+i6Ubu0tFN1DLNbzASW6SoipHsV9oMhbaeASBvP3WrnJNKin16fTZoXtdSFxN58fmI0ESL8xCHOSQoIAzzx3ptXWg1KzdyhZajdiQwwTtHayROkiwfNsiY5dRn6dKkudUkk0+3sLh7lrNCxSP5VyhJKkHGc5J/+tUsWpxRRX95BLbfarlxB5As1UGEfxLxhSdq5xz155pl7q63OgWulpHHBFHI1xO/lAvLKcgNuznaB8u3gDGeTRt1Hu9jJ2uTJJDGwQE4OM7RnjJqa5VoEcJHJFFMoKLvJDAd/wDaGQce9SSWMsD2zTQyQRuiyE3AITBzzxztJHFE+oNNfxzrGDHGMRQuS6xLzhBnqBnpS2Re5ppZaJFbSz3U7PHJASkdu++SFxx8xOF+Y9BzxVWTRroTx+ZALBZbUXYMz8LF03+uD0ApdS1G3W3u7ayLkTSDzDt8uNwgARthJw2dxI96pvcu9tP5luZg5RpJpRl064UN/CD6d6bsSlIqOEEhCbvLzxnrimDOOcZ9qtXdobOWFZnjlEkSzDyXzww4BPqO4qt25PesmtTVMTtjFHbPanYBUkE7sk4xwB9aTOSSTSGICcH360U5gQFOQdwzwckdufSmnvSASvqL9iP/AJnT/ty/9r18wRoH3bpEjAGfmzz7DHevqD9iP/mc/wDty/8Aa9DWgmeVQjc7EHkdeOtdD4fsjJJAqoJ/NB48s5C9wcc4+lc+ibZSewzyK7vQbJ5dNtmXeDgAMCBtUHk+gb0zwandnTBHA+OYsXUoctvyfvJsIxxgjAyeK84lGHYe9eqePYFR3QM7HORvPQe456/WvLbgYlYe9RDdmmI+FCR7fLJ3DeD0xnjFaIheHTnnubdBIXR4ZH6sA2GQDOCPXgkcetQ6KxW6YBY2zG2d4yBx1pNrfaEVydhYSDLbsAkZxnqT1xW6dzka08i3aT6e+nXkFykwn5e08uMEqxIzlwRkY3cEEDt1qWOGN7aK1jkgt4HHmM9xN8uShOTwCCPujAxnjvUV7JamON7a3D3cU8rSupODDkBNyBdq9+QT2BA6kQTWxi1SFPMhVjEnnxI2Ts5yjZBHJxx2z1pvXRkLRXRryaxFMtpZ36ahNE8kZa3TZCrjZ5eQ+N3TacfdOTkd6qQWFq7iwaSCCP7f+8nluAGgThSZAqH5QCeVzzninQQ2h0xW+driUM0MKuX+zKD0JcjGeT15yMYIIrSg0fT9c1HUxcRS6Q1vYNe+ULcJ8+B5YjjJzsIYM3VscjIFF0kQ1qUFubiWyfT5pbmRFLT6cxAYLhjvORyCdnPB5JJAJzUdlpqzW9/9naLUBDHK37x1WJI+PmRnwWk64VRn2PIrW0nW4LGzsvOZJW08tIbN4zGl4FC7MFRkEHq2QxA65AqWN4L2W+t54hagTy3h1DbukS2EYLRAM+18FeFyGJPLHpTB+67M3Na0Sxljt4tfuL83NgZIGeWJkaPZEzxxMCc+Y/y9MbcDIOSRykLatprRaRd3i2+nMRMlveHz7YuVzk8EIB5mGI9TnJrat9a+2hI9fs8ySpBHeTMSGjZtxZyX4aaVMYBwpAxkCoXN7NrU1hcyNFqtsGhNxKVkZIhhlddp2+YFQHIyzFu5xi9zLXYzYLjWtQSx0/SZrt7tWKlLdn3yhGzFlOnG5tpI4GecVn24u7zX57a4lM146rAPKkVklKkbVYc7l+QcD2rpfDSaxp93JY6TdXr3ms20sZg+yid53+bd8rDIwDkFQT945GKisnhv9Qt720065s0nij09JLMbjK6FTJIRggtt+8OAScjGDQtQ2JvFVxpGuaFbXEMsNq1uYxa2ZmkuJ5g+VkzIcIuHUHAAyG4J24rh7/SLu1Tfd2xiLSbOMFAQcHOOlbJtH8vUPNgN1Ctx/pl1FmT7L8zAfdymTyQ3IGKp28UWrXUNnYwF2IkVZp3Azgly2QMZwT65OKGr6MqLtsR+I9POkXKxz38U+po6sxgmEihNoKMrL8vTHGcjHNZzlriSKNVCm4xuklY/M2fmYsRwCevpWxaafBHqCpfztaQyRMsUpRVKykZRnBPAPHzehyM1kmWa2MsVwPNWVGjHzEjk5yjfXB460mUjuvENq+oWGnW1zrZu5TZK1tA8YCxFpM7A2flQA5BOeTg4rlNOsbcKJdQhIV7V2gzJhWlBI+buOh49R36UyHVJba8jumke4vWBaXzU2mFg+fkPQkgDkjAyeO9QQazdw3E9wkzGabO5pAJTyGyfm/3m/Om5K9xKMkrIgdolvkaH5IkYYdyctt/iI5wT+lTx6iBABJaRz3LzNO075ZmyMYI6MB1Hoaz227VVF4Hc9Tx/L0+tNzwCBjGeR3qOaz0NOVPctai8b3AELI0SIqIUUqMDvgk4J5J96rA4IJBI9M0h4JGPz4pT04/Wpbu7lJWVgUZyMEn2pV+XPHUYPfg05Ecq0qIWSPBc44GTgZ+tRj36Uth7j8JtULnecEsxwBx0x/WmfgaVuPXHYkdaGBXhuuBxnPvQCEIIVWI+U5wfXFfUX7Ef/M6f9uX/ALXr5dB6AkkAHAz0r6h/Yi/5nT/ty/8Aa9J7CPLbGRpLlYyMKcjPpXrnh2KebSBa2UhU7lURqxzKxwFO3oQCeST3OOa8p06LMydM7uDXsOjW4l0C3ZIJJ3GVCKThlyAz5A7FhjHfg80qerZ1rRHlPxAiEbSRsgSbO4rkn8c59q8muf8AWk17H8Siskrsm1WBYMFXAHPSvHbrmYnHWoStJjrO8EWdCZhqKKq7g6shHqCKmvIS0hACqoPXHy4z1+vr7VW0c41O3yMjdz+VdL5CxsXWNWL/AHkcZAFNu0iIK8NTNhs/k8yRXhinkdY5gq7AQoLpgdSeMDPQ561Y0myilvIILh4bi3EbTFbcje4VSdoJ7g5PPampbul/m1ZlEf71FAwFAOTx26dfen3NzAt5MILeOxlV2eNI2OIyTny0zzt9MnPWqvcjlcTSgj0yVGQyW8d4TvgIjYmTPBj74J5HThjzxWteeIprhdNuDfrKkVrNC0M0AjkEToVdCU/1gIVQX45OPWuckZjby3DTragtuW3CiXc+CpYlsbTyDnnrkdKprNKJrVNNkL6hdIg8qOJR5W37m1wTnI2luB3BGRVxVkY1JXkal3EsmgTR6e6ebKkbOpZi0jEg+TsJIwuwYb+IBcj0vTRXOqaHFZ2F4JGsItqedGsUyxlA5BAyrR7txViSwyBxnFZUM6/2paq2bmfkSRsxhWNgCc+YeBg7Tn8Ks29rAHivdTje3syDHdiymX/WFQVL8HCtkAjBHJximkRK25f0fWIra0s4Y/DukvdaGftEdzJOSH6MyNHu2yMcHgk4BwMYo0vTLHUtFW8k1CeK4R/NktI41j8pCCSQ5OWbGNqgc5JJ4rDutQsZft9lBZraWbSfaLJUbzHhYEsFkwo8wEFlyAOxzgYNhtflfXL24neK+spo5BMLeEQJPGxOGEYwSVY8bugA9Ksz1udUuty38OkX2qXS3c0LSQwSyHY0qRAQp02jIEmA7HJxycjFcne2k2nMY7BmtWmlaBGEwy2OZBu4zhsjcOvI7c9PNDJqN19rNm00NlbmK4eVVjeRpZSqS7QTuKKRngY2Y7AnI8SaCpvtXvdJlsbuxRmeC0afzJDHgkMD0LBeeD26HNNElfR7u2guI7bRpdR05phJuc3Cyxys0eEVgqj587+PRh0wSbGjwz+H2XXZPtVmyA3Uf2eT5BHMpQYI6N8rKSBgD8q5uK1urCQW8MiZaWJWKScP5iZHB6Yzgt74zXXeFodU+wwxW/huO4hF8bU38QTzpVVd4gw+VxgFgcc8dcCnEJaFW9lj1TVn1FNPh8mYrtt4j5jLtHytIjMcKVG0DIHpWHeXc1jNcwRWo0vTr4puUw+cVMZDYjZskYb0IPY8VviVrfQIIokEK6k7SQXTyCMNESVO8BPuh8gEng84AGa5m9v7lZLm3vrq3IhRoQluFdFdSMY2/KwYqBuBII9c0NjSMzUpnurgSyXUlyFRE8yRcEADhff61WkC/IUDnCgvuHQ+2O3SpbyQT3c0yIiiRiwRDwuecD2qNtrIpjUR7VCsNxJc5Pzfy4rJ6s2jokR8YHI9Md6XGQBn8PWnpLIkEsSMRFLjeMfeK8jn2zTrWZrd2dWYFkZMo2DyMfl6+1JblajGJfJcnfySzEnPoKb296sW0sXnyve+ZIWRgp4PznozZ7Dk+vSmN+7G9ExG4IUNznsfy96dr6iT6EYRipcKSowCwHAJ6UgqSNoldRM0pgxuYR4Bzjjrx1xRNG8J8mUR7gAxKsG6gHGR/KpsO+oxnZlRWYlUGFB7fShXKB8BTuXacqD37eh96Tt0oP3RwOPzNFx2ExgZ7V9RfsRf8zp/25f+16+XRxxjNfUP7Ef/ADOn/bl/7XpPYTPPdOhaSUKiFmHPB7CvVPDWsQW+lBZpJfMZQyJtIQgA4VgM55IweOevSuG8LQLm4nc8qh2qOTn/AArZ0eWWG3jctjbgxuyghTxk/TH5VMJOMro7Erqxy3xGm3qcnkLznJOc9vbnH6nmvG7g/vmr1b4lSrGZAGLh3LBi2S3v7V5O53yE+ppL4myar91IuaIu7VbYf7Wf0rqZo8IXKltknTPPrn8OKw/C1u0mpKwUnapI+tdSlqTKyZ2nOQazqP3jShH3DKvLi6N0ZQQiydQADuHHH0zWddtFezq0uxJnkCSkdG5/h/xFbOqERuBKjZzvcjCgAdvXGT2rIS0+0Row+0SRwkI8eRtX5s/K2enJOcVrBp6mNROLsXILW6thJGJYf36MhE0u9ZOfusPfaOmOcVmsTakQXMxtlQNIrQLvcsPuDdkfKMYyDn61r6dG17qZGojCKjOxVSqk4AG0DgnnHpmrOrxDTr2CLUJLeQxqNkpw8ewfdC+pHTp6/WtFIxcEyja6nNPAvlFLR5AqXCoojt5o8jYXAz3GWOMZAODmnGRv7Nne7tYpoY7pFcBPLBVeSqyDkBsjnqeDg9qWrz2V0b9Y4oi4cObwZClOOQowC3Xr68YxW/FaxjQILXUblUWK3FxGrA7W3jOXyP8AWbQgHJwCMGqM2uxi2UJuLT9x9skv4JA7gKFeMk4QhyRhTlRj15qopubnVo7WxnvFXGwb4wkoIjAkG1fxGM8gDNXYna8gube7aG4jkSNsSK6SuQDiTdjBKgYy3XJ4NZXkOzGCcIDlWCPNnJ245PIB+vfgUyDqvCOsxWRke9uJGwGS2Zo43MqSHY7AyZ2YO0jrj5jx1qzLfXBe2uLy5W/nSKJTHBHjyZVUohyqBSCOhB6dyRkY0dqkXh2388sUnYeewQMwiVxxED/F/PJBrUVLeTVrfThNLaYXZPzlI0GcuXQ5J+YkqAcAYByBVIlmd4lPlX18l1a3NpLPP9nmdsMqIvVFJ5YDao6/w9e1Yd9O8MX2eG3W3Eaj5uRI6kcMSeobqD6Y+tejtpI1e20yPVtYi0tpGkiia4tttvDEEY7tzNnLEDryC45rzS9fULlWN008qQKil3ycIvyJ15IAAA+lEmEUXhdC5v3kvLnzIGsyf3eSEULgIFc+oUEA8DkVRukWKKKe3ikW3G5EZo8biPulzkgk/NwOy1UffdSO5VSeXdgAAMnr7DP8607BZdUhs7K1t4TLArEiNSGYDc5lc5w2AcdugFK9yrWMvYZZF2IEDjIVATgAcn17E1NYJAwuhLtLG3YwljgB8jGODkkZx0+tS3dw100Ia4luTGDBEZFxhQflAz0XPbtk0n2yUTTebHbpLuEjOUVSrLkfKOhznp3xSskVdtFNyGKElT8oBKj/AD+lMBqw0sJt5E8hTMzBhPkgqoGNoUcc8VEyqIh8x8zcQV9uMH881LKQ1du8eaGKjg461IWAt/3iK+5CkZVsFCCCSR37jn+lRA8MDt+buR0+lOV2RiyEq2MZHBwRgj8qVx2G0YAGVBxxk470g9qXpxkEdeDxSGBY7QpY7RyB2B71JFEZ7lYoypZ22qcEAmo8fKfQVNawrL5zPNHGsUZkw7bS5BGFXg5bnOOOAaEJ6EA44OR7V9RfsTqVj8YMjRsW+x5XJBXBn68d6+XT1Pf3r6i/YjHHjPnr9i/9r1E02mk7Azl7IKlk+MqxJC8de1a8IlVViDyhAfmGc7Bxzk8VlQvgQxscLnJ7/hU90xjs5c5TIIJySAOvA+lZpnelZHnHxG1Az3bJuY4Yjk579a4deorX8SzmbUpDuLDOAT1xWUq9KuO1znq6ysemeCbmzl8GG0a1jF5HdGQXA+8UI5U028Ki6V8HGcYXj8KyPAikW85YnYWHSt2dN7jnJB71lUk2zpoxUUQatERBEVZ125+YnopGD/8Aqrl1ZtPFxDahrleXVlQhmXrk46dOD7GuyuYvNtAdy/u0JG5s78noffrzXIyxpKywyz3nylohF/sg5wMfeANVTempFWPYdbXsuoyGaVpPlwSyybSq4JYg9xwOox9KpXkr/aJw8k80ls/zuTvLJnAyTwPlzjFXJ4kMbyRi3tkUeYX3kkjICKV9DjkY7ms+8CzWMf2aCWONXIhUuG3K3VT6nd0AGcVvGzOefukytBFqFzAfms5pApO0xq8ZGcbRuIwSpGMng4rovDiRmASalfp9iiDMJ/JMwBCDavJB6jHHT0rlrQkaqiYcSLAYW81AjKwT0zwQQRknJ/HFbl3Ok1zJa3yzWjSKAQRvBBGck9zyMYq5PUxS0M7VNVWS/eRJ/tMqyLIq7QqS5HzKcemSO2O3UYzRbzy7bmMTK0iMWeUhdxB2t82eeoHODzWrDBCjRZsg7orFlkysTYQqBgAHeGO7O4j2IGKt2N7bSG1ttVtZFjErGMKu5GU4+VuMsNwA4POCOM00Q3YhuZ4biaGBLZ9UMKpCk8Ts/wB4AhBkAht28cg57ZGKkt5dM09rWSKeS6vY7pIzbxxsQsa53EjjO5iBjg8ZI5qXxFHEmqW1pZSCW4dBEHFxsiVxJnchwpAABGHwVPQmsZrie31a3vtPXyXRQ5+yO4KjdjdznaTkHqQCRTuTuemS6pcp4Zk+16Lc3dgpE96l6qhYt65Tyy3ziMhlJbrjgdAa4bUZbvWtLu9SnuGlTT3hs4DJKg+RhiONYzzsVU+97DPWklgvpfOSe7eSQXItYWFwJMuTnBZuMHHDDjPtTPEdobnWZILWC3tltYlWSYSq6hhgs29fXcCRyRggZxTbbJSSZX1DVdMu9Ahg+xomoRkRIYl4SIHcDnoXzkEkcg+1UDqflq7WsRt52SRHnibZvDsD8ygYHGRgYGKkvVmuEBui7G3URbx90IvGcAcKM8Hvms+aJhb28m9MPlRGn3hg9x39jSbZcUh8ljMkf76JY3cBk3NjKYOTj075pJ7fMQlhDtEgCl/KKD23decc1oqpsXtpo2G6W3LSRhg6BG4fcP4c5xtHoPWna3cacrrDohv3tG3O322Tlx0TKqcAgdvXpxRyoabMEEg/KeR36Yq7fQohSKFcuqhztjI3JtB3k5+vtgZqJbiWKa3lh2xS2+DGyKMgg5BJ7nPc0S3cs0brI5O+VpmO0ZZm684z+GcVCstC3cgQBnUFgoJwWIzj34pp6U8MMBSoPBC44OSepPegjlQFAZeST3qRgSoJ2DAIH3jnn/8AXTQMjo2R19MVJuMkzsVjBkJJGNqjPp6D07U2NiqsqsQHG08kDGc8+vSgBmO5FP2r5RJJLcYCjjHfJ/L86WNUbh2CfMPm5Jx3x/OnTIFMnktviViu4cbgDwxHbPFCXUL6kNfUX7Ef/M6f9uX/ALXr5ihiEqzEzRReXHvAkJBk5A2rgHLc55wMDrX07+xH/wAzp/25f+16l7Azmrcgsu32B7fhVfX7p0tn2NjC8Y6cVNaMRJKGyFHXArn/ABpeFLVkQkAr681zX1PTXwnmV8/mXbtnOSf51EAAKWT/AFjHOeamtY/MmjQ9CwB/Ot+hybtndeGLf7PpNtklHcFmPc1fnjITdkZJxUNlJ5oIBxDGAqjHBrQVFa2YhTknIz61zS3OuC0KaHAkXy924YIJx+dc/roaOX5USOEHAYtgbsDpz1rfGEBYjAPy1S8RRxSxQyKFAj+8XUHcfUU6bswqq6MJliYM8sVpfbRz+8YNzkcY5BXr+HpWTJp1w9yrW1tMYnLtBtBcvsGWwQAeACScDFas8DxoGjjSOFuS2zPPfBH5GmwQbvt8thDBNHboJHndlgPlhgvCE5ZiSBhckdegNdcWrHDUTvqVD5os7eUzwJPaSMwkZi7sGwRuBJHXpj+9z2rUWR47E3IE6XEORCcho41b7seSeTkE7u4+lVdctXWfR0Swey8+Jvs7mX5ZiXZd4z90bgFOeODzVZ2e0tZobmd4rmECL7I8W1MgENlunBGMd81pa5hc2NevEv5Vga+lvITsTzG+VQyjhgTzjqPp9az5LR4lU2ttMbFcbf3gRwC/RvfcMhh0BFXLfUpdkn2u0OZo9/2e2tlCqNmfM44Axj8CSTW1BaXMEKm9j3XEsI2ssSsCzLkL1wBsz78UXFa5z7Wax6dC99NHKZPnl/ehnDFmHzKcZGEB5JOcHvTtPs4Ft3urVoJJmt3+1p/rFiRmwrMOzeo46jmtTUIII7JEXyGxMLhVnUYyQMq2OuT09eBjk062Jvxf6ixsEWSTfLZQqIVtlHJaNegxjpz1IA71S1Iehv6Tbajb6VYJp0t+tzNH9ht7sonlxQsGUxZkGVVmLbj/AA84zmse08OtDLPavbo0SK6slukx5zjeoXAdeCc5PAyK6XQfENmbGNbPS7SScQhtqoZYomU5DlmOS7tjcx4GRwMGs7UNU1KOZ31OaW+SRJTEVdm8kA4kD7AGKgA9CVHcVWhGxi6xfX+nxzI99aRWrXhfEMJCmTaNuVxtAxkgZ6hsiua1uT7PCLAXkF3DCylHWIgA7MfK3VhzgH6GtfVA+oLf3IuZNRKRpLK8jeUF3ggRgNksykjGOvNU9S0a50qBtQvbSa5iuIsRXJg2RK+MNlWHOMjkYwcGh9io9zmmVvLXjKFieP72Ofxp8sUiwwzOSY3BVTknbjsfT1A9K0beM2NzFc6paqw5cWrvsaXI+9x0GD17kYp638baRLbR2tq8kuCJJOsGGJ4yeSeFzjoMd6ixrcxmcFEXCqB3A5P19aXakjxpAsm4qAR3Le3tVgtLcm6AgiJb53Kqq7AM4C9gPp16VUcEYyMZGRUMaFdyzEoqKDhcIMA8Y6eppBG2xztICEBs8YJ6DH4UpckFzgseeONpz2pZJnlkeSZzI7ZLM5ySfX60DQjyNIFEjZ2jAJ647D6DtSBfmVWdRkDnOQM+tPnjeDEUnlnOJAyFW6jjkfypFA2gOuGYhlctwF5ByPr/ACpddQ6aDWOcc7goAzSKAWAJAz39KVFaRgqKWY9AByaEJw2FU7lxzzjnqPejcY3cQNpPAJ47Zr6h/Yj6eM+n/Ll/7Xr5ihZ9k0caI+9OcgZULzkHt0r6h/Yq8rzfG32ZpGh/0LaZAFY8T9QCR1zSewmcgZDGXOOM+vWuJ8YT7wwJ69B2rtZpNtuw44U5NeZeKboGfZxkdK5krs9JvliYBw0h+tWrXPmxrH99iFFUlbHaum8GWZnvWnkHyoPl+ua1m7K5zUvekdVpVuYLRIxknv8AWtIqcKMA49KZIRHwQevapwdiDHHGc4rjvfU7+Wxm3qgIVXOOwrKcEymWQcA/Ivc4Gea1tQk2gtjO4Y69DWRChuLpFiUvJnAH3i34VcSWUL6VUMHlOADlT1wSfQdj70yayMCGOdPtMo+ZJkcHbnPfpwSaXWFMDMV3SLyjM0eNrHt7c5qhA1s0TK+I0UMRh/mz7n09q3jsc01qO1SO32iCKSSbMoNyjKq7cjAO/sPrwOtGnxOdRgVh9oPkNHFGwEi45zuOORySCPTik08R22oyFnZ7YxnfldrZ28A54IyQeeoHrip9Hu4oLAW73RKFy8hjdVAUdACR19M+tbp2RytJsQxRWbz2/mvbsQqI1uxUIHyHBPVgenJA6/St22ntIraWwRZbpQEZLjmEhVBLgR/iPm3ds9OKzLLUWTTI1DIPtHmI5fClhnksfQGpdaXTbW5mdZLlYJtmYXUPIF2Ej514H5DIPTiqM3oVdZmnk8jyZTNESNr5HnHP3cf3hgdfXnvToEvZtFuHEV2/lylGZFVYlTB+XJ56nkYFLHZSLb79yII8zC9LHC8/eXnAzjG3rWjaWslhHFuvIJvs37yNAwAyehAIO5MHBPXkEVaM3qYto7wmWK3t2mVB9nhaSIfKDk5JAwTzgE123gTSTps9i+rwR3WmXLFWhlnMSXGBlVWbBMQz17PyPXHP/ZkXZHaWc6yXLlWbzdyooPK4yFB7YPXgjriugh+xCxbTJmt4VmXiSR5FW22ckNC2cEjPzAgH0polmd9ss7N3EdrosLrMzAq08jwAv9SvyjABGelQatfXUpvbeEQanaX5cx+dv8xMYI4Y/KAAcHOMnnniiSTUI9L/ALOSNNkcjTNLCoWNUJBQE7cqoxnBPFU9SN7cW8MKBLoq+6OKKQyGRcbpGJxhs55HHI6UwRhaxdpcG2kt/slvH5EaeREz/vCp6yE/xeoBAx0qhqYjlvnaG3NskyrMkRXO0kZ2pjomc4zzjGa3dSltLeG4tXNt5ahXiQTGTdnkFSAOR6HtxV+y0MNI4tYWldlaZp7RSfkHUbWGMfdP9alq5SaWpxj7vs6BIpk3o3msMlZADwcdgCMH8KbaW8l1OsECPLM+QiL1Jxnv+NXHsJ4XbyjlGBDbvl+XvuH5HHNUFVlBIUlSCMlcj/OOah+ZovIjHKhhgqelTRYiZJJIhJn7qPkBgcjPHPWktlQ3EXmpJJFvG9IzhmGeQp5wfwo2hmVFRd2TyW4YduenHrSQyMkcfLt9cd6csbSOoijY7/uqBknHp60pVgFfbhWyAR3x1pzYSGB0nbzQWzHtK+UARtIbvnk8dMUgCBDKsir5IKr5mXOGO3+FT6nPT2pHSFZgqyM8ORlwuDjvx6igshhAMapIuWMhJ+cYGBjoD15pJ4vKk2bg3AOcEdQD0PPen0F1I1DOTxuwMn/GvqP9iaKVIPGE3lsYne0RXGMFlExI/Jl/OvlwkkAccDA4/nX1N+xYqxJ4wZc+Q/2MpI6hSx/fbh17Gs6luVtu3mM821m7KqyR43NwBXE3Ph7V7/UmWO1kk43EqMhF9TXQaXefafEsAuFBhLhQOgzXR+IL/wASeDdcXXLVUSC4XasckJMU0Y4yp4z16qaqnTVuZmlWtJy5EeX6ZpD3epNbB1wjEMw6cV6HpmnxWGyOBQVA5Pv61pX93Z+I2TU7azjsZZVBcRgct3PHWmxlY3KHrjrXPW6pHTQ0s7WIbhAG5571Oqb4dyemRTpMMnzdxUYcJhRkAjpXMkdjZl324uE7kdDxioLaJrbE1vlZBkF88++Ku3sSsSffhvSo7gRvbKVJ3AYIxjFbR2MpPUrXEIlt5YsjDoQWPPXsf51zNraRRNKLyIIsWP3ifdLHoGB6fWuiZmZIYJXTy0JPA5wexPWqd9ZyITH5qzIp3s3ONoOQDnrnt3q6btoZVbtXOdvCZGaJ5w277xPY+vHUf0FTwWSxWN99oleOe3MYigaM4kJPzNu+6RxjaeTkY6YqUBbxmtliVmZjIIoxhhnBIB7jjit61gSS2eydLhImbcE4ZiFIK4bB28jHH411KyOKV2cy7s9219ck/bPmeZGg2pDIWwgHbI9+me/NGpebBPNH5iXDyFXjnUNkqRzw3ftn244rvPDVnoEeu6Kkr3xtNxa+kmVSxUxjciKSV+9nDEBsc9a3msdKN959nYx2xL4S1lHmYc85OepJUDA4AOapNWuZuLvaxxmi2kl0klvZ20JgOws9wqjeBjgkcLgnr3JxXWaFp0N3ew2aQQG4mUtA8yB9oC5AU4yoDcY5656VueHvDVheQNeyWMqW63cJlkgUh7VJWO8Op5ZRgYboCO4q+mnWgW4vtInEH2W5ZYEjh/emNn2ghj8rHJB2kZxyDxiri0yGmeTeJXmt7rUYpWQCAJuAYnJ4IYDGCeOTx1HpRplvZf6Tp+tLc2+oea7RCFmMiEplMptIKE4B5+vBzXplxp8K7LnU9NZzaFVKORGrr/EHU8kkhiT36cVm6jJZuL97Oxt7LUPtCKiWuSYyqAPhWySpHOc4B79KdrEO6MRLu5a4mku7u+lgwsd7CJWMEoQAFGAxtjxwuOR0PpWNN4aiyL3ybvyrwTG2kOHViOgIX5h1HUc59M1rX+pyppS29osNxeaiEHO5DG3AV1+YAggDO7OSKz77XHtVhtbTUbq50i1VlEajKISeSiEDbzuyOuec02xJMo2ei3KiB7extf3ebjyppE3zKMK/fjHOMjcc9OK3fCetCO3l8kuzygxK53gWy5IL7f4dw2qR0bHNZc8z3krfYb6285S04ud4858e5AzgdFyc54NY15qt0J83s9xG0T7BJs2sc/ePAwcZzjvgUnLl2KjHm3JfE9raBo0umdrpWBjRYAn2jLDjd6entmsTUGkt0urVooJC0gLsF2+XJ3j9yoGMirHlNca8gtvN1GyKswefarOgHJIJIB46GsuG2HkSp5yKqlZTzjIzgAH19sZzU3NLIoLsEP3pDLu+5jC4x97PrntU0YRFhe4CSROTwrZKgHByO3qKL0bbyRZUeIq+HVvvjnn/AIFTLjymV5E3pufEceBgKM9TnqOO3c1m0WmMCoFd2kXCY2pnls+n07mh4ZIx+9jdScEHHHIyP0IP0phGGw3IB5wetCEgbQ5Vc56nHpn8qACIF2xvReDgucDgZx/n1pXcsOO/qck/U/hQCPKYdyRj6c+1NPHSjoAgHB657V9RfsRkY8ZgKAc2ZJHU/wCvr5dBIyMnB7CvqH9iMEDxmSCAfsWDjr/r6l7AzjF0ixnZX2gemDW58XdU8Q634P0zT9Ujgt7OyiDRlYCrz4AUE5OBx6YGT9APRtG+Hfh6w/ty01nUxHd2J3xSZCbYtuRJg5zzwQOmPcV5L4x1+/8AEV9a2E9wkltCm07Vxxx19+KcYezi5SY5VPbSjGCM7w9GY9Ftxt2/L+dOlYecOKtqQkKxKMKox+FUJZME4GTmuNu56CViy7/MoU8D0qCVmb73JHf2pVY4y3y8UoBYHA5xU2LuMYjDAnGOQMfeNVZtzOofoOemKvyLuUNgFc4NV3Us+OuentSGZrZ3sUQllG3kcjNYd7fCIZSL5nG3y89geMV0uppOIQYpRuVwCc4Len/165qO18ycJLMFfOW80blJ5xwD79K1ppbsyqt2si9olpatp891cT2ZngQP5DFg5DHoGBAOPTtiuhsrJ7pE3/6PKoCCcxCMlTj52KnIIHHAqhoGniRUtHkd4l2hVfC7WPOWHfkfrXQaFZiK4aJ4RIIW5JA4HQg+pyce9dBzLW5qaNY2NtZ3sM0Mksgi3wyKxyMHJVgBySM88c8+1Ok+zF7Yx3Hl+ViXbLgSKQcKhJHJA5x0qW0sZFumEIU2pPluUUiUp6nsM9B9a3ToN1fOmrtaKYLVEd9uGO1yQm4/xMOhPbHtU8ysPWT0N/w59s0nWYktNTsrN3jzeyPL50EsYUMBzjkBivy55FVNCU3dulxfXKWF3IhnjhkdmednzvmOAWZflbPHNK9hJo12iTWyJGoZZVSFXDrIAPmYEjABBX0ZvrWhc3GjWzpKxguHhPkSpMxBY7ypwy8ABSCSOOCe/Nwly7HPLzMC8tpY9A/tcWosbe1kEbyFt8N26jALxEnMgJbDH5QGx1Fc3LqVzpmv6VdX8Ms0FzBLapPOhdxbOchU/hVxnvnG7OMYr2L4iQQRwNa3ot4GuEbyWaQHzJOAGK4J5HH1HPQGvPFhur6xkW3v/kSdl+zpCF/eYTdt6tghRlhxwOeaI1OZuJCjfVnASaP/AMVBqh1e1mk0gu58u0iIRmPOxcA7cdQeBkVykmjNDPcvBBcJbZY26O22SVSemOvRsHGep4r6KPh61g1Oy8i9uLA3U7Rz6cCtxjIACrKv3lPyKVY8Z56c8p400uKx8R3Mulq4/s24E0n2uREErE7MKo9CSMjsPxrTmDlPL5NEX+xbmHVInhubdxss5QVdVcZSQf3gD09jXHXV9em2it72Z0KEOI5PuOCcda9LlMF2NYkihla8ZlMCByxQg5ZdxGWPVu2QK4u7kMgtw3mSSKgChYg4C/xDafcE+vNHMpbBGLW5ybspRnVolLjOB94dsVI+J4Xlllj84MAqlsFOnzH24AH19qV8XlzIIYdnmElUGFw3bJPbvQkVw93EIrVm2H5Y5BvVtpzgnjIx/OmNlaV1aR8SO6NjLOBuJ/8A1570qW75HyA7vwyMZ3DPUdef8asS25jtdrxQ+YziTzBu3BSD8mOm3P4g+1VlRpLYsT8qcfMePoPf0H1peoxigI0bna8ZbO3PJAPcDkZokUl2KK+w5Zdy87c8GmHgmprK3nvLqG0tI2luJ3EUca/edicBR9SagfmQsy7T8uDkYO7p6/nSxtsfdhWGCDuXPXjOPWpFeW1uSUzDMhKEEcqcEEHP402MIsLsfLfqgQsQynHDj1A6UARHjgHNfUX7EZ/5HMc4/wBC/wDa9fLoNfUX7EfP/Caf9uX/ALXqWNnG3Yl1Bla8neRl6EnmmCBLY/u15PWkhk65qbG9R7fpXLOTk9Wd9OMYrREWcDBPHeqc5+fgjHerzjAJxlqo3SjcCKktj4W3BRjpzUqHBPIH4d6gtztzg9amCeY4IPAHNAD49g8wHJA6Z9aYv7sqACX/AJUJjY3yknmk3F4pJVxhAOMfeo3C9iswM8xyAcZUA9PqaZ9k3OzMBnOMRr/CRzgfXFWWeOCHZlTnv6Z7im2TmZY8t1bapByABVwJmhB5qvcSJEBH5ZVmZsMCBgYI6da7DRbq3Etjb3XmDcd0zSH1ULkEegx+Vdf8NfDGi68IZNRge+jiYptMnlgZByp5G7JwevasXxvog8OauktoscElyJG+xwvva1w5C5z1BBA/4CetapqpdJ7GGsX6ncXOn6Ja6XLJGzxQXMIlUkgK7LjGe+/cQR24961NF1eFoHtpZbQXK27xQC4ICbmXJweAN3cnv9a83s9YWS9imluQ8JjEDrHjAHQ7lPAPOc47nipvPg1C/mEeI2Eh2RqxbeAMB1OPm6YNYqk3ZN6mvOrNGr/bYvCIpYBHbSo6yxzr9yRhtLq3bkA/XtVC8u0huYFRLLzIkETuAGCKvAPu2BnOOajgvI3hlRrQXl8MbJ2XdtGf9XtBxk9m64PAyAat2umy281wlxY219JPGGjj8osYyT84EhxiSM8FGyQfrXRGGiSOSb1bFa3utZvIZdfZGs541to7uOdV8zy352pj5m2tjgdeasz2/h0ak1vpWsaho8UxO1b2NzCZFOArNu+XJJ6jjBq7pHhvVJZ7+3tINtmcXJtbxxGykrt3JxkAndnoPl7nFYdtp95pejy6jdW4SzSYq0MaZEjfd3AMT8hIO2QggEnjFaw1TMkrMeUk0/V5rcXJuklhkjmuEnITBGQqF9xboOTz1wMiqE2mjUPDMupfbc3cCLgRIAkmWIIJY5+UDIwO+PeuPuC05vIrfT5HSGQBCXMqpEGyCSuF4zjd056c1PZrayXab7dxbMd7rC3zEDkgZNZyu0aqK3M86HdXr+RNkWkcu5yzndIz42hCePqecda4jxPahb7UJXWVJDhUjV8oMdfmHPQdO4r1P+1rK1slYpHLK6uCsrErAB0OM4xj17kcVxeuabcXtvcGK2d57rbuuBKMIvo3OOgyCOe3tT5lFha6OVTSY77U47fUpo9qRvI9xbygo6hSQFIGMg4AHUj3rprtbZv7KGSLmCRVMcilYlAQ8/j+vfFYmrTwG+SGzgFtb28OTEj43yqpDMD2XpkevOOa276FE0pxeXQlu1jVlVArCFiBu3Y/2cc+3qatzZkorS5y+u3f2rUrudI3xIdp8wjcRjDY9zyM/SubdYo54vMjlWE4LrvG4gHnB7Guhu7+2YSRpFFIRGp3kH5MDkDPPPP8xWDPIoknMOH3gj5kB2A45Hoc8Z9KSbb1NJJW0IxCksQeKX980uzyX+9g/dIPfng+nXvTtot2MdyoMkbNHNEUIZDnBOc8sCOO2fWoSI/s4wxMu/ldvG3HXP1zxTreV4YbgRFQskexwUDZUnpz09cjn6UzMiKtsDENhsgMRw3rg0pOWyx3PkEMenHrThJ+78tx5ihTsBJHlknkj8qjZSuNylcgEZGMj1pbDELbmZiBlueBgD6V9Q/sR/8AM6f9uX/tevl7Hy598dK+of2I/wDmc8f9OX/tepewM4GJ+OTx61Zjb5cDuaybeUMgIOQRmrlvIWPBrlaPRTLwOTwc4qhekB1I6VYjIJOeMVDdkEbu1LqPoMiXfnb1HSptoBJDfN3plphpMnhcetTsF3KVzmgQkWcjJ+Ug4HrUITy0w+QoO7jnP+c1YBUZOMjtTnQL5bMcgndilcpK5Qv7Qyw7wzgKcgio7IybBII2EYPfg/l0rTQqiEOSY8HCnoBWddRLujVi6nHytjI/E1dN9CZq2p3ngTxR/Y6XEM0EsiuwkhZJMCNxnnYRtYn39Kp+MfEk2v3yXVxsSZY1QkOQWA4BINReALjRo7m+/wCEjjkOYtsAXlVcZ4OPX1rfWysrkxzQ28V7BINiKzshBZcKd3TCnqD1xjvW1oxld9TnlJtadDiIZj+7IcEqNwaMnkjsfY1v6LdRkzSm4Cv5LR2pZ2UwOx6jAxn68HPanaetnDGLcwwvMrBVkkJZSG4YYHQ459RVHVdPfT794VZm8lc7s7kB9iOoxjBPP0rVqyuc3Nd2PTdKWwXw1byaW8sd/cSO8sbE+baOiYcll4dUZQykkYBJ55A1vEclvBpkF5qGqLH5d1vufLmJZbpN2ViQDvwQzegyRmuW8H+L7rR7CEacbcLMFMwZNzLJ0YlcjIwFxz2q3rdxo2mTS6j4YHkXESJMk6RFWiPzb12tkMCWH3sgDgdBWH1pRfK0dSwraUkxmrTeLfEUNvdWcE66JIHjiZ7hE84DklsHI+7kDpx361xviK4mihgtl1b+0o1XMkVvIzx25O0Bd2BznHQEDHeori+i1K9uLvV7aa4nluFmllRmEZyp3AohAyT3HPBrYe7n10rcJ/ZNvZIN8VsQttFbKAQFKjOScDk5zwBiujWa0OeXuMwdPRdRuhaWlglu0TF5J/tTAyqR9xmPHXtjjvViaG60sSDVWxqBXku4byxxt4HOdp7ithNVD/Z7bXYJLq1g4ESbY9mejIQAd3fdzngVmy3enQ3U8y6Or6cEVWt5LnExzxndnJcnkgcD0quRJCTbIRoVzqWnpa2sYECB5SQ4jwp+9jPJzxkegFYPiPTjBp1vdM7eVuKRsFIKkHnDZ+Y7vyrt9E8WWsBlIs5PsuxUS0knZkGP4Tk5IzzyetY/iy6fWbSzthDFa2luC0UEQ4Vm+8cepPNJwi1e41Np2PJbuWaHVLySF0EvKTq4yXXIJGCOpwBxzxVq82QIVt3lilmQylCuwKp6DP8AEOR04GKz9eRLPXZRJtkVVxtbOMtwSO/Gc59qw2gT/SBcpNtiYgPHiQDGQAR6E45zwKzcbsd0tUWrgQWxmiWP9/kIfM5Bweo7Y6g849Kzri5FxCiJGkSxRhSuc72yfmHHXB6e1QyyB9hZDG4ByMkqRnhQOwxSR+R5c3miXzCB5RB4BzzuHfjpVrQh6jI0aSRY0Us7EKoHUk9KbnBIPUdafIGCRZQKpBwwH3ue9IGdk2A/KoJx0pDGnAYHHGQcH0pXbc7HAAzwoJIUeg9qb70pJKgE8DOB6UgG19RfsR/8zn/25f8Atevl2vqL9iP/AJnT/ty/9r0mJnj+jT+ZbJk8itq1cE9OPWuM0C82N5bH/wDVXUW8uCAp4NYzidsJdDWPPSornoKTzNwFMnfcmTWaNBkDYc9at7lVs8MP5VTiK8GpC2JF7g9qGG5difLluApGfXmp4yrLhiN3QD1qsnythemc5FSoSUIweueDzmpZSHKoln8lSQ2M7cdKo3O94WV2ZDjb9Pwq3cALteMckZ3Hr70t28TQnJUO6/KR06daqLsKWpTtFIhE8bNuUbAGbcJMe45B+vpWvptzLaWjWUkk8KzqHjnjfG1gc+uMVyiLLal4w6l3xhuzD1z61v6ffbrA28pilbOR8ufyrqTTOKUGjrtAv9Omtrm+1RLkuHVkgjP35FPI3D7oI74qTU7ebTpIoIp/NUt5gjVRLHuZQecdeMDj0rm4B9kjnWXzfIYLhAwDK2Rz+QrRiurZ0aTzZxJGm2KNZCFDY649eOtN33RnaxLquo2Vm8UIszDcPgNLBMdokHucjGCDj1pkd/LPvhs5/OUKS2wkK6twynpzzg/Wq9teXZmj2zCKbaGmRCNh+Xhm9Dj0555qx4bkliubiZLe0mtYogZGlBVlG7JddpBMgOecHOeQaLQvqClOK0MTW54r22JtwYtRQ7AkeQGU545PX6D0966DRtAvLHSQZ5tPE16HuJXmuCqp5a/6p1PBlB5Hb5hg1vrJprtazahBdajAcLFDtVWAbnLtg4+bOB14z3rT1zTdOuNKkurOS5lt2YkWruuyOTBAjVTmTeq4JYfLjPpT2s76i5m9Dg9curjTZJrhIHS1UJCbrd5qh8ZKK/K5wc8E9O1QvpdzJaxXGoRJZQuiyI0pJIDLlWOOuRgj61i+I9U1bUrq3tr5JfO80gbpGKksAoGPu9NvIGeBnpV+Wye6DbXFz5H33gjJiGB/d9OOnsacZa66g00itHLHbpKFdJ5M589flyOABt9qzrzU9RYpGqLu4HzDG0fU1avZ45Z7hzK7oELEKgw8nGBx0wM9PSucv764Dy/aJHVoo96DIYFu24H69KemwXY3xCNItdKe3VDd6tM7y3F7M+whB0jjTPG485OScDgVzjXXmtaWlpH9jNvEUkdMuXJ5LHjJ7DFRahfGdVEsWblTlGOQQDj8P/11TOYJC0UjeYq/MVPKk8EZqUkGo/UYrRURrISeWrlC0jgnpwP/AK/TtVVo9jsodWUHhhwG9Dz0qS4KhjjbjILKp+U8dvzpspPlpuUIG5AUYyOmR7E/qKqwEfmyeT5O8+SX37e27GM/XFMPGc4z605Nu9WkDeXu+bbwcd8Uh7nt2GakY31pMcZPSnDGepx3oxzyTikA3HANfUP7Ef8AzOn/AG5f+16+Xu/SvqP9iYBT4zAIP/HlyOn/AC3oewmfNltKYZlNddYzCSJWBziuavLQoxK1a0W4ZCY36dqzaudPwnY2025QM81JK3y881nQuUYehq1I5K1nbU2TuhA2HHXFWlY8AkcVUTcQTjkCrERJG7GeKljiy6jggBj+Iqb0Ksc/zqnH2569akDOPu5z0GagssN8w3YA28jHPNMwsuYAcsWDA9h9famwv8ww65HDcVMEiD+Yq7u2WOAapEyIr6zcWcksSESx4Rsjjrzjt9KqWyo0jFJwQvC4G4N9SO9biTDDrhRFnBB5A9RXO63avHKrweb5ZY5SHAAya1g9TKa0NNw9uyef0ZdwOeT9adBLFKh2vyfmGzkn6Vkb4pYlimmO9nB81Y9xDdjj+lOhiliR5g6yMr5URqRkf57V0qxyu50UFxLfutuEJmaRVRI0Ay3Qceprf17StYs3EWvWU9tGzjO4hgCueMjrnJPXnrXJ+H9aurHU1vp7YXMhBBSReCPwrZbxTd3DW8zybBCcoHAwvPYdPxo0vqNRujS04TWZtNQtmQwxyCTHnBzgHup7VbvtJkv5xcI5SylBuNockqS3pjH1rAtNXsoZJjMI3mlIZtyja3J4z1UYJJx3rfsbm2ubForwiFTlE3KZTHCSGO1TjJ9DkelZVGmxRv0MHxnqMMuoR3cs8s9yWOV2scJ03KfU/wBO1XdL8YWWkaLc2dnHPEjBt24Am4/3iOCQc/hWVe6lH9ouDcGRSpIt0jmAWJPTA+vtz1rlL68hlUqblyQCqqOepqlFWtcXK+o2e5luppdqkI7lht4AJOck/U9TWFr8BjeQRuGLKCxBAYg+qjjNbu020IadJBHNzGjHBkx/EB/U+9ZupIgMn7tVmZs4VtwK5+6fb9TV2C/Y5cRyMsbSLuUckhiSSffse+Kdd2+2ba6bsOCzITucEcfj+FbkNu8UB5jyxJ2kZKn2Hv8A0ps8KxpM7bSpIBORuQ/T19x0pDOfzLCCY02EJhg4HIz6f5NRvDI6oWR14x8xPOPQdvpWpcwxgMzPlmwUUtnvVKeV2lb5iTnI5zj8aTZSiiqI2T5tuRwTnkAH+tMYY7ZA9auQIZSRHhn2lm34AUDqfyqpuZurnpx/hQJpEZ5PC0ZyP8KU46ZyKToaRIsZIyVwDjvX1D+xS0bS+NjErLH/AKFgMckf6/vXy3X1D+xH/wAzp/25f+16G9LCZ4bOo3HcM1WEQSQOgx6ity5tg3IBzWVcQtGeBWSZ1tWNK2k3IAe3SrG5icd/SsGG5MR+Y1p28/nYI5oaEnbQ0Isk4NT7tvc1VTOeTmrK5ZevFQ0aRZYR/l7Y9qeGYHKmq4OT1NSFtj/KOKixpckDfMcKMjoRViOZDGBtGACdv86qrlOMjJ9qcq9BtBbgDBosK5cini8qNMsN3PK8gVFIyzbxCPl/AA/nSLEkhKqHDDtnGMUKFiiZSr7m+6rcmqRLK0KKPMZY2TcfkJGGX0wemKEgVJ/MLuZS3zKM7Tx/KpxHI6DacOBjezdfbHY+9PWEqj4IJIGcclT7dq1UjGUSg8giYKPNCAkyLk5X3AP8vSiYgIMvujJ2787WzjP3a1oUAXETlmA+8wDHPvVi3tozcK6ojuiZXevGfp0BxnrWqkYuJzaojt5dyWSQEDcwwAPcn8KsSatqMWntZpek2yjCm4PK4P8AB6itqaO2iTy8REtgBWHzLx04H61T8lIZwnnttOFfH7zb7YI609GTqc0kTmfZJMctgHbl8Z6cAVcFoLW13yK8cqdfMx834dQfYVtNBcMisLa/khBLcDaCO/UDBrPniXySUi3EcN58g6+vWnohasrTF7i8GzzDGVIUO4IGB93PtVcW0UaeWDufeoG1gCD+ZJNXruEArDKTt4JGBkZx05JzVC48tVOPNZQdoY4DH8B0/GhsaRUlkMMk4tYzuUZLt94sD1PoPp1rO1CaMu0gmZSBuOUzuP8ASrrRoBK20yLgA7zjH4Hr+FULhCXR5n3/AO8wx7cVDZokQkgxA+YzFm5zgZOO/wBKqyuyFuFXJJJxgsPr6VYbYHJ+8gzx3JqlKDsYmVcngAHP60FbEUildys3zH7wHf6nvULZycgH6VIykqpHTGSR2571Ex7KeKZm2MNJS0hpEiD619Q/sR/8zn/25f8Atevl7vX1D+xJ/wAzn/25f+16T2Ezy11JJqlcxK39K37ixKZ4rKnt2yeOaxTO9xOdvYOTipNEcjcpzmr11CQMniqNiCl0w/GruZNWNtOMHuKnDYOccVWUsB159KepPQk1LQ0yyrZJ5wRzT1YMcDdnHr1quO3NPAKgHOKmxpctKvILHIznmnoxVhjOPUiqSyt0IODUyykoxIwV70WC5bXDsVJHHf3qQKuUzlWz1J7fWqkE8bN0+Zj6Zp5lV/mGcD5cgd6LCbLB2h2TBKHn5j/WnpII5kaMNuHTtx6ZqpvIYZchSMknsamHlSKsiMxC9VY/1q0iGyw0yxuoUqoY+vNTRyusuYSynZlj03c/54rMkkDvhV2nr8hzuOevHNaOiWM2o3XlQQj7U6SOFeTBKqMnHuPStYxbMJSSJ47kFFieUrtbPmEgsG79s9O1LqGBcBo42eNgV3+YQzk8bu31x/OozFO42PAVSRSoIdcZ6e2M4qC/ybWO5cCJVPlEsCRwB1bjJx+NaWaRndNiDcV3O8hJGGwck47ZPBqhKo3uHijVwhxuXJ698YApzTsIC4i2R8jO05Y4z+VQTTGWGIP0xn5s/N7GouaJEEzk7/Kgx0CpuAyccnP9Ky2nUZDKXZCT8vUE/Wrcyqx4XY4/iGT8vuaz5iTCOQMnJCjtnqM0hkMrLtCNkkbskdvbI61RuIwCFYr0wExjA/rVlhuGVJ5OCw6moJdwLcAA+nXFAJlNkPQfvASB0P5e9Vpfkkljx5Z+6ysO/p7VZd9owhKjGTiqc+7iTBBJ6GmDImycHAHHSojmpGOWOfrzUZ/SghjaSlpKQhO+K+ov2JP+Zz/7cv8A2vXy7jOK+ov2JB/yOf8A25f+16T2EzCuLbltw6VlXdmGOcAV3sunpLGSBg+9c1qVubdyCPeuKM7nt1KDWpyd3Ygq3HT2rn5bfyrgEY/Kuwum+U1hzxZfJHPtWvMcrjpqVV7U/Oee4ppBBoCjBbGCT1rWxzXHbv8A9dOEmAcnrTAKeU7nPFKxVx6lh93p71IgBO8gnHbOKRABjBOQOKkKknGckc9O9AXHxhXyMbc9M9BUjBo4gx4B9BnH4UxQQSXOWPTA6+1KG+TgEN3zyKdguSKdnRRtBwCe9KwjERxuOT94duOmO9MQlSAd3A6noKfuaAEJJtbJw4PPrVJENkcJaO2dwrmYEAALgEHr+NTpseVJX80tISN0WBIT0GB0P09qLXzFuN0xLRY5O4DA68H/APXUk6LM+VLKEAKIEJTI5IODWiZjJEizESRx3YlNxhYRGU2kjqMqeAe/em3TXAd0mk3sHyyMSXUjnp0APPT0q9EYIwB5ZGFPDSEDGOdvOfzNUJSxhEbuJ3DFgTycDoPcY96ptEK5QZmZ5nlZPMY53AEEeg5/pUSySxDegLEsDyAQM+oxVjcGjRh5a8/Mx6flntVeWcqwkRAxJwr7unuPX6VNjS5SnKiQsjfu2JPykd+Bge1UZh8370ru2/UAfh3q9cbvJdkbOOD0yTnqKpTYwgJbIGGBHfHr60mNFScKx3ZCgKcZPUYqjKWG0H75GSCcfnV2Yb412uflJAJ7cc1Tk3BigHAyoyBznvSGipOAzuEYlc/Sq0pJ4JP59KsSg54PsTn9arSkcgc47iqE2RscVH/OnH600daCBD0opccUuKQXGV9Q/sS/8zn/ANuX/tevmDFfT/7E/H/CZ/8Abl/7XpNaAdePBvilTgaXkf8AXxF/8VVS++H3iS5Un+y8H08+L/4qiiuZUYo7ZZhVlul/XzMK4+Ffip87dK6/9PMX/wAVWXN8JPGZJ2aMDn/p6h/+Looq1TRi8VNlJ/g/453HGiZH/X3B/wDF00fB/wAdf9AP/wAm4P8A4uiirMudjl+D3jj+LRPw+1wf/F1LH8IvG4BB0Tr/ANPcH/xdFFA/aMT/AIVF45DEjROPT7XB/wDF1I/wj8bH7uiYJPP+lwf/ABdFFIPasUfCXxv30U8cg/a4Py+/QfhL42ySuh7T1/4+4Ov/AH3RRTF7Rjl+EnjVNwXRyc85N1B+X36cfhN41LKG0TdGOP8Aj6gz9fv0UU0xc7A/CnxwDtGiExgDA+2QY69Mb6k/4VT42U4j0hwudw/0yHA/8fooo5mLmZM/wq8Ys+4aOOuShuYNv/ofFQH4UeNSG/4k+OSQftMBP/of9aKKfOxEDfCTxsyJnRAWUgkG7hwQD0+/TZ/hH41lDbtBwGYnC3cGV+h30UUc7C5U/wCFP+OlZiPDykcjm7tz+WX6+9Vpvgz49dyw8PrluTi8gGD/AN/KKKXMx8xUl+CfxAdAP7AGR3N5b5/9GVWPwP8AiH8x/wCEdyc8f6bbkfX/AFlFFFx8zKz/AAL+I5Of+Ed6jn/Trb/45UDfAf4kEkjw31/6frb/AOOUUU+Zivcb/wAKF+JOf+Rb/wDJ62/+OUD4C/Egf8y5/wCT1t/8cooo5mIX/hQvxI/6Fz/yetv/AI5R/wAKF+JH/Quf+T1t/wDHKKKOdgJ/woX4kf8AQuf+T1t/8cr3f9l7wF4k8Ef8JN/wk+nfYvtn2XyP38Um/Z5u77jHGNy9fWiihybQH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The photo shows kerion - a boggy, indurated erythematous plaque with pustules and exudate. Kerion is a form of immune response to the fungus that causes gray patch tinea capitis, Microsporum canis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John T Crissey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_14_25825=[""].join("\n");
var outline_f25_14_25825=null;
var title_f25_14_25826="Wearable defibrillator";
var content_f25_14_25826=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Wearable cardioverter-defibrillator",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 504px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH4AYYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDKdmDNyep70m5v7x/Oh/vn60lfoB44u4+p/Ojc394/nSUUCF3N/eP50bj/AHj+dJRQAu5v7x/Ojc394/nV7RNG1HXLz7NpNpJcyj7xXhU92Y8CvTND+Hul6QEn1+VdTvOot48iBTnv3f8AHA9q48VjqGFX7x69uprTozqfCeURxzyRGWKKeSIdXRGKj8QMVGJCwyGJH1r6abV4NO0O3mKpEsmViijUKqgew7Vweu2PhvxI7G4iFhenpd2oAyf9tejD9fevMpZ7TlK04WXfc3lhJJaM8i3N6n86Nzep/OtjxH4b1DQGVrpUms3OI7yHmJ/Y/wB0+x/Wsavcp1IVIqcHdM5GnF2Yu5v7x/Ojc394/nSUVYhdzdifzo3N/eP50lFAC7m/vH86Nzf3j+dJRQAu5v7x/Ojc3qfzpKSgB25v7x/Ojc2PvH86aaKAHbmx1P50bm/vH86SigBdzf3j+dG5vU/nSUUALub+8fzo3N6n86SigBdzZ+8fzo3N6n86SigBdzf3j+dG5v7x/OkooAXc3qfzo3N/eP50lFAC7m9T+dG5v7x/OkpO1ADtzep/Ojc3qfzpKTIH48fWgBwZv7x/OlQySSCOMSSSHoqAsx/AV3Hhr4fXF1HHeeI5H06yblYB/wAfEo+n8A+vPtXo+jXejaAgt9Ls4LOLoWHMj+7N1P414+Lzmhh3yw95+W33nTSws56vRHgMglik2TLLFJ12OpVvyNN3N/eNfRvihdL1iC3i1C0hvYZYt67uHQ56hhyO/SuYPw48OXdtKLE3UdySGVJJySAOoU+/vms6OfUJL94mn95UsJNbM8Z3N6n86Nzf3j+ddp4z8FjRY1ktVuY33BTDc4If3SQfKx/2eD7VxTAqSGBBBwQeMV6mHxNLEx56bOedOUHaQu5v7x/Ojc394/nSUV0EC7m9T+dAZv7x/OkooAlgY7+p6UUkH3z9KKhlIY/3z9aSlf77fWkqyQpKUAsyqiszMQqqoyST0AHc16j4a+GkMMMd54smIJG4WELYP0dv6D865sTi6WFjzVXb9TSnTlUdoo860jS7/Wbv7NpVpLdTdxGOF92bov416TofwoRYjN4k1HbtwWtrM9M9i57/AEH412P2+CxtBZ6Tbw2doPlCQqFHp/jTZLp/sZ3N987j+VfM4rPatTSiuVfid9PBxWs9R8cttplmlhpFtHaWiEYSMdT6k9SenJrMlmLAEnJO0/zpGcl/+BH+VQ4yo+g/nXhSm5vmk7s7EklZFDxpKRpGiHccDzkIz3yDXHvNk9TkfmK6nx4WHh2xdBny7tgfoyf/AFq4D7UG4B59KtMhnRWGv3VirxMEubSQbZIJQGVx6EdDVS98OWWrRvdeFXxKBuk02RvmH/XNj1/3TzWO0+aYJ3SVZYZGjlU5V0ODXZhMbVw0rwfy6MyqUozWpmMGV2R1ZXU7WVhgqfQjsaTvXY/btP8AEqrB4gItNSA2xalGv3vQSD+Ie/UVz2t6Pe6JdLDfxgB+YpozujmHqrd/p1FfXYLMKWLVlpLt/l3POq0ZU/QzqWiiu8xCikpaACiikoAKKWigAooooAKKKKACikpaACijvRQAUUUd6AE7UUtJQAtFISAMk4HvXWeF/Bs2pQpf6tI9hpJ5U4/fXHtGp6D/AGj+Gaxr16dCDnUdkVGEpu0UYeh6Pf65e/ZdLgMsg5dzwkQ9XboBXpWhaLpXhfE0JXUdWXrdyL+7iPpEv/sx5+lTy3ltY2K2OmwJZ2K9IY+rn+856sfrWBeXzOSM8dMD/PNfI4/OKmJvCl7sfxfr/kenRwsYay1ZpaprUsrszSMzHqSev+fasm1SXUrkpvKxJzI47D0HuaoEyXEqRxAtI52qo7mussLRLO1SBCDjlm/vN3P9BXjnUa9i0CxLGjBNq7V3ZOMdK0YW2RgyPk5wNo5J9AK58gAEngDkmtTS4zEqPID5rNwD/AuOn+NNaks3VNzqdo1pdXQiikGMbFc4PY5yDXlviv4barbXFxeaMkd9ZliTDDkSR+o2k/N+B/CvRoZMbCPQfzq7b3bxXLbGOSoP5cf4V34THVMJLmh13RjUpRqKzPmxgUdkdWSRDhkYEMp9weRSV9Ga7ouieJ48avaKLjHy3MXySr/wIdfocivIvHHgW98MKLqOUXuls20TquGjJ6Bx2+o4+lfU4PNaOKajtLs/0Z59XDyp67o5CiiivTMCSH75+lFJD98/Sipe40Nf7x+tJSv99vrSVQjs/hVZJJr0+oyqGXT4t0YI481jtU/gNxr0O4umkcs7FjnJz+dcf8NI/L0C9lxzNdY/BU/xaumIyG/H/Cvh86qupi5LpGy/D/M9fCRtTT7ictge3+f51euT8m3sBVeNfnP+e9TTck47n+teSdJAOXH+81IPuD/dH86evUH3Y00D5B/uj+dAGR47O3wuT/duYz+eRXmc+2Xn7reor0jx/n/hGJgvP76I/rXmie9aLYgRMngnn3qVUOfel8oHkdakQ44bpTAAgIwwznsa2tJ1lrW1aw1OAahpEnLQSclP9pT1B9xWWF49qeB/n/P86qM3F3TJaTJtc8NeRaNqeiStf6R1Y/8ALW39pAOo/wBofjiud6jjpXTaXf3Wk3YubCQxuPvKfusPQirl7otl4iR7rw9GtrqY+abTSQFkPcxeh/2eh7elfT4DOFO1PEOz7/5/5nBWw1tYHG0GlZWR2R1ZHUlWVhgqR1BHY0lfQHGFFFJQAtFJS0AJS9qKKACkpaKAEpe9FFABRRRQAUUUUAHanwQy3NxHBbRPNPK22OONdzOfQCrug6Nfa7ffZdOjDMo3SSudscK/3nbsP1PavSdLtNP8MWzx6WfOvXG2fUHXDN/soP4V9hye9edj8ypYNWesui/zN6NCVV6bGfoPhO00LZda8sV5qgOUswd0MB9XP8be3Qe9XdT1SW4laSWQvIeMnoPYD+lU7q6Jzzx3z/X/AArNmlJJz/n/AD6V8ZisVVxU+eq/8l6Hq06caatEdc3BYnnOfx//AF/SqbEvnnjuTTnIVd0h2rTtJiOp6ikW3FtH88nuB0H4mucs2/D1gIYvtLj97KMJnqqev4/yrXGCOCCMkceo7U8qcMNxUkcFR0Paqd7cR6bpsk7L8kKgKo5yegH1JNAFpFEjsDykfLD1PYf1rSWT94Mn+P8ApVW6iW2kkiTOAinnqSRkk0gkw4/66f0q0Qy/HJwv+6f51Y8zbdqfUEVmJJ8o+jCp5X/eRt7/AMxQBpxycr9R/UVM3l3drNZ3SiS2uIzFIjdCCMVlibqfx/UGrCS4br0J/nTTad0D1PAb21exvbi0kOXgkaMn1wcZqCuh+IEIh8YahgYEhWX81Fc/X6HQqe1pxn3Sf3nizjyyaJIPvH6UUkH3z9KKt7ghr/fP1pKV/vn60lUSepeAI9vhO2J/5aTSt/48B/St8DIHvj+dZXhCPyvCuljHWHf+bMa1vTnp/QV+eY+XNiaj/vP8z26KtTj6EkA+bND8lfqKI+FP+e1NlOPwB/lXIajB9wf7hNHcD/dFDfdYf7IWnfx/8C/kKAOa+Ic7xaEfLYqxmjGR+NcDBLFckKwEU3bsrfT0PtXXfEmf/QoogfvT5I+in/GuB69a+sy/AUsVgkqi1u7PqjzK1aVOq3E1CjRnDDB6U8YPWq1rfYAjusvH0D9WX/EVcePADIQ6HkEcg14mNwFXBytPVdH/AF18jspVo1VpuMBKHjpUqMG5Wowc0hUg5U81xGhMKVSySLJEzRyoflZeCD/ntUaSZOG4NSimmKxsXH2XxWBHqDx2euqu2K8PEdxjosvv/tdR3yK4+/s7nT72W0voWhuYjh42/Qg9wexHWtkqHGDWqk1trFpHpuvPseMbbTUMZaEn+F/7yH0/EV7mW5q6NqdXWP5f8D+kclfD83vR3OKoq3qmn3WlXz2l9GEmQAgg5V1PRlPdT61Ur6yMlJXWx57VtGFH1oopiCjtRRQAlLRRQAUUUUAJS0lLQAVu+FvDdxrzvMz/AGXTIWxPdsM8/wBxB/E/6DvU/hLwydXzfagz2+jxNhnXh7hh/BH/AFbt9a7S/vk8qK2too7e0gXZDbxjCRj6dyfzPevEzPNlhv3VLWf5f8H+mdeHwzqe9LYkae10+wXT9Jh+zWKHO0HLyt/fdu59/wAqx7i4JPX8uMf4fWoppyxPPf6//rNVSxbnOB3P+etfHylKcnKTu2emkoqyHO5ZsDk+3+eKr3E8duPmO5+wFRXF3j93bjJ7tVUR4JeQ7mNIYjs87b5ThewrtvDFiLbTldhiSb5z7DsP8+tcjp0P27U7e2/hdsv/ALo5P+feu/nLrC5gTdIB8qj17f59qaV3ZCehK3X6VxPxC1NomtbCFyMYmlI+vyj+Zrs5HWNHd2/doCzN7Dqa8e1e7fUb66u3+9MxI9h2H5V7eRYVVq/tJLSP5vY5MXU5Ycq6ntGqtuuGcfxRK3/jtU92Of8AaU1IJvtNhp8+R+9tUP6CqxP7sn/ZB/KvHa5ZOL6HTe+pYV8H/gRH5ipi+6NefSqbNhifRgakR/kA/D9aALXm9R7f0/8ArVL52Tkd/wDCqDMQ4waRJOF/D/CkBw3xLUf8JIkg/wCWluh/LIrla674jAtd6fJ6xMpP45rkK+7yyXNhKb8vy0PIrq1RksH3z9KKIfvn6UV2PchDH+8frTHOFY+gp7/fb6063iM9zDCOTJIqfmQKq9tWSezabF9n0myhxgx28a4/4CP8ask5P1z/ADol+V8AYCnA+g//AFUzPX/Pb/69fmc588nLvqe+lZWJkPyimSHcSPXA/M04Hr7DFREgNn0y39KkYpOWHu+fwFLGeQT2GfzpnTjuFx+JqO9mEFlPL6AgfyoWomee+PLnzbm0jznG+Q/icD+VcvWn4kl83WJgDkRKsX5Dn9SazK/Q8BT9lhoR8vz1PErS5pthU9pdSWzfL80Z+8h6H/A1XoroqU41IuE1dMhScXdG6nl3MZltzkfxKeqn3/xpACDzWPBNJbyiSFtrDv2I9D6it60miv4yYxsnUZaP+o9RXyOZZTLDfvaWsPxX/A8/vPToYlVPdluRmMN2pFynB5FWAhBwRg07YGFeMdNhijIzmnlAy4IyD7f5/KmhTGfapl5GaL2CxbieDUrFdJ1h9qLzaXhGWt2PY+qHuPx61yWo2Nzpt7LaXsflzxnkA5DDsynuD1BrpGQMCDirbwJrtjHpt26x30IP2K4c/wDkJz/dPY9jz617mVZl7B+yqP3X+H/A7/ecmIoc3vR3OIpBT5opIJpIZ42imjYo6MMFWHUGm19ceaJS0UUAAooooAKSlpKAFro/CHhz+2Ha91AtFo8DYkccNM3/ADzQ/wAz2HvVXwtoMmvX7IXMFjAA91cAfcXsq+rt0A/HtXcapfRCOG1soxBZ26COGFeiL/Unrnuea8XNsz+qx9lS+N/h/wAHt9514bD+0fNLYdqeo+ZtjjRYoYgEiijGFjUdFA/z61iTT56Hj6/5/Oo5ZS2eeKgLBfmfp2HrXxurd2eoSMwA3SHC+nrVWWR7g4X5Y6cVaVsv+XpSsdowOKAIiFjGB17mqlxNjgck8Y/pT7iQ8KvLHoB3rNnnKnbAd0x+XeOxPZf8a7MHgqmLnyQ+b7GVWrGmrs7TwNp7Kk+oTY3SfuYxnoB979cD8K6s1T062XTtPtrNf+WEYQn1bqx/MmrIbNc1RRU2obdC43srmD44vfsuhvEpxJcsIx/u9T+lea/yrpPHl79p1kQKcx2y7f8AgR5P9K5yvtsnw/scLG+8tfv2/A8rEz56j8j1bwzOLjwjpb94lMLfVSR/hVjHO33K/wBRWB8O7jzdFv7TPzQzCQD2Yf4rW855LDuAw/Cvlcwp+yxVSPnf79T0KMuanFjScr9U/UU9W7++fzpnQ47Bv0NNHA57DH5VyFk8p4BqJmxn2z/PNKWzEPY1CT+Z/wD1UkM5vx6u6zs3/uyMv5j/AOtXG13Pi9fM0V26lHV64avs8lnzYVLs2v1/U8vFK1Qkg++fpRSQ/eP0or1HuYIa/wB9vrWr4Sg8/wATaahGVEu8/RQT/Ssp/vt9a6f4cw+Z4heU9IYGP4nA/wAa58bU9nh5z7J/kXSXNNLzPR2JLc9T/wDqpAcsPc5oJ6n/AD/nmkPAPtxX52e4SbsR59eaj7ke4X/GnycADsP/ANdRZwue4GfxNADt3Vvct+XSsrxFOIbaCJiME72/3VGTWpjkL9B+VcR4zvtz3e09Atuv1PLfpXThKLr1o0+7M6s+SDZxbyGaR5X+87Fz+JzSUfSiv0U8MSloooASnxSPFKskTFJFOVYdqbSUNX0YHUafdR6lCRhUuUGWQdCPUe38qlAIOD1rlYpHhlWSFikinKsOxrq7G6j1S2LqAlyg/eR/+zD2/lXyGbZX9XftqK93qu3/AAPyPTw2I5/dluBXIpgGxvVTUwGDg8EUOoI6V4h1AOmc++aGXPThh6dqYh2naTx2qUf/AFqE7A9Q1qyOvWLXkIzq9qn71R1uYgPve7qPzH0rjAQRkHINdtDLJbXEdxA5WRDuVqy/Femxrt1awQLZ3DYmiXpBKeo9lbqPfIr6jJsw5l9XqP0/y/y/4Y8/FUbe+jnaXvRRX0RxBSUtFACVb0rT7nVtRgsbFA08xwN3CqByWY9gByTVX6Ak9AAMk+wr0vSdPHhbR3SYAavdqDcnqYU6iIfzb1PHauHMMbHB0ufq9l/XRG1Gk6srdCa5Nro+mxaTphJt4iWeQ8GeT+J2/wAOwwKw5ZCxPJPr606aQuxJ6moGOBzXwc5yqSc5u7Z7CSirIaxAGT0/nTVUsdz9ew9KEG9tzdOwqQ/r7VIxrcdKp3EmOAMk8ADvUtzKEU/lgd/asS9uTlkU5Y8Ow7f7I/qa7cFgp4upyR26vsY1aqpq7Eu7nJZIzknh3Hf2Ht/Or3g6zF54htg4zFBm4f6L0H54rFru/h5aeXpt7esPmnkEKH/ZXk/qR+VfVYpQy/BSVLTS3zel/XqedTvWqrmOkuDIUAj5mkcIv1J5P5ZNOu5o7WCe4J/dRKz8+g6VIpIBx34rm/Ht55GkJbKcPcvg/wC6OT/SvkMLR+sVYUUt3+H/AAEj06kuSLkcDNK9xNJNIcySMXP402kpeK/Q0ktEeIdL8PrnyfEPkE/LdxNFj/aHzL/I13EnGD6HH4GvJ7O5ayvbe6jOHgkWQfga9butjuWj/wBVKodD7EZH86+Vz+jy1oVV1Vvu/wCHPRwcrxcexXOTx3K4/EUm4E57HDfnwaaW43dxhv6Gmng49yv4HpXhHUSoeGU1Azf5/WnK3zg56ioZWwx+v+f50AU9YTztMuo8Zyhx/OvPRyAa9FmIZWU9CMGvPHXY7Kf4WI/WvqMgn7k4dmn9/wDwxwYxapjofvH6UUQ/fP0or3nuciGv98/Wu4+GUOF1K49SkQP5n/CuHf7zfWvR/h7F5Xh0yY5lndvrjAH8q8vOp8mDku9l+N/0OjCK9VHTD/P86MZZB6nP5Uf0/wA/0oX/AFjH+6APxr4c9cST5iR68fn/APWpuQSD2JLfgOlIx5yOuM/ieBQcAn0Hy/gOtAEdxMttbTTyH5Y0JP16mvK9bnaVoUc/MQZn/wB5j/hXdeLrjFlDaA4a4f5v90cmvN7qbz7qWXszEj2Hb9K+h4foc1V1X0/X+mcONnZKJHSUtFfWnmhRRRQAUUUUAFS2s01vdRy2xPnA4UAZ3Z7Y759KirsPhrbxnUru+kUF7dAkWf4WbOT9cD9a5sXWjQoyqSV0lt36WLpQc5qKLk1vObaGee1ltZJBny3GCDVUH8+mK7W4uLYIY7oKyMeARmsqW20Vn3fvx7KxxXwDTm3KMbI9rZWbOcmB25AzSxOrR4LDeOx7iujVdEjP+od/98k/1qdbzSkHyWUY/wC2Qo9nN9Aujl96/wB5eff9altLhIjJFOgls518ueLruX/EdQfpXTDUrEH5LJfwiWpBrEa8payD6IBVRjUg7pCfK9DBh+HNtJGrjW5NjDcubbnHbPPWpB8N7Tvrc34W4/xraOtdT9mlI79Ki/t9Mf6p/wAxXo/2nj39r8I/5GH1ej2/My/+Fb2X/Qbn/wDAdf8AGkPw2tO2uS/jbj/GtX+3k/55P+YpU11WOFgck+4o/tPHr7X4R/yD2FHt+ZQ0/wAJ2Xhu6TVJb430sIzBEYdoWTs55Ocdh689qzL27NxM0kj5JOck/rXSDWl5HkuT6BlNDarCw+ezYj3QGuPEVa+Jlz1Xd/L9DWEYU1aJyBcZ6rn61GxDthTlR1rrzfWJ+9Yj8YRUUlxpL/fskH0jx/KsPZT7F8yOaHA9KhnlWNCWbAHJJro3j0Vzwkyf7rGkhtdCSVZGR5SpyPOJYA/ToaPZy7BzI4/VrTUrewivZbK5jtZxlLgp8gU+/Yn3rBFez3Wqg28kUpElvOux0PRlI6V49dw/ZrueAEkRuVGfQHj9K+ryKvCVN0lGzX4nm4uDUua5CxwpPXFeu6XZjT9HsbPGGiiG/wD325b9TXmvhqy/tDX7G3YZjMgd/wDdX5j/ACr1OaTdIXbgu36k8CubiGt8FFev6L9TXAw3mNrznxrefatdkRTlLdREPr1NeiSyCGN5JOBGpZvwryCaVp5pZnPzSOXP4mseHqPNVlVfRW+//hvxKxs7RUe42iiivrDzQr0jwvd/bPDVsScy2pNu/wBByv6H9K82rqvh9dbNQurFj8tzHvQf7ac/qM15Wc0PbYWTW8dfu3/A6MLPlqLz0OrfAcjtnP4GoiTt564x+Ip8oxx6fKf6VEzdT9G/xr4xHqCs3GR9aiuDz9RQTgEenH9ailbMQPccUxEEj1xeqLs1CcerZ/Outmf8v8/41y+tLi93f3l/lXuZFO1eUe6/Jo5MWrxTKkH3j9KKWH75+lFfUvc4UMf7zfU16r4Vi8jw5pyHqYgx/Ek15TMM7wOvNexWS+XaW8XQJGq/oK8DiGdqMId3+S/4J2YFe+2XF5NIpPlE92JNIWxGx74/nQ/yqB6CvkT0huQOew5/AcCkI6Kfof5mjpwemcfgKq6pdiy0+4uX/wCWaE/j1/wpgcT4rvjNqF5Ip+WFRbp/vH7x/KuV9PSrl+7FYUc5cgzSf7zf/WqpX3eUUPY4aPd6/wCX4HjYifPNhRRSV6ZgLRRRQAUUUUAFdp8Pm22l97zJ/wCgmuLrr/ADfudRX0aNv0IrzM4V8HP5fmjowv8AFX9dC14r1WWxe28pY237s7xn0rnH8R3x6fZ1+kQq748b97ZdPut/MVyjP1xXxlNvlPUe5sP4h1EjInVf92NR/SopNc1J+t7KPpgf0rILdcjNITViNF9WvWPN3Mef+ehFQvfXDffnlOR3kJqkxHHfNJkevGKALsF/LBMkscrBlYfxGu5LHGeelecM3B5HTNegxtuhQjuoNa0t2TIm3dapa3O8Gk3DoxVjhMg9iasjPP1rK8TNjSSP70q/1q6nwsS3OaEvJwe/Y0+O5lXG2Zx16Oaq556jrSZwOua5izQXUbxVOy7nH0kNTLrOoL0vZvxbNZQI24HpQT7cfWmBtf2/qQwftRPPdQf6U5vEeobc+ZEfrEtYZfnAx+dMdwUPTpTTYj0hrxpdHtpmxueJWOOmcVyus86td/8AXT+grZib/iQWI/6ZKKw9VP8AxMrsn/nof0r28gX7yfp+pyYvZHUfDm1zNf3zDhEECH3blv0H612exGeJ3J/dOJAo/iYA4z7ZOfwrK8LWn2Hw7ZxsMSSg3En1boPyxWiWNeVmeIdXFznHpovlp+Z04eHLTSZkeMLn7NoFxg4eYiIfj1/SvNq6vx/db7i1tFPCKZG+p4H6VydfS5JR9lhVJ7yd/wBP0ODFz5qluwtFFFeucwVPp921hf212n3oJA/1HcflmoKKTSkrPYadtT1a9Cl90RzHIu5T7HkfoapF+hPrk/jwar+Gbo3vhmEE5ltGMLfQcr+h/SpZD8xHY/1/+vX57WouhVlSfRnsxlzxUu4jHB569Py/+tUTnKOPxpGfufY/0NRMxBxntioApTv1rC1fBMbccEita5fBNY98waNvZga9PKpcuKh53/IwxCvTZVg+8fpRRB98/SivsXuecgRd9yi/3pAv5kV6+p+YgdBwK8ksxu1K3HrMv/oVeqxtiRue9fMcRvWkvX9DvwP2n6FwnOxfVv0FDH5s/j+XNRq2ZF/2Vz+ZpQcnn/PevmjvH/XoBj+prlfHFxvSz08Ngzvvk9lHJrqAcgZ78n+debeIr37Vqeo3IPypi1j+p+8f5104Oi69aNNdWZ1Z8kGzFuJfOuJJf7zZH07fpUdJS1+iJJKyPE3CkpaSmIWiikoAWkpaSgBa6r4ftiXUl9Y42/8AHj/jXK10ngNsajep/ets/kwrgzRXwlReRth9KsRnj7/W2X0YfyrkuQB0x6113j/g2R93H6CuRbqR3z6V8RD4T1nuNPAHSkY4Hb1pfpwKRiePp6VYhOM80jED34oJ9s0hJ9vwoENbGG69K7+zO6xtz6xj+VcAxGDycY5rutJO/SrY/wDTMVpS3FIuev1rG8VnGnQg95v5A1sAdefSsLxacW1ovq7H9K0qfCKO5zXfv160LjFAPP0NGTjGMVzli9qDntjijnPpxTSTg4z+VACnAB+7gdKjlOFIPHFO5x3FNk+6ck9PShAdvbDOkaYnqkY/Ws2C1Op+Ihar/wAt7kqfZdxJ/QGtW2GLXS19BH/jU/gK28zU76+bpCCiH/acnP6D9a9fK631ejWrdkvv1t+Jy14884xO3lYFyVGF6AegHSoWPvTZNz3ECAHYWLSEdlAyefc4FUdcuvsWlXM2cME2r9TxXhwpSnKMVvLb77HY5JJvsef63dfbNWupwflL7V+g4FUqQcACiv0WnBU4qEdloeHJ8zuxaKKKsQUUlHegDpvAV35WqTWjH5LqPj/fXkfmMiugul2OV9Dj8D0rz+0uXs7uC6j+/DIJB+Br0fVgrlJojmOZQVPsRkfoa+Uz6hyVo1l9pW+a/wCB+R6OEneDj2M125578/n1qB3xgntSyNn8ePz/APr1VlfOffmvFR0lTUG2uwrJZt6Tj/ZB/IirupSZKn1FUUz5VwT1KY/UV2YF2xFN+a/Myq/AyOD7x+lFEP3z9KK+3e55iJLM7dStz6TJ/wChCvTgdspB7Eg/nXle7ZMH/uuG/I5r1N/9aT2LZ/MV8zxHH+G/X9DuwL+JehajfLSH6D9KepyOO/8AX/8AVVSN8Bz/ALRqZW6CvmT0CPWLwWWl3V03HloSPr2/pXls25La2jb75Bmk/wB5j/hXaeOpi9jaWKHm6mAI/wBkVxV7IJbuZ1+6Wwv0HA/lX0PD9Dmquo+i/P8ApnDjZ2SiQ0UUV9aeaFBoooAKKKKAEpaKKAAVv+BjjXWX+9bSD+R/pXP1t+DG2+JbQf31kT80NcuNXNhqi/uv8jSi7Tj6lzx+uYbM+kjD9K43k967Xx6M2FuwxxN/NTXEn3FfBU9j2HuJyCOtMOcDk0pBJ59fWmnjr1rQQcjP8qQnI6dKU44AoIx1HFACH0+XpXaaAd2jWx/2SOPrXFA8jIycV2Hhlt2kR57Mw/Wrp/ETLY1cdeTXO+Lm5s19Ax/UV0Vcz4sbF1br6Rk/rWlXYUTC78460ZIHtRnB6ZoA5zWBYvQ9aBwAecUD360hySADz60AOyfccVDNkI3U9akxgdcg+9RSd/fihCO/j+T+zh/dRSfwTNbXg+3+zeG7ZiMPcs05+h4X9BWLKrNcQRR/eMJUD3KY/rXYiNYI44I+EiRYl+ijFaury4ZwX2n+S/zaJUb1L9l+Y4OQpAPB61ynjq5K29tbA8uxkb6Dp+tdQa8/8WXH2jW5QDlYgIx/WujJaPtMUpPaOv6fqTi5ctO3cx6KKSvtjyQFLRRQAUUUUAHau90KY3vhKME5ltSYj9Byv6H9K4Kuq+H9xi6vbNj8ssQkA91PP6GvKzmj7XCya3jr/n+B04WXLUXnoOnfBbH1H86pyyc9anv8wzuh6oxX8jWXNJivj1qeiyK9fcEH1FRquIJuekZ/Uio2k3bT1xmrEqbLOQ9MhVHvzzXbgVfEU15oxq/AyrB98/SiiD75+lFfbPc8xEcoyWHrkV6ZZSfadL065HSWBc/7y/Kf5V5o/wB9vrXd+BpxdeH7m1JzLZS+Yo/2H/8Asgfzrxs+o8+GU19l/g9P8jqwcrVLdzWH3PxNSo9RL9z8TQv3h7kV8Yeqcp4muN/iBj1WytiR/vHgfzrlwMAVqahL5rarcE5MtwIgfYc/0rMr7TIqfJhubu/6/U8nFyvOwUUUV7RyhRRRQAdqKKSgBaKKSgBa1PCzBPEumN/02A/MEf1rLq3oz+VrFhJ/duIz/wCPCs60eanKPdMqLs0zpfHSA6OpxwJk/rXBHHcivRfHKf8AEnuh/dkU/k1edEc9D9a/PKXwnty3GHgnnk9qTqcDpTjjB5phBJ/GtCBDknvgd6QDkgZP1oxnH09aU9eOuaAEycZOcV1fhVs6Y4PUSNXJqTtzn9K6jwkc2dwp/hk/mKun8Qnsb3rXK+KjnUo164iX+ZrqfWuR8TNnV2A/hRAfyq6uwRMs57Udu9GefrQOeB2rEoTBznmg+h/OlUc0EAjnP1zQAHGc9frTcbpFUdWYD9ae3UHOeaW0Xdf2q8kNIoH/AH0KAPSNKA/4SWEkZEcTtz7Dj9a3nk2kZzljjA7msXRRu1e9kx9yIKPxb/61bSRh54pCdohbzPcnBAH5msnq0m9Bra6GySiKF5WPyopY15dNIZpZJW+87Fj+Jrv/ABJL5OiXZB5K7B+JrzwV9Nw9StTnU7u33f8ADnDjZe8oi0UUV9EcIUUUd6ACiiigArS8NXP2TxBYSscKZRG30b5f61m0hYp86/eX5h9RzUzgqkXB7PQafK7o63xbH5GovnjcA39DXLXM3BrsvHpEltZ3a9JFzn/eUN/jXAyNuNfnkE0rPoezLcs25yV/E1paiGj0+2V+GkYvj2Ax/WqOlRNNcwIoySTV/wARSBtUaFTlLdRCPqOT+pr2Mnpc+JUv5U3+hy4mVoW7mfB94/Silg++fpRX1b3OBDH+8frW54K1FdO8QwGZsW1yDbzegDdD+Bwaw3++31ppGQR0qatKNWm6ctmrDjJxakuh6tNGYZ5oWGGjcg1G52I7f3VLfpUFjff2npdpfMczOgjmx/z0T5Sfx4P40ag23TrpvSJ/5V+c1aUqU3TlunY9yMlKKkjgZj/xKrUnOZZZJD+gqnV/UVKWOlIRg+Sx/NqoV93lkeXCwX9bs8eu71GFFFJXeYi0UUUAFFFFABRRRQAlPhby7iJ/7sit+RFNprnCMfQZo3A9E8ax7tK1Ef7Jb/x7NeYHpXq3iBfO0657+ZBn80BrycEEA88jPSvziC5W0e69dRpximjvgjmnkjH/ANamnOf5VoQN6cjjimjcHOScelKMYGSOnXNIrjpkZ9PWgBRnjk+xro/B75W9X0YH9K5pSCevPNdD4PbM96PVVNVD4kD2OmrjPEDH+2Lr2Kj9BXZjr+Iridabdq956eYR+laVegolLnsD09aXnjNJnAoODgEisChemCTk0EDPGKMjI6fnQDj73tQAYyRnrz+NWtGQSa1YrxjzQcfTmqj8rjkVoeGV3a7bHrtDPnHopoA9F0BMJeyH+KVVH4D/AOvWnmqGjkJpyZxl3d/1x/SrfmCsHuWtjC8aS7dLjj/56Sj9Oa4uum8by7ns4h0AZz/KuZr7bJYcmEi+93+P/APJxTvVYUUUV6pzhRRRQAUUGigAo7YoooA7DXj5/wAPtPmPLJHH+hK1wiAmu9nBf4XqSDwkmPfElcXbR+1fBYhcuIqL+8/zPXi7wi/I2vDgFoZ76QAraw7gD3cnCj86xyWZiznLMSSfUnrWlfv9n06K0H3pX86X6AYUfzNZtfT5Ph/Z0PaPeX5dP8zgxM7yt2JIPvn6UUQ/fP0or03uYIY33m+tJSv99vrSVaEdP4EuwL2bTpD8l0N0f/XQD+o/lW7q2RpV8p4IibjNeexSyQTRzQMVljYOhHYg5FelatJHf6Gb+3wIru3L7cdGxyPwINfJ5/heSosQtpaP1X+a/I9LB1LxcH0KWpaUt58JbXUI1zPp1ydxH/PN8Aj8yDXAV7T8O4F1fwDrOlMMmWJgo9ypA/UCvE0bja5w44YHqD3r08kq89Fwf2X+f9M58VG0r9x9H0oor2TlCikpaACkpaKACikpaADtSMMqR7UtFAHpQJn0q1Y8+Zap+qYryhEBIXoBxXqejP5vh7TGzn9wq/kSK8zuE8q/uI/7sjD9TX55XXJWqR7N/mezf92n5EZiTuPzNROY0kVWUAMCQ3bjtU/+elZ15DMzsPP4kYeWuPuY5JrBO/UwTberLTeVGgdgqr24605CCobYVyM4IwRVK3tpYCJiftHHCtkFfcZ71djcSIHAYA9mGCKGJjZsbSQORWn4PbF/cD1j/rWZJyh5xV/wo2NVYf3oz/StqW5rT+E7FAdw+orgtRffqF0x7ytz+Nd9H98fUV57P89xJ6Fyevua2q9C4kowFAA6U2ZikTuE3FRnFO71XvUBMcu5t6Haqj+ImuJbmC1ZOhSRWIAKjvimoYZd2wBgOpA4/OqMensoBEhfacGNyQrf/WrQhcSLwpQqcFCMbab02G9NhGiQqRjH0NaHhJf+JvIxxlIG/DoKpHpWl4T/ANbqEnGViC/mf/rVcG7Mum29ztbRsafbevl5P5mkWSRhuxhSSAc9ccU6AYtbcHr5S/yqSURrDGseeMs2fUnP+FRprfc37HKeKH3X8YJ6R/1rIrS8QnOpkZ6IBWZX3uXLlwtNeSPHru9SQtFFFdpkFFFJQAtFFFACVJBBJdXENtAMzTusSD/aY4H86jPA5rrfhRYjUvHmm8bo7YtcOQMgbRx+pFZ1qnsqcqj6K5UVzNI7T4mWMOmeHv7PtgBFbWCwrj2PX6k815lpNsJJ1L8RoN7t2AHWvUPi9MHW/Uf3Ej/HIrzi/AsdGWMArNeHnnog6/mcCvhcJSliq3J3ev6nq1ZKnG/YyLqc3NxJMf4zkD0HYVFRRX3sYqKUVsjyW76kkH3z9KKIeHPPaik9wQx/vt9aSlb75+tNqhC12fga7+06ZqOjyH5gjXEGfphwP0P51xlXNGv20rVrS+XkQSBmH95OjD8ia5MdhliaEqXV7evQ0oz9nNSPTPhDqQs7rZIcRSLsb29P1/nXXeJNN028u5PtFlazkMcl4QT+fWvMNIkXTfEE8KNmISsFb1Uncp/IivTElE0KSKcgivh4zlHWLsz1Wk9zlL/wzoqrldMt0P8Aslh/Ws3/AIRnR3GTZMPpMwrrb4cGsoff5roWNxC2qP72Q6UOyMYeE9FY48m5H0nP+FI3g3SMcLef9/8A/wCtXQL7Gg++fzqv7QxS/wCXjF7Gn2ObbwdpY6G9/wC/g/wpp8IaWO97/wB/B/hXSHGOlMOPSj+0sV/z8Y/YU+xgJ4Q0ruLw/wDbbH9KlHhPRV6xXR+s5/wraXrwKeD71LzHFP8A5eMfsafYyU8LaKi5Nkzf70zGpP7E0qBQY9NtQfUqW/nWqOBxxTb1o3wYRhduPx7596zeMxEt6j+9j9lBbJGe6hIFREVEXIVFUADnsK8u11PK129wOPNJ/PmvVJh+7U+5rgPEOjyXWsTTRS7VcL8uwnnFc17zdzS142OdLr6mmM6ZDEZI4Bx61q/2AD967YfRKd/YEGMPczn6ACqUEZeyRjeaoGADgfhSGdRn6etbg0Kyxy87fV8U9dE08cGNz9ZDT5Yj9nE51pty/KKv+Fj/AMTpNv8AcbOOwrXi0WwdwqWyZPdiT/WtK20uK1YGFY41zkhEwTj3qo2RSSWxeXIJI/zxXnLNh2zwdxBH416OVyD71Ql0iCZt0iRuT3aPmrqNN6MIo4sS9iBThMMZA7+tdI2l2BJBto+vbIph0fTzx5JH0c1jZdg5F2Of8wY6H60vmLxW2dEsiPl85fpJTG0G2PSecenINLliL2cTGZl25GTxWx4XXZpuoynOSyqPwBP9ahk0BTxHdSk+mwGtSwsW0/RpYmcu7yFiSMegAxVJJbAoqOx02NqIM9FX+QpjU6T5ZCO1N9vWsTUkh0HT763W4u4HaZiQWWUrwDgcUDwppDdEuh9J/wD61amnjFhBx1XP61ZH1rpjj8TBcsajSXmR7Gm9WjCPg/S+32wf9tR/hQPB2ln+K9/7+D/CugA9RUi49Kv+1MX/AM/GL6vS/lOfXwZpR6/bT/21H+FSf8Ibow6reH6z/wD1q3hj0p4zj0pPM8X/AM/GNYel/KYcPhDQyQDbzt/vTmtCLwfoC8/2duP+1M5/rWjD+dXohx6VLzDFPepL72Hsaa+yjOh8NaHDgx6RZ5HcqW/ma6vQJbTT4J2jjhhRE+5GgXJzwOKyj0qGaQRRu7dFGazlXqVPjk36tsfJFbI5Pxk7X9ykJOXnuFB59yT+WK8+1u8F7qUskZ/cp+7iH+yOB+fJ/Gum8TX5RpZFb94EZE9mfjP4DdXFAYAAr6Ph/D2hKu+ui/U4cbPVQQtJS0V9GcJJB98/SiiD75+lFS9xoY332+tJSv8AfP1pKoQUUUUAbNtcF4LaYn5kAgc+hX7p/wC+f/Qa9U8KzPdaKsrqwBcqCR1x1x+NeKI7ISUYrnrg1esNb1SwXbZahcxJ/cD5X8jXz+KyR1KkqlOSV3e35/1Y7IYpRik0ezXw/dkk4rH6ueK4A+MNeIw19uH+1Gv+FMHirVs5M0RPvEK5P7DxHdfe/wDI0+tQ8z0ccd6XcMdf0rzoeLtWH8dv/wB+RS/8Jfqvf7Mf+2VQ8jxPdff/AMAf1qB6EWHv+VMLD/IrgP8AhLtTx0tf+/VIfFup+lr/AN+qX9h4ry+//gD+tUz0AHJwD+lO6da86Pi/Uxx5lsv/AGyFA8TazMf3cuf+ucAP9Kf9g4nuvvf+QfW4eZ6QpyM8fjxUc3KEgV5+up+JphiP7c3+7bEf0oeHxVccPFqjD3BX/Cj+xJr46kV/XyD60nsmdvLgREHGQ3TvjHXFY0hAlaofB2j6pBfXR1C0uIo5Yh+8lIOWB4HXPc1pXml3ayMViJz6V5eNoLD1uSMubRao6KU3OF2rGf5UJJJiTJ68UCKEHiJPyqYafe/8+7/lT49MvS3MLD61z3LIAkfZE/75FLtXsq/lV+PR7s4ymPxqwmi3HcAfjRcDLwOwH5UY4rbGiTdytO/sR8dRSAwQOKTHtW9/Yz46ioJNJkHcUDMdgM9B+VMIX+6v5VensZI+1Z9xvjOGUigAZY+6J+VNMcJ/5Zp+VQNIfemGYAd6ALQSJTlUUHpwKqahgqir0LL0+tAnHYmp7SD7XMg3AbSG59qqLJaLFwxUyNjOCaXa8e5ZMb1646UvEhO/7rHnFTXMiSTM4GFJ6e1T0KNS0G2yt8n+AVOozzx+dcDPq+vWrMrG4jiU4UNb8be3OKiTxXqinHnwk+jRCva/sDEyV4yj97/yOX67BaNM9GU46n9KkVh7/lXnQ8W6qOptj/2xH+NOHi/VB2tf+/X/ANep/sDFd19//AH9dp+Z6MGHr+lLnPf9K85/4THVfS0/79f/AF6P+Ey1fsbUf9sR/jR/YGK7r7/+AH12n5np0C+mDV1Dgc15IPGetD7stsPpAKD4017tdxr9IVprh/E94/e/8hfXafZnr7VgeK7/AOx2oRvlDDeT6ivOpfF+vyAg6lIo/wBhVX+lZNxe3dzKZLm6nlc/xO5Nbw4eqv45pel3/kQ8bHoifVrhp5lBPT5j9T/9aqNHU0lfS4egsPSjSj0Rwzm5ycmLRRRWxBJB98/SiiH75+lFS9xjH++31pKV/vt9aSqEBooooAKSlooASlorq/BPg+TxCkt5dSvb6XC2wsg+eZ+6pngY7selZ1q0KMHOo7JFRi5OyOT/AIlUAljwAOSfoK2rXwzqs0YlngWygbpJeP5efov3j+VemW2mWul/u9ItIrTPG9fmlb6yHn8sV5z4r8bx2mozWulRxTyxErJczZcFh1Cjv9TXhVc7lN8tCP3/AOX/AATsp4NyaTepYi8O2UZxLc3d4/8Adt4xEn/fTZP6VoQaLCP9TpFso/vXDvMfY8kD9K5DSPiRqNpcj7fb217bE/MqoIpAP9lhx+Yr1Dw94i0rxFbPLpU+Xj/1sEi7ZIs/3l7g+o4rzcRjMZ9uTXpp+R1PCKlvEpWtrNAMiO3iXGGEUCLt9+laKNOFUPPIAOjKcD9KszDHOSMcZ9PY+oqEZBwMKx6jsfpXmznKesncpJLYfukOPMkkz2YMSKcckDf849RTU4OF+U/3W6GlGAe8Z/SsrFE1oyrMp3/L3Bq99pQ5yazG3bclQf8AaFRhqQzW+0R80ouEzWUCc04E5FAzT+0JxQbhazs807PFAGgbhaabgYqlmgk4oAtGcYqF5s1FnrTSaBDZfm7VSntUfqKttWP4n1610CwNxc4eZ8iGAHBkYDn6KO5p2C5k+J73S9AtVm1CQh5M+VDHy8n0HYe54rzTUPiFcKzta2FvHEOgkYux/kK5rxDrF3rGpS3d7KZJ5Op6BR2VR2A9KxLpv3RHqRXoUsNFK89WddOgrXkenaD49tbpkXVbY2wf/lrEdwH1HX8q9EsbZJViu7WdJoD8yuhyGFfNlsSIF/Gu6+F2p30XiW2soZ3FrMH86I8qwCk5x2PFRXw0Yx5oE1aSirxPWSc84qOQ/IfpinE9+lNfHG4gDIBJ7DNcKOdnWQs6oF3tgAA4PXjoKJra3uRi5treb2eJT+HSliKyHMTo4/2GDYH4d6m2sv3lK+x4/ClGcoO8XYbSe5jXHhXRbnObLyT/AHreQp+nIrKu/ACNk6fqJU9kuY+P++l/wrsoxmrUa13Us1xdLabfrr+ZlLD05dDyLUvCutaepeSyaeEdZbY+av6cj8qwwQSR3HUdxX0DGhDAqSD6g1S1XQ9O1Zf+JjZRTPj/AFq/JKPow5/PNevh+IeleHzX+T/zOWeC/kZ4XS13GufD66hDS6HKb1Bz9mkwsw/3ez/ofauIdWSR0dWSRDtZGBDKfQg8g19Bh8TSxMealK5xTpyg7SQlFFFbkCUtFFABSUtFAEkP3z9KKSH75+lFS9xjX++31pKV/vn60lUIKKKSgApaSnKrOyrGpd2IVVHVieABQBf0HSLvXdVh0+wAEsnLSN92JB9529h+p4r3ywtLew0220+xUraW0flx56t6sfcnmsfwr4fj8M6V9lOH1CbD3ko5y3aMf7K/qcmtyM18fmmP+sz5IfCvxff/ACPSw9HkV3uzl/Ft1/Zmh6pe52mC2kcH0ODj9SK+YLRX+x+c5O5yMk/jX0V8bFnX4e601rGXYRoZAvUR7xuP5V8/xyCe2ULlUbMYRgQyt1XP15ArjwrtNHbQdqiuVS1XvD2s3ehaxDf6e8aTgGLMq7kKtwQw7jv+FZjNS2sZub21gHJlmjjx9WArvqRUotM7qqUotHuU2oeONMy9/oemaxbrjL6XcFJdp9EfqKsaF4t0jWbhrSCWS2v1+/YXqGGZT7A9fwrsLmLa7KgwF+UccAdPy/lXP+I/Dmna/AItZsVuRHykmSs0B9UccivGujzUaQz0xvA7HqKcvIwpDD+61cOV8R+EF3Dz/Enh9Ocj/j+tV/8Aaqj866jQta07X7AXmlXUd1B0Ypw8Z9HXqp+tS0NF9toXgMp9Oxpi9akJJQ4cMvoetRj+lQMcOtOHWmilHWgY+nUynUAOo7UUHpQAg6Uw9af2qM0xDT16gepPavDfiXrg16WzvksWj0pWms7S5duZ3UgswXsB0z3r2u/z9hu8dfJk/wDQTXDeGfD2neI/hdo1jqSP5YRnjkiba8T7m+ZT/MHg1cdNSWeGscsTVa84iA9TXW+M/A+r+FVafb/aGmD7t3EuNv8A10X+E+/Q+tcXcXCzRqACDnNepTmpq6PRhNTVy1AP3KfSuz+FClvGCsP+WdrM/wCgH9a4aG4eRooLeFpJmwqIo3Fj7Acmvavh34Ln8PWMuqauWGrXKCMQA8QRk5Ib1Y4GfTp1zWeJqKMGurIrTSVup1RR5JUjjIBOeT6AZpogivCltcIHinIjkQnhlPUVNFKInL4BbaVHtnvTNNbzNXtF6jzMn8ATXlnIDfDrw11t7a7tPQ215ImPfqaRfBV9af8AIG8X65Z46JOVuEH1zzXYL/k1Ig5pczHZHIovxC0w5U6F4ghHUHNrKf6E1bsfiBZQXcdl4o06/wDDl65wv21Mwuf9mQcV1sQp91aW9/ZyWd/bw3VrIMPDMoZT+B/nRdPdBYtwlXjR0ZXjYZV0IYEeoPerAHHNednw/q3gtpLvwWXvtIzvn0OdyzKO7QMefw6/WteT4g6GvhKXXoZGlSNhF9jyFmEx6RsO3Q/N0wD9Kai38Oor9DpdRuLOyhWXULq3tYmbarzSBAx9BnrWXrHhuz8WQyJOCt/Gm+G+iGX2jsw/jX9fQ14npkOq/E3x1BBdzqs9wGy23MdpAByEU+mQB6k819W6RptvpFhDbW4O2NFQu33n2jAJ/Ku1RnhJRnCVpDxFJJKMtbny9rekXmiag1nqCBZANyOhykqdnQ9x/LoaoCvpDx/4XtvE+hyQwhU1CImW1fph8cqfZuh/OvnAqysyOpR1JVlbqpBwQa+vy/GrF0+Z/Etzxq1L2crdBKKKK7zEKO9FFAEkH3z9KKSH7x+lFS9xoa/3z9aSlb77fWk71QgpKUUUAFafha4jtPFGj3M4zFFdxs303CsuhshSVPzDkfUVMo8yce407O59J6ihju5c9GJYH1B71DGeazodbjOn2U90rPaXEKSq6ctESBnHqM5yPyq9GUaIXEU0ctr1M0ZyoHfP936Gvzt6Nxe6PZ8zi/inqc7f2f4d0s51DUmAkA/hiJxg+mcEn/ZU+teDeNfCfiDwzqF7Lcxvf6XI+Fu41wpUfdbj7jD0PHvXt/w/hGva/wCIfFUylw8ptbInnagA3Ef8BCj8TXWRMEdh68EdiPQ1afLsI+P47yJwAz4f0Ixmu4+DmgyeI/G9jKFzpunSC6upf4Rt5VM+pbHFepeJND+Hq3ZuNU0bTmuidzRxBhvPuikD+VUpvG62lotn4f0y3sbRPuKECqPfavGfrXp0qeJxMLQhv12RpPGqMeWT1PV5mt0yQAW61h6jqNnD9+WJMdMsAfw/wryK+17VL4n7ReylT/Cp2j9KzWJYksSx9Sc1008gm/4k0vRX/wAjheMXRHqUmv6bG5Y30KsO6HP6VyGvx6JPfnV9C1FtG8QDn7VbxExXH+zMg4YH16/Wubx7UtdcchoreT/D/IzeLn0SOz8L+NBqd3DpetWi2WsSZ8tozugucDJMbev+yea65RXkMMskEqSQuySI25WHVT6ir39u6r/0EJ/zFclbh+Tl+6mreZpDGK3vI9RA5pcc15b/AG7qv/P/AD/mKX+39W7ahP8Ap/hWP+r1f+dfj/kX9dh2Z6nTu1eWDxBq/wD0EJv0/wAKX/hItX/5/wCT8hS/1fxH80fx/wAh/XYdmep0dq8t/wCEj1j/AJ/pPyFIfEern/l/k/IUf6v4j+aP4/5C+uw7M9R7Uw5ry86/qx66hN+GP8KibV9Sf71/cfg2KtcP1us1+P8AkL65HsenXak2twMHmJ//AEE1y/wvOfh/pB44Vx+TtXEXGqXMB1i5uLq4eKIIQrSEglowFUfVvzpunpLaafbWxkcGKNVIDEAHv+uazoZPKrJw59vLs2u/WzY5YlRV7HsBZQpyy4IwQSMEe9cvf+CvCN7M0tzpNgJGOWMbmPP1CkCuMJJ5LN+dN+Xuf1rrXD1v+Xn4f8Ez+u/3fxPQ9F0TQNDYtpFlYWkhGDImC5/4ESTVrUJIzbHY6N8w+6QfWvMsp6j866LwqFNlespH+sQcH2JrmxuSrDUZVue9rdPO3c0pYrnko2NKU02xvILLUobi7cxwruBbGcEjApJGAJrJ1YNJDsiR3JYHCKWP5CvLwlFV60aUtmzepNwi5I9FsdRsbzH2W7gkPoGwfyNaccZGMjFeO22havdkfZtIv5T2K27fzxXVaJ4d8ew4+x2t1Cn926lQL+TGvUxOSU6esKyX+Ky/H/gGEMW3vH7jv0FWEFR6DpXiFkA1tNMi/wBqCVmb8RjH610EWlW6j95LI5/2QFFeFUpunLlbT9Hc7FJNXMpOMH9a8n+Ivg7UvE/jmKHwzou1hAr3t837qB5GPBZuhYL12gk5r3aOK0txlYkz/ef5j+tRXesW0CnzZ1AA6Z6VdKTpy5kNT5Xc5/4ZeAbHwPayymb7bq9woWe5xtVVHOxB2XP4nv2A667u0jQvKwVR61xWreOrS3DLA29vauN1LxTcXzEySYT0zxVycqjvIic+Z3e5315r4adzExHGxMHueM15p8VNJSC+t9ZgAVdQLJOg7TqBlh/vDn6g1rWQ+zJFfaxKbO1J3IHGZZvaNOp/3jgVi/EXWG1W00vbH5FuryNFDnJA4GWPdjXp5RKUcVFR2d7/AHXOXE2dN3OJooor7E80KKKKAHwffP0opYPvH6UVL3KQx/vt9aSlf75+tJVEhRR2ooASloooA9T8Ky/bfAdn3a2eS3PsAcj9DUVrPNayF7eRo2I2ttPDD0I6Eexql8L5/N03WbFjypS4UfXKn+lW5F2TOPevgc0p+yxc153+/U9nDy5qaN3Q9ZtNPtUtG0yKC2Ulh9iHl4JOSdh45PpiuZ8TQ67qc0n9mXto9ox+WCGTyZSP9oPjJ+hqzmkYAjnkVjhsVLDz50k/VXKnSU1bY4K70fU7Nm+1addxHqWaIkfmOKzw65wGGa9OjnmgGIZpIx6KxA/Kmzzmcf6VFbXPb99Aj/rjNe9T4iX/AC8p/c/6/M5JYH+VnmtFd5LYaVJnzNJtR7ws8X8jiqsmi6M3/LteRf7lzn/0Ja7IZ9hZb3Xy/wAmZPB1FtY4ylrqn8P6UT8t1qMf+8kbf4GoT4csj93VJU9pLT/Bq3jnGDl9v8H/AJEPC1V0OboroP8AhHIz9zV4P+B28i1GfDrbsJqmnE+5df8A2WtVmeEf/LxE/V6n8ph0elbZ8NXOMre6Yw/6+MfzFM/4Ry+P3ZtOb6XaVax+Gf8Ay8j96F7Gp/KzHpK2T4a1MchLZh6rcxn+tN/4RzVu1qrf7s8Z/wDZqtYug9qkfvRPsp9mZFLXQR+DdckjV0tYDuGdv2qLcPqN3FMfwh4gTn+y5W90kRv5NQsXQe0196D2c10ZhUVpv4f1lD82l3fHXCZ/lUD6VqKff069H/bB/wDCtVUhLZr7yXFroZU1lBNdxXEisZI8YG47CR90lehIycHtXaeBvCJ8RPNdXkz2+lW7bHkT78r9di54HHU1zD21ynBtbgN0AMTDJ/KvTZNQXQNDs9IhGBbpmQ9N0h5Yn8Tj8K8rNMUsFS/c6Sm/+HZ04en7WXvbI6Cy8M+FbVAqaRbzEfx3DtIT9cnFX00vw8BgaLpQ/wC2ArzWTxTMp/1ige5pn/CUynP7xfzFfJPFV5O8pv72ej7OC6I9STT/AA+Pu6PpX/gOtcn8Q2srZLBNPtrW2Vt5cW8YTd0AzjrXMN4ol6mVc49fSq17qLajEjOwbYxAI+gqXVqSVpSb+Y1GK2QxU862muDI26OVYwnYgqST+grp/hhfR2Ws6hLK+wfZVUH6v/8AWrlEm2W7wgDDMGP1FFj9r8+Q2cM0pKgN5aFsc8ZxSA9rl8T2qjmdj+NUp/F9mncmvLGt9XcfNbSID0Mjqg/U1VltrgZFxe6fDjqHugT+S5oUUFz0u68dwJny0z9TWLe/EKbBEYVa4SSOyX/XayjH+7BbO+foTgVXkuNGjGfL1O7PozpCp/IE1SiibnQal43vpQcS7RnFYX9pavrEvl2EdzdMTyYkL4+p6D8apSa1HCc2OkadC2c75VNwwPsXOP0qteazqeoJ5d5f3Dw/88lbZGP+ALgfpVpEs3BYrasDrep21o46wxH7TP8ATah2r+LVPF4ggs+NDsfKkH/L5eETTD3VfuIfoCfeuUiUKAFAHsKuQdeef6U7CNhZprq5e4uppJ53OWkkYsx/E0/xWcf2ZGf4YGb82/8ArVDZDkU7xa2dWjTtHbxr+mf6162TRvib9k/8jDEv3DG7UUUV9YeeFFFFAEkH3z9KKIfvn6UVL3KQx/vn60lK/wB5vrSVRIUUUUABooooA6r4ZXPk+K0gJwt3BJCfc43D9RXUakmy7bjrXnGjXn9naxYXuSBbzpISPQHn9M16p4kjVbrfGQUY5Vh0IPIP5V8lxDS5a0andfl/w56WCleLiZYNKaaKU9K+fO4YaYf8/wCf6U9qYf8A63+f8KQDG/l+n+FRt3//AFf/AF6kPX6VGfSmIjb0HHt/+qom61KfzxUR74/z+VAEb8Hn9aYScYz/ADp/fjj6Uxuv+f60wG/57UE5/wDrE0Z7D9D/AIUhH979R/jQAhUdwPxAo2r2Vfwx/hS59P0xQAT1/kaAE2A/wjHuDSbEHRFH0ApxP5fQUnXpj/P4UAJnZ93Kn1GBSrcTqcpPOp/2ZG/xpjnkjvUb+4/MUWAsf2lfA8X10Mf9NmH9aRtW1D/n8nP+8S386qk+/wCv+FRt+P5f40AWjq1+Ot0x/wB5UP8ASmtq94eDOh+saf8AxNVCcd/1AqMt7/8AjxpiL41i+HAnUfSNP/iabPcz3UKNcSmRgzAEgDA49BVIt7/+PmpwwFun1JpiE61DJI6uQjsoI5CtjP8AjT9469vWoZTl+vYVSJIXUE4IB9iP6GomwBx0H+fwqVvT9Mf0/wAKhc98/r/WqERSf/XP+f6iq8h6/wCf8/Wpn/z2/wD1VXlPWqQitIeaclMY5NSRiqETJ71ct+3GKrwxM2COladpHGiksctTEX9OiLOuQeSKreKW3eIb0dkZU/JQK1dJIlvYEUcFwKwdYk87V76QHO6dz+te3kUb1Zy8v1/4BzYp+6kVKKSlr6Y4QooooAkg++fpRRB98/Sipe5SGN98/WkpX++31pKokKKKKACkopaAErsPD/iATWEWmX74kiG23lY8FeyE+o7H8K4+lIyMHpXNi8JTxdP2dT/hjSlUdOXMj0leODTq4zS9entAsdwDcQDgZPzqPY9/oa6mwv7W+XNtKGbuh4YfhXxeMyyvhHeSvHuv17Hq0sRCptuTmmGpGqM15xsMPHtio2+n4f8A1qkPHt+mP8KYw7f5/wA/WmBE3Oe/6/8A1qibke351K3TNRP/AJP/AOugCMn/AD/+qmHj2PvgU9+ff9aYT6fof8KAGnJ65x75NIcDp+mKU8D3+mP50nU9/wDP0pgA59T+dI3vx9QKG9xx7igcnjH4GgAHPT9DSnPvj3BoJP4e4NN/zximBG3U/wBCajbA9B+GP50+TkkdfwJqM8H0/IUhCMffP4n+lRnr0P5D+tOY575/E0zHPT/x0UxjGb3x/wACxTS3v/48aczY/ix/wMU3d/tf+PUCELf7X/j5qx5iQ2qzSIsrA7I42Pys5PG7H8IAJI79KgLf7X/j9LdJ51rHGTg/eB685NUtxGv+6OnzTy6xcI8QAyGCqWP8Kxgbfw9KwBL5wMmFUnghOFJ9QPQ+lVry1nuorWEGOCKFSHdXLGRieW29jjAqdI1hj8tOgwBz/nNaPYkRu4x+GP6f4VC3r/X/AD+tTN3H6Y/p/hULH9fxz/jSQiFgc8fT/P8AhULRE/T/AD/n2qZ3/wA9agllPOKtCGGELyxpVKg8VWLlj1qVKaEWllO0KOKtW7E4z0qrBGztjge5rc023jjIYjc3940xF9La5stBuNVDCLYyRxAj5mLHGfbArmP8811fia9MukWlhArsfM86XCnjAwo/UmuY8iXvE/5V9Xk9NU8PzPeTv8uhwYh3nbsRUtSeRL/zzb8aRoZVBYxtgd8Zr1VJPRMwsxlFFBpiJIfvn6UUkH3z9KKl7jQOPnP1pMVI4+ZvrSYp3EMx6UYp+KMUXGMxRin4oxRcBmKMU/FGKLiGYoxggjII6EcEU/FGKLgX7bWr+3AUTeYg7Sjd+vWtGHxIDxcWpHqY2/oa5/FGK4a2XYWtrOCv5afkbRr1IbM6uPW7GTrI8Z/2lI/X+tTpeWsmPLuIm/4F/SuNxSbRXnzyDDv4JNfc/wBDZY2a3R2xIYZVgfcHP61G4I5x+P8A+uuOAx0JH0NSLNMpys0g/wCBGuaXDr+zU/D/AIJosd3idQw7n8z/AImozyfX9a54XdyDkTvn3Oaf9vuu8pb6gVi+H63Sa/H/ACKWNh2ZuH/PSgjjof1NYn9oXI/jX8FxThqM46iM+5Ws3kOJXVfe/wDIpYyn5mvxnjH4ECnE/X9ayBqc/dUP6Uf2nJ/zyT8zUvI8Uui+8f1umav+e39aMgdD+v8AgKyxqb/88l/Cnf2of+eRP1eoeTYtfZ/FD+tUu5ck+8f8D/Wozx7fiBVJtQZiT5SD8SaBfHun5HFN5Li/5V96BYun3LJOe+fxJpuMfw/+OimWs63F1DC4ZBI4QuWztz3xVm6tGt5GUlDtOPu1xYnCVcK0qqtc1p1Y1FeJWY++P+BAU3d/tf8Aj9Kd+cZH8qblsZzkfWucsXd/tf8Aj4qWQfJF/uf1qEluOf1pGLkclSMdxTEPzxzULdX9z+f+NB3AHBA/DNMOehbj0A4q0SMfv6D9P8KhkOM5/HP9f8akZc9Sx/GmMqjoBTEVnOScZJ/z/nNQNGzdsA+tXHYCq0sqqDyOn8jVoRAU24JOecGpo8Cq7Sh2ZVBYE8YFXILKdgDJiJPV+P061cISm+WKuyW0tWS27hcFjjvWrFc+Siu6nB5VTwW/wHvVFEih5jHmP/fcdPoP8aGJZizEsx6knmvbweTybU8Rou3+f9fcctTEJaQKV5YwXl1Lc3QleaVtzHzmA/AZ4FQHRbA9YZD/ANtn/wAa08UYr2vqWH/59r7kc3tZ92Zn9i6d/wA+oP1dj/WpLfR7K3drmAPaGIZMscrD6AjODn0q7PJFbRCS5YqG+4i8vJ9B/X+dQhZbllkukEaJzHbg8L7t6n/PtXLWo0JN0aNNc3ey93zb79luaRlNe9Ju35kpO/DAY3AE5GOaMU8+vejFelBcsVG+xg3d3FhHzn6UU6EfOfpRSbGhWHzn60mKlcfM31puKdxDMUYp+KMUXAZijFPxRigBmKMU/FGKAGYoxT8UY9qLgMxRipMUmKAGYoxT8e1GKAGYoxT8UYoAZijFPxRii4DMUYp+KMUXAZijFPxRigBmKMU/FLigCPFGKkxSYoAZgjBU4Ycg+9dDc3CX0AuYyAxH7xe6t3/OsLFKjNG25CVb1FcGYYGONglezWzNqFZ0nfoTStgnNRGYZNOMgf8A1kMbH1GVP6VGY7cnmB/wmNfOyyTFJ6WfzO763TYvnAH8c00zgYzSG3tT/wAsJP8Av+1J9ntc822frK3+NCyXFdl94vrVMablRmoJLxAOWX86siC2HSzg/wCBAt/WnqqJ9yC3Q+qxCto5HiHu1+P+RLxcPMzTeBuEBY/7IzTljvZhmO2lx6sNo/WtTzpeRvYA/wB3j+VRtluWJY+5zXTDIX9uf3L/AIJm8X2Rn/2fcN/rp4Y/YNuP6VImnWqHMjSzt7/KP8at4oxXdSyfDQ+K79X/AJWMpYmb20EjIiGII0iHqo5/OmnJOSSSe5p+PajFejTpwpLlgkl5GDk5atjMUYqRVLMAoJY9ABVS7v7a1lEOWubo9LeD5m/E9BSq1oUlebsOMHLYsKhOSMYAySTgAepPaqRvvNdo9MjW4deGncYiQ+3qf84pDaXN/tOpsI4AcraQnge7Huf85q+kaxoqRqFRRgKowBXP+9xG/uR/8mf+X5+hfuw83+BUtrQRStNLI09033pn6/QDsKs4p+KMV006cKUeWCsjOUnJ3YzFGKfijFWIWEfMfpRT4R85+lFSxoVx8x+tJipWHzH60mKLgR4oxUmKMUXAjxRipMUYoAjxRj2qTFGKLgR4oxUmKMcUXAjxRipMUYouBHijFSYoxRcCPFGKk20YouBHijFSbaMUXAjx7UYqTFGKLgR4oxUm2jFAEeKMVJijbRcCPFGKkxRii4EeOKMVJijFFwI8UAVJilxRcCLFGKkxRigCPHNGKkxRii4EZFGPapljZslVJA6kdqzL/W9J08lbzUbdHH/LNW8x/wAlzUTqwpq83b1KUW9i7ijFcvJ46077SkdtZ3s8ZOGkwq4HqF5J/SmXnjqzEpg0uyubyfOAGG3/AMdXLfyrleY4Zfa/M09hPsdXjkADJPQVWv762sCEuZC07fdt4hukP4dv88VVjOsajChcLpEDqCyL8059if4au2GnW1gp+zR4dvvSsdzt9T/hT9pWrfw1yru9/kv8/uFyxj8WpSMeo6gCLhv7OtG6wxHMrj/abt/nirtnZ29nGUtYljU9T1Zvqepq1toxWtLDwpvm3l3er/r0JlNy06EeKMVJtoxW9yCPFGKkxRii4EeKMVJijFFwCEfMfpRUkI+b8KKlsYrD5j9aTFTuvzH60m2lcCHFGKm20badwIcUYqbbRtouBDto21NtpNtFwIsUYqbbRtouMhxRipttG2i4iHFGKm20bfai4EOKMVNto20XGQ7aNtS7aXbRcRDijbU22jbRcZDto21NtpNtFxEWKNtS7aNvNFxkWKMVLtpdtFxEO2jFTbaNtFwIcUYqXbS7eKLgQ7aMVNto20XAhxXPeOddfw9oqT24i+1XEwgiaUZVOMs5HfA/nXT7a8n+Nt2Tf6TYj7sULTt/vM2B+i1xY+s6VBuLs9jWjHmmkznptbvdURzquszSgHG3kA/RBgVT+2WkHEEDyH1dto/IVio2C1KZPevlG3J3Z6NrHonh3whqWvabBfXOqJZWU4JSK3j+cqDjnoB0PrXp1hZwafax29lEsMSKF+QAFsDqxHUnqSa5f4dalZ2vgOyk1C9trdVklRfMkAOA3HHXue1S3/j7SLfK2cVzev2Kr5afm3P6V9FhZ4XDU1NuzaV+rOKoqk5NdDqcU4RsV3AHb69vzrzG/wDH+rT5FnDbWS+qr5jfm3+Fc3qGp6hqLbr+9ubg+kjnH5dKVTOKa+CLf4BHDN7s9ev9e0ewyLrUrZXHVI28xvyXNYF38QNNiJFpaXdz/tNiJf6mvNAoHAAA9qdiuGpm1eXw2X9eZssPBbnbz+P70ruhsbCBOzTSM/8AUVlyfEvUI34WwkA/uxHH865mSGOUYkRWHbI6VEbAE/IxA9MVyvG4hu/Oy/ZQ7HcWfxMkeZUuNPtpCef3MjKT9OorqNJ8Y6RqMixNI9lOxwEuMBSfQOOPzxXkkOlfOrksWByCBirc8McKE3EkcY9GPJ/CtqWZYiD1lf1/q5MqEH0PcypHBHNJtrI8DM8vhHTJJHZ8odhbrs3HaPwFbu2vpaVT2kFPurnDJcraGwj5j9KKlhX5vwoqmxD2X5j9aTbUzL8x+tN21Nxke2jbUm2l20XAi20bal20badwIttG2pNtLtouBFtpNtS7aXbRcLEW2jbUm2lIouBFtpNtTbaNtFwsRbaNtS7aTbSuBHto21Jto20XCxFtpdtSbaXbTuBFtpNtTbaNtK4EW33pNtS7aXbTuBFto28VJto20rgRbaXbUm2jbTuFiPbRtqTbxRtpXAj20baj1C7tdNspry/nWC1iGXkbt6ADuT2Fed6v8UkBZNHsQB2mujk/XYOPzNc9fF0qHxvXsXCnKex6SsbNkKCT7CvEfjVKj+KoVikR/LtEVijBsHLHBx3rP1jxdrGq5W7vpmiP/LNW2J/3yuB+dc1eAzLnHzDoBxXi43MFiI8kY2R1UqPI7tlWMk5JOa0Z54/spVEVd2MgCqEEL5G8YHvWiBbx/dDu3r93/E15huFnIyxd1VRnO3k/Q0pmkycsSD2JqaKEyx7lIQN2AyT+NO+xYGWlVR9KAKhds8Fh+NSRzyKRkkgcdame3QKSrMR/ebCioTLbxnG4yt6IM/rQA9JptxO5iD2NakVtKYw8khTIyQQOPxrKFzPnMESQ+jPyaZIjzHNxNJKfTPFAGnLcWlv9+73t6IoY1F/azgYtrbI/vy8fyqiiKg+RQv4U760APur++aMlrgIM/diGP1qgrFpMkkn1PJqa6/1X/AhVdeCT6A0AfRHgWPb4L0MdP9FU/mTW5trO8JR+X4U0ZPS0jP5jNa23mvsaGlKK8l+R5s/iY2FfmP0oqWJcMfpRVNisOZfmP1pNtTMvzH60mylcZFto21LspdlFwIdtG2pdtG2i4EW2jbU2yk20XAi20bal2Uu2i4EO2jbUu2l2UXCxDijbUu2l2UXAh20YqXZRtouBFto21Nto20XAh20bal20baLgRbaNvtUu00baLhYi20bal2UbaLgRbaNtS7KXZRcCHbRtqXbRtouFiLbRtqXbS7TRcDiPi3bPN4KleMbhBcRSOvcjJXj3BIrwouG6V9DfEn5fBd8f+mkQ/wDHxXib2MN398FXP8a8H/69fO5ppX+SOyh8BhlvenMVbaQu3jn61rah4eu7SFGS4gmjYZAdSrCsgWt0G2hIif8Afrz7mwoXNSrCcbmwq+rHApFiuY+WeOP/AHBk0nlIW3Pukb1c5oAl+1KqhEd5McARjA/OmGSc/dWOEev3mpFkXesUeWkY4WOMZJPpgVrax4a8Q6NpNvqeraJf2FhcP5cU1zCU3NjOMHkcdCRg0AY5hVjmVnlb1Y05WUMEjHzH+FBk/pWp4U06HVbqc3e5oYVB2BsbiT3x2ruLS0trNdtpBFCP9hcH8+tOwrnDWmh6ndYK23kof4522/p1pNf0aXR7GK5muBOsj+WVQFQGxn8RxXoH1rmPiIf+JFaj1us/kn/16AucdZOXWQkYAPAqxVXTf9VJ9atUhkN3/q1/3hVcfdf/AHTVi7+6n+9/SoB9x/8AdNAH094fi8vQNLT+7aRD/wAcFX9tFnHssbVQOBBGP/HBUu2vsIaRSPNe42Jfm/CipYl+Y/Sim2FiRl+Y/Wk21My/MfrRtqbjIttJt96l20u2i4EW2k2+9S7aXbRcCLbSbam20m2i4Ee2k21Nto20XAi20m2pttJt4ouBFto21NtpNtFwI9tJtqXbS7aLgRbaTbUu2jbRcCLbRtqbbRt5ouBDto2+9TbaTbRcCLbRtqbbRtouBFt96NtS7aTbRcCPbSbam20m2i4EW33pdtSbaXbRcDj/AIojHgm795oR/wCPV41ag7xj1r2f4rDHgi597iH/ANCNePacu+VB7189mf8AG+SOyh8Joa+xEMKDsgrmgMOa6HxEw84qOwArnSeTXno2Ip6LCFbnUrK2k3eXPcRxPtODtZgDg/Skmqx4fXd4j0ZfW+h/9CFUI9ZbxTNok1zaeFtP0zw9bRMY/NsrYG4fHHMrZYnHU5FcF44vru+06Se+vLm6leVMvPIWY8n1rZ1DMmoXWD/y2c/Xmuf8UoZNPSGMrvMoJBYDAGeafQBvw+H/ACED/uD+ddarBhlTkVyfhGF7a3vUyHkdoyNgJ4wa6GGOZERn3F1IGN2cjp0/z0p9Lkt6lvIxnI2+tct8Rm/4lNgB0M7n/wAdH+NdCIXbbvbAU9DyDXN/Ehv9C01fWSQ/otIEcpp3+pb/AHqsmq+nj9yfqasUiiC76R/U/wAqjhG5wv8AeIH5mn3fWP8AGn6cnmXtun96aMf+PCgD6wWPYiL/AHVVfyFG2rEq/vG+tN219eecMjX5vwoqWNfmP0oqWwJGX5j9aTbUzKdxpNppXKsRbaNtS7KNpouFiLbRtqXYaNpouFiLbRtqXaaNpzRcLEW2jbUu00bTRcLEW2jbUuw+tAU+tFwsRbfajbUu00bTRcLEW2jbUuw+tG00XCxFto21LtNGw0XCxFto21LtPrRtNFwsRbaNtS7TRtNFwsRbaNtS7TRtNFwsRbaNtS7KNpouFiLbRtqXYaCpzRcLEW2jbUoXn3o2HPFFwscR8Xcr4Ik/6+of5mvJNATddZP3U+Y/SvaPifaNd+D5I1xn7TEx/WvFLndprNBEwbzADIR29h7V8/mP8b5I66PwkOrTebO7eprJJ5NWZmLc1WbvXEakUvSmRTS21zBcWzFJ4JFkjYdQwOQadL0FRnvTEX7zVbu7kkaSdxvJJEY8sHP61SDN0TjJ/h6k/U80Yxu4wOB83+FB+Y92y30B/wA/yoA6PwRnztQ5OMJ37811Vcv4H5/tA+8Y/Q11AqkSw71xvxKPy6UO2JT+qiusmuoIeHkGfQcmuJ8byTXs1vIqYt4lKp6kk5OaTGjFseLYH3NTVDZ/8eyfU1NSGV7r76fQ1e8Np5mv6YmMhruEf+PiqNz/AKxf90/zrX8ExyTeLdGSGMyP9tiIUd8MCaqOrQmfVcy/vpP940zbU8i/vHI5GTzTdpr6q5w2GRr834UVLEpz17UVLYWJWX5jSbalZfmNG2lcZFto281Lto20XAi20bal20baLgRbcUbal20baLgRbaNtS7aNtFwIttG2pdtG2i4EW2k21Nto20XAi20bal20baLgRbaNtS7aTbRcCPbRtqXbRtouBFtpNvFTbaMUXAh20u2pdtG2i4EW2jbUu2kAouBHtpNtTbaNtFwIdtLtqXbRtouBx/xPmNt4RdgcFrmJf514RfMZJSxr274yNs8Hx+95H/Jq8PmOWFeDmH8d/I6qPwlVlqBhV11qtKvWuM1KcvQVEalmqI/j+FMQ88FjgDkcsckUfe7E5b+I4FIeCei8/UigdQSO55bpQBteFrx7c3saIrFtj5Pbt0rYkmuJ+HkbH91eBXKafdtZTSyKiyF1C4Y4wfWnXGo3dxw0xVT/AAR/KP8AGmBvzTW1qP38yKf7vVvyFZt7q0U0LxQ2+5WGN0vH4gCsgqIwTIVjHqx5P9a0tC0TVNfl8vQtLu77HWQLtiX6seP1oScnZC2MuNcAKoJNOYBWCu4VicBerH6AV654f+DF5NtfxJqiWydTa2A3N+LngfhmvTfDnhDQfDij+yNMhimHW4kHmSn/AIGen4YrspYGpP4tCJVUtjwPw58NPEXiCWOVrU6bYEf8fF6CpI/2Y/vH9PrXtfg3wJo3hQebZI9xfFdrXc+N2D1CqOFB/P3rrmySSSST3NJtr0qOEp0td2YyqORHto21Lto211XMxkS4NFSxr8x+lFS2MkYfMfrSY9qlI5NJilcZHj2ox7VJijbRcLEePajFSYoxRcLEePajHtUmKNpouBFijFS7aMUXAjx7UYqTFGKLgR4ox7VJtowaLgR4oxUm2jbRcLEeKMe1SbaMUXAjx7UYqTbRtouBHj2ox7VJijbRcCPFGKkxRii4EeKMe1SYoxRcLEeKMVJijFFwI8e1JjmpcUbaLgebfHC4WPw5p1sR8892XB9Ai8/+hCvE5AQ3FfRPxK8It4u0KOC1uFttRtJDNayv9wkjDI3oCMc9iK+eNYt9S8Pah9h8SWMtncdVYjKSD1Ujhh7ivFx0Je0c2tDopNWsKvzDFQzpgGrMDRTKGjkRvoaS5XCHOPzrhNTFn61D/Kp5+T1AA6kngUlhbzahcC3022ub+4PSO2jLn9KpaiIs46YHOaUrgbnwg9WOK9F0H4QeKNRCvfm00SA8/vW82b/vlen4kV6JoPwd8Maayy6gtzrFwOd10+2PP+4v9Sa6aeEqz6W9SHUSPn3TLO61W4FvpFld6jOT9y3jJA+pr0LQfg74jvwr6vc2ujQnkxr+9m/IcD8TX0BZ2sFjbC3sbeG1twMCKBAi/kKl21208BBfG7mbqvocD4d+FXhbRmWWSzfU7pefOvm3jPsg+X8813KKEiWONVSJeFRFCqPoBwKl20YrthCMFaKsZtt7keKMVJijFXcRHijHtUm2jFFwI8UmPapcUbaLgNjHzdKKkReaKlsCQodx4NGw+lFFK4w2H0NGw+hooouAbD6GjYfQ0UUXANh9DRsPoaKKLgGw+ho2H0NFFFwDYfQ0bD6Giii4BsPoaNh9DRRRcA2H0o2H0NFFFwDYfQ0bD6Giii4BsPoaNh9DRRRcA2H0NGw+hooouAbD6UbD6Giii4BsPoaNh9DRRRcA2H0NGw+hooouAbD6UbD6Giii4BsPoaqappdlq9k1nqtlBe2rHPlTpuAPqO4PuMUUUnrowPO9V+B/ha7cvZSanppPO2GUSJ+TDP61lD4Badu58Q6iV9Ps65/PdRRWDw1Jv4SueXc39E+DHhPTZFkuYbzVJFOR9rlwn/fK4z+JrvrCxttOtxb6daQWcAGBHbxhF/SiitIU4w+FWE23uT7D6Umw+lFFaXELsPoaNh9DRRRcA2H0NGw+hooouAbD6GjYfQ0UUXANh9DRsPoaKKLgGw+ho2H0ooouAqJ83Siiik2B/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The wearable cardioverter-defibrillator consists of a vest incorporating two defibrillation electrodes and four sensing electrocardiographic electrodes connected to a waist unit containing the monitoring and defibrillation electronics.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: ZOLL Medical Corporation. Copyright &copy; 2012. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_14_25826=[""].join("\n");
var outline_f25_14_25826=null;
var title_f25_14_25827="Seborrheic dermatitis axilla";
var content_f25_14_25827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intertriginous seborrheic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_14_25827=[""].join("\n");
var outline_f25_14_25827=null;
var title_f25_14_25828="Liposomal cytarabine: Patient drug information";
var content_f25_14_25828=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Liposomal cytarabine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/53/34645?source=see_link\">",
"     see \"Liposomal cytarabine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F156098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DepoCyt&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F156099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      DepoCyt&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700582",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause brain irritation (chemical arachnoiditis). Very bad problems may happen in some patients who have this health problem. Call your doctor right away if you have a fever, headache, upset stomach, throwing up, back pain, or neck stiffness or pain. You will be closely watched by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3533631",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a type of cancer in the brain fluid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701880",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cytarabine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a brain infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3796262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loss of eyesight. This can be long-lasting.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3796283",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Damage to the nerves. This can be long-lasting.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F14457280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698974",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Neck stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in hearing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into the spine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dexamethasone will be given before this drug to lower side effects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11713 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-188.40.116.55-6D8648E745-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_14_25828=[""].join("\n");
var outline_f25_14_25828=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156098\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156099\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011402\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011404\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011403\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011408\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011409\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14457280\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011406\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011413\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/53/34645?source=related_link\">",
"      Liposomal cytarabine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_14_25829="MRI urethral diverticulum2";
var content_f25_14_25829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance image of female urethral diverticulum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    T2 coronal contrast enhanced MR image shows a diverticulum (arrow) wrapped around the urethra.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_14_25829=[""].join("\n");
var outline_f25_14_25829=null;
var title_f25_14_25830="Prehospital fibrinolysis (thrombolysis) for suspected acute ST elevation myocardial infarction";
var content_f25_14_25830=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prehospital fibrinolysis (thrombolysis) for suspected acute ST elevation myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/14/25830/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/14/25830/contributors\">",
"     C Michael Gibson, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/14/25830/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/14/25830/contributors\">",
"     Freek Verheugt, MD, FACC, FESC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/14/25830/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/14/25830/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/14/25830/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/14/25830/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous placebo-controlled trials have demonstrated the benefit of fibrinolytic agents, compared to no reperfusion therapy, in most patient groups with an acute ST elevation myocardial infarction (STEMI). Reperfusion of the occluded artery is associated with an improvement in survival, smaller infarct size, and a reduction in the extent of left ventricular dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H2#H2\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, these trials have shown that the degree of myocardial salvage is greatest when fibrinolytic agents are administered within the first four hours and particularly within the first 70 minutes of symptom onset (",
"    <a class=\"graphic graphic_figure graphicRef53374 \" href=\"UTD.htm?30/18/31021\">",
"     figure 1",
"    </a>",
"    ). For instance, in an early meta-analysis of fibrinolytic trials, a 30-minute reduction in the administration of fibrinolytic therapy within the first 90 minutes after symptoms onset resulted in one to three lives saved per 100 patients treated [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25830/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H69239847#H69239847\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Timing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will discuss the use of prehospital fibrinolysis, which has the potential to reperfuse patients with acute STEMI very early in their course. The broader discussions of fibrinolytic therapy and fibrinolytic therapy compared to primary percutaneous coronary intervention are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H33#H33\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link&amp;anchor=H22#H22\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other issues such as the applicability of the above findings to general community practice, necessary equipment and capabilities, requirements of prehospital providers, and quality assurance are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10264?source=see_link\">",
"     \"Performance of prehospital fibrinolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FACTORS RESPONSIBLE FOR DELAYED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unfortunately, many patients present to the hospital late after the onset of symptoms. In different registries of patients with acute MI, the time from symptom onset to hospital presentation was &ge;4 hours in 50 percent (a value that was changed little from 1987 to 2000) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25830/abstract/2\">",
"     2",
"    </a>",
"    ], more than six hours in 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25830/abstract/3\">",
"     3",
"    </a>",
"    ], and more than 12 hours in 9 to 31 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25830/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Delay is greatest in women, older adults, low socioeconomic and ethnic minority groups, and in those with symptoms that occur between 6 PM and 6 AM [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25830/abstract/2,3,6,7\">",
"     2,3,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to delayed presentation, a number of in-hospital factors further delay the time to delivery of fibrinolytic therapy. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Delay in patient registration and triage",
"     </li>",
"     <li>",
"      Delay in emergency department bed placement",
"     </li>",
"     <li>",
"      Delay in the initial evaluation of the patient, including obtaining and interpreting the electrocardiogram",
"     </li>",
"     <li>",
"      Delay in drug preparation",
"     </li>",
"     <li>",
"      Request for consultation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These potential delays to the expeditious administration of fibrinolytic therapy discussed above provided the rationale to study the feasibility, efficacy, and safety of prehospital fibrinolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFICACY OF PREHOSPITAL FIBRINOLYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial nonrandomized studies supported the hypothesis that prehospital fibrinolysis would improve outcomes (eg, smaller infarcts, higher ejection fractions, and lower 21-day mortality) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25830/abstract/8\">",
"     8",
"    </a>",
"    ]. These were followed by a number of randomized trials comparing prehospital fibrinolysis to in-hospital administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following significant benefits were noted in a meta-analysis of six randomized trials (6434 patients) comparing prehospital to in-hospital fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25830/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A shorter time to fibrinolysis (104 versus 162 minutes).",
"     </li>",
"     <li>",
"      Reduced all-cause hospital mortality (odds ratio 0.83, 95% CI 0.70-0.98).",
"     </li>",
"     <li>",
"      An absolute risk reduction of almost 2 percent that translated into one life saved for every 62 patients treated with prehospital fibrinolysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following is a review of the design and specific results of the three largest of these trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     EMIP trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the European Myocardial Infarction Project Group (EMIP) trial, the largest of these studies, 5469 patients were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    before admission followed by placebo in the hospital (prehospital treatment group) or placebo before admission followed by alteplase in the hospital (hospital treatment group) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25830/abstract/10\">",
"     10",
"    </a>",
"    ]. Prehospital therapy was administered by EMS personnel and the diagnosis of acute MI was confirmed in 88 percent of patients.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    administration was not uniformly given at the time of randomization, but about 80 percent of patients in both groups received it sometime after randomization.",
"   </p>",
"   <p>",
"    Patients in the prehospital group received fibrinolytic therapy a mean of 60 minutes earlier than those in the hospital group (130 versus 190 minutes after symptom onset). At 30 days there was a significant reduction in cardiac mortality (8.3 versus 9.8 percent) in patients assigned to prehospital fibrinolytic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     MITI trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Myocardial Infarction Triage and Intervention (MITI) trial evaluated the outcomes of 360 patients randomly assigned to prehospital or in-hospital therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25830/abstract/11\">",
"     11",
"    </a>",
"    ]. The prehospital treatment group received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    immediately upon arrival of the team in the field, while the hospital treatment group received the same regimen upon hospital arrival. Ninety-eight percent of the patients had subsequent evidence of an acute MI. All patients were treated within three hours of symptom onset, but the prehospital group was much more likely to receive treatment within one hour of emergency care request (95 versus 16 percent).",
"   </p>",
"   <p>",
"    Despite a significant 33 minute reduction in the total time to treatment (77 versus 110 minutes), there were no significant differences between the prehospital and in-hospital treatment groups in left ventricular ejection fraction (53 versus 54 percent), infarction size, or all-cause mortality (5.7 versus 8.1 percent).",
"   </p>",
"   <p>",
"    A secondary analysis was performed to compare outcomes with the actual time to treatment; a 70 minute cutoff in the duration of symptoms before the onset of fibrinolysis was the best discriminator of outcome. Compared to patients who received therapy between 70 and 180 minutes from symptom onset, those who received fibrinolytic therapy within 70 minutes had a 55 percent reduction in infarct size, an 85 percent reduction in mortality (1.2 versus 8.7 percent), and a slightly higher ejection fraction (53 versus 49 percent).",
"   </p>",
"   <p>",
"    The overall benefits of prehospital fibrinolytics in the MITI trial may have been mitigated to some extent by the trial design. Prehospital ECG interpretation allowed significantly earlier fibrinolysis after ED arrival in the control arm, lessening the difference in overall time to fibrinolysis in the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     GREAT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Grampian Region Early Anistreplase Trial (GREAT) randomly assigned 311 patients with a suspected MI to prehospital fibrinolytic therapy or fibrinolytic therapy after arrival to the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25830/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients in the GREAT trial were treated by physicians in ambulances, and were subject to prolonged transport times due to the remote and rural prehospital setting. Patients in the prehospital group received fibrinolytic treatment more than two hours earlier (101 versus 240 minutes after the onset of symptoms). This two hour difference was correlated with a significant 50 percent risk reduction in mortality at one year (10.4 versus 21.6 percent for in-hospital treatment).",
"   </p>",
"   <p>",
"    The mortality benefit of early fibrinolysis was maintained at five years (25 percent versus 36 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25830/abstract/13\">",
"     13",
"    </a>",
"    ]. A delay in fibrinolytic treatment by one hour was associated with a loss of 43 per 1000 lives within the five years; a delay of 30 minutes reduced average life expectancy by one year. At 10 years, the difference in survival was no longer significant, a probable reflection of the natural history of coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25830/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Adjunctive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early initiation of anticoagulant and dual antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    is recommended by all major society guidelines for all patients undergoing fibrinolysis for suspected acute STEMI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H36#H36\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=see_link&amp;anchor=H37#H37\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the trials discussed above were performed before the routine use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . In a substudy of CLARITY-TIMI 28, which randomly assigned STEMI patients undergoing fibrinolytic therapy to clopidogrel 300 mg or placebo, the 216 patients who received prehospital fibrinolysis were evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25830/abstract/15\">",
"     15",
"    </a>",
"    ]. As was found in the main CLARITY-TIMI 28 trial, there was a significant reduction in the frequency of an occluded infarct related artery (12 versus 22 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H13#H13\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'P2Y12 receptor blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     POTENTIAL FOR SUBSEQUENT PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, the preferred treatment for many patients with an acute STEMI is primary percutaneous coronary intervention (PCI). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients who receive prehospital fibrinolysis, persistent ischemia (failed fibrinolysis) or threatened reocclusion are clear indications for subsequent PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25830/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=see_link\">",
"     \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A separate issue is the role of routine PCI after the fibrinolysis. The main rationale for routine PCI is that TIMI grade 3 (normal) flow is achieved in only about 50 to 60 percent of patients treated with fibrinolysis and it is only these patients who benefit (",
"    <a class=\"graphic graphic_figure graphicRef77370 \" href=\"UTD.htm?2/40/2688\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H69241007#H69241007\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Management after fibrinolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The discussion of the optimal timing of PCI after fibrinolysis is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=see_link\">",
"     \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     COMPARISON TO PRIMARY PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prehospital and very early fibrinolysis have been compared to primary PCI, but the evidence to support one modality over the other is weak. This issue is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link&amp;anchor=H262942297#H262942297\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\", section on 'Presentation within 12 hours'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The CAPTIM trial compared these modalities in 840 patients with an acute STEMI seen within six hours of symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25830/abstract/17\">",
"     17",
"    </a>",
"    ]. The patients were initially managed by mobile EMS units and assigned to prehospital accelerated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    and then transferred to a PCI center or primary PCI. The median delay from onset of symptoms to treatment was 130 minutes with prehospital fibrinolysis and 190 minutes with primary PCI. Rescue angioplasty was performed in 26 percent of those undergoing prehospital fibrinolysis.",
"   </p>",
"   <p>",
"    The rate of the primary end point (all-cause mortality, recurrent MI, and disabling stroke) was not significantly different in the two groups (8.2 versus 6.2 percent with primary PCI). The lack of statistical difference between these two groups may have been attributable to the failure to recruit the target number of patients.",
"   </p>",
"   <p>",
"    In a post hoc analysis, there was a marked trend toward reduction in mortality with fibrinolysis (2.2 versus 5.7 percent) among patients whose treatment assignment was made less than two hours after symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25830/abstract/18\">",
"     18",
"    </a>",
"    ]. These findings are consistent with the hypothesis that the earlier reperfusion achieved with prehospital fibrinolysis might be of benefit, especially in patients treated within the first two hours (",
"    <a class=\"graphic graphic_figure graphicRef53374 \" href=\"UTD.htm?30/18/31021\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2013",
"    <span class=\"nowrap\">",
"     ACCF/AHA",
"    </span>",
"    guideline on the management of STEMI makes no specific recommendations regarding prehospital fibrinolysis, although it may be implied in their recommendation that reperfusion therapy be administered as soon as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25830/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The 2012 European Society of Cardiology guideline makes a weak recommendation to start fibrinolysis in the prehospital setting [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25830/abstract/21\">",
"     21",
"    </a>",
"    ]. The performance of prehospital fibrinolysis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10264?source=see_link\">",
"     \"Performance of prehospital fibrinolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A protocol-driven approach to patient selection for initiation of prehospital fibrinolytic therapy is both possible and beneficial compared to in-hospital fibrinolysis. These benefits include a reduction of infarct size, an improvement in ejection fraction, and, in some settings, a reduction in cardiovascular mortality. However, prehospital fibrinolysis should be initiated only after consideration has been given to whether primary percutaneous coronary intervention can be delivered in a timely manner. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link&amp;anchor=H22#H22\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with acute STEMI, we recommend primary percutaneous coronary intervention rather than fibrinolysis if high-quality PCI is available and there is no significant delay (",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    ). Significant delay can occur due to factors related to both transportation and PCI hospital mobilization and is commonly measured by either door to balloon or PCI related delay times. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link&amp;anchor=H22#H22\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend prehospital as opposed to in-hospital administration of fibrinolytic therapy for patients with acute STEMI in whom a decision has been made to not use primary percutaneous coronary intervention as the reperfusion strategy (",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    ). This recommendation applies only to patients in health-care settings where prehospital administration of fibrinolytic therapy is feasible. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25830/abstract/1\">",
"      Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25830/abstract/2\">",
"      McGinn AP, Rosamond WD, Goff DC Jr, et al. Trends in prehospital delay time and use of emergency medical services for acute myocardial infarction: experience in 4 US communities from 1987-2000. Am Heart J 2005; 150:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25830/abstract/3\">",
"      Gurwitz JH, McLaughlin TJ, Willison DJ, et al. Delayed hospital presentation in patients who have had acute myocardial infarction. Ann Intern Med 1997; 126:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25830/abstract/4\">",
"      Eagle KA, Goodman SG, Avezum A, et al. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002; 359:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25830/abstract/5\">",
"      Grzybowski M, Clements EA, Parsons L, et al. Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis. JAMA 2003; 290:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25830/abstract/6\">",
"      Goff DC Jr, Feldman HA, McGovern PG, et al. Prehospital delay in patients hospitalized with heart attack symptoms in the United States: the REACT trial. Rapid Early Action for Coronary Treatment (REACT) Study Group. Am Heart J 1999; 138:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25830/abstract/7\">",
"      Foraker RE, Rose KM, McGinn AP, et al. Neighborhood income, health insurance, and prehospital delay for myocardial infarction: the atherosclerosis risk in communities study. Arch Intern Med 2008; 168:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25830/abstract/8\">",
"      Linderer T, Schr&ouml;der R, Arntz R, et al. Prehospital thrombolysis: beneficial effects of very early treatment on infarct size and left ventricular function. J Am Coll Cardiol 1993; 22:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25830/abstract/9\">",
"      Morrison LJ, Verbeek PR, McDonald AC, et al. Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. JAMA 2000; 283:2686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25830/abstract/10\">",
"      Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. The European Myocardial Infarction Project Group. N Engl J Med 1993; 329:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25830/abstract/11\">",
"      Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 1993; 270:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25830/abstract/12\">",
"      Rawles J. Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). J Am Coll Cardiol 1994; 23:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25830/abstract/13\">",
"      Rawles JM. Quantification of the benefit of earlier thrombolytic therapy: five-year results of the Grampian Region Early Anistreplase Trial (GREAT). J Am Coll Cardiol 1997; 30:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25830/abstract/14\">",
"      Rawles J, GREAT. GREAT: 10 year survival of patients with suspected acute myocardial infarction in a randomised comparison of prehospital and hospital thrombolysis. Heart 2003; 89:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25830/abstract/15\">",
"      Verheugt FW, Montalescot G, Sabatine MS, et al. Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial. J Thromb Thrombolysis 2007; 23:173.",
"     </a>",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (accessed September 18, 2007) www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25830/abstract/17\">",
"      Bonnefoy E, Lapostolle F, Leizorovicz A, et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 2002; 360:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25830/abstract/18\">",
"      Steg PG, Bonnefoy E, Chabaud S, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003; 108:2851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25830/abstract/19\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25830/abstract/20\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:e362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25830/abstract/21\">",
"      Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33:2569.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 70 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-3033BD7A4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_14_25830=[""].join("\n");
var outline_f25_14_25830=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FACTORS RESPONSIBLE FOR DELAYED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFICACY OF PREHOSPITAL FIBRINOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EMIP trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MITI trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GREAT trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Adjunctive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      POTENTIAL FOR SUBSEQUENT PCI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      COMPARISON TO PRIMARY PCI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/70\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/70|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/18/31021\" title=\"figure 1\">",
"      Mortality and time to reperfusion in MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/40/2688\" title=\"figure 2\">",
"      Reperfusion checklist STEMI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=related_link\">",
"      Anticoagulant therapy in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=related_link\">",
"      Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=related_link\">",
"      Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10264?source=related_link\">",
"      Performance of prehospital fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=related_link\">",
"      Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_14_25831="Plasmacytoma CT scan";
var content_f25_14_25831=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extramedullary plasmacytoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 583px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The CT scan through the mid-chest region of an&nbsp;80-year-old male patient reveals a destructive soft tissue mass in an anterior left rib (red arrow). A core biopsy performed under CT guidance (B) confirmed a&nbsp;diagnosis of plasmacytoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_14_25831=[""].join("\n");
var outline_f25_14_25831=null;
var title_f25_14_25832="Management of single magnet ingestion";
var content_f25_14_25832=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83942%7EPEDS%2F86069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83942%7EPEDS%2F86069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 606px\">",
"   <div class=\"ttl\">",
"    Algorithm for management of single magnet ingestion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 586px; height: 408px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * If magnet might be or is known to be a high-powered type (neodymium, or \"rare earth\" type).",
"     <br/>",
"     &Delta; Radiographs do not reliably distinguish between single and multiple magnets, since it is possible for magnets to stick together or overlap on a single view and be misdiagnosed as a single magnet.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     The following \"magnet precautions\" should be for any child who has ingested one or more magnets: Remove any magnetic objects nearby, avoid clothes with metallic buttons and belts with buckles, and ensure that no other metal objects or magnets are in the child's environment that could be accidentally ingested. Maintain these precautions until magnet has passed out of the gastrointestinal tract.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Hussain SZ, Bousvaros A, Gilger M, et al. Management of ingested magnets in children. J Pediatr Gastroenterol Nutr 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 650px\">",
"   <div class=\"ttl\">",
"    Algorithm for management of multiple magnet ingestion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 630px; height: 741px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * If magnet might be, or is known to be, a high-powered type (neodymium, or \"rare earth\" type).",
"     <br>",
"      &Delta;&nbsp;Radiographs do not reliably distinguish between single and multiple magnets, since it is possible for magnets to stick together or overlap on a radiograph, and be misdiagnosed as a single magnet.&nbsp;",
"      <br>",
"       &loz; The following \"magnet precautions\" should be used for any child&nbsp;who has ingested one or more magnets: Remove any magnetic objects nearby, avoid clothes with metallic buttons and belts with buckles, and ensure that no other metal objects or magnets are in the child's environment that could be accidentally ingested. Maintain these precautions until the magnet has passed out of the gastrointestinal tract.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified&nbsp;with permission from: Hussain SZ, Bousvaros A, Gilger M, et al. Management of ingested magnets in children. J Pediatr Gastroenterol Nutr 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_14_25832=[""].join("\n");
var outline_f25_14_25832=null;
var title_f25_14_25833="Treatment and prevention of Bordetella pertussis infection in infants and children";
var content_f25_14_25833=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of Bordetella pertussis infection in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/14/25833/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/14/25833/contributors\">",
"     Sylvia Yeh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/14/25833/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/14/25833/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/14/25833/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/14/25833/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/14/25833/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pertussis infection often results in a protracted illness. Frequent coughing paroxysms interfere with daily function. Young infants can develop serious complications, including failure to thrive, apnea, pneumonia, respiratory failure, seizures, and death. Throughout much of the protracted illness, the child is contagious. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=see_link\">",
"     \"Clinical features and diagnosis of Bordetella pertussis infection in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment and prevention of pertussis infection in infants and children will be reviewed here. The treatment and prevention of pertussis in adolescents and adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=see_link\">",
"     \"Treatment and prevention of Bordetella pertussis infection in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care is the mainstay of management for",
"    <em>",
"     B. pertussis",
"    </em>",
"    infection. Supportive care may include hospitalization for close monitoring of respiratory status and fluid or nutritional support. In addition, known triggers for coughing paroxysms (eg, exercise, cold temperatures, nasopharyngeal [NP] suctioning) should be avoided (although using NP suctioning to obtain samples for diagnostic purposes is optimal). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13911?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Young infants are more likely to need hospitalization than are older children or adults [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Among 1082 children younger than two years who were hospitalized with pertussis in Canada between 1991 and 1997, more than 90 percent were younger than one year of age, and 79 percent were younger than six months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/1\">",
"     1",
"    </a>",
"    ]. In the United States during 2001-2003, 69 percent of infants younger than six months with documented pertussis required hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Canadian study, indications for admission included severe paroxysms of cough (90 percent), cyanosis with cough (62 percent), and pneumonia (9 percent). Intensive care admission and ventilator support were necessary for 16 and 5 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Indications",
"      </strong>",
"      &ndash; Indications for hospitalization in infants and children with pertussis infection or suspected pertussis infection include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Respiratory distress, including tachypnea, retractions, nasal flaring, grunting, and the use of accessory muscles",
"     </li>",
"     <li>",
"      Evidence of pneumonia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link\">",
"       \"Clinical features and diagnosis of community-acquired pneumonia in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Inability to feed",
"     </li>",
"     <li>",
"      Cyanosis or apnea, with or without coughing",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Age &lt;3 months; among such infants pertussis is frequently severe and often fatal [",
"      <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]; hospitalization in a major medical center with a pediatric intensive care unit is desirable because the severity of illness is unpredictable; clinical decline may occur rapidly and without warning [",
"      <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Isolation",
"      </strong>",
"      &ndash; Isolation of hospitalized patients is discussed below. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Isolation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Monitoring",
"      </strong>",
"      &ndash; The respiratory rate, heart rate, and oxygen saturation of infants who are admitted to the hospital for pertussis (suspected or confirmed) should be monitored. Accurate documentation of oral intake and the frequency and severity of coughing spells (eg, whether they are associated with hypoxia or bradycardia) are helpful in discharge planning.",
"     </li>",
"     <li>",
"      <strong>",
"       Discharge criteria",
"      </strong>",
"      &ndash; Most infants who are admitted with pertussis will continue to have coughing paroxysms after discharge. Minimum criteria for discharge include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The infant can tolerate coughing episodes without becoming hypoxic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bradycardic",
"     </li>",
"     <li>",
"      The infant can feed enough to gain weight",
"     </li>",
"     <li>",
"      Caretakers are reliable and comfortable with the child's condition",
"     </li>",
"     <li>",
"      Close outpatient follow-up can be assured",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fluids and nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and children with frequent paroxysms of cough may have increased fluid and energy needs, which can be difficult to meet if the infant is coughing or vomiting. Thus, close attention should be paid to the child's fluid and nutritional status, whether the child is admitted to the hospital or cared for at home.",
"   </p>",
"   <p>",
"    Intravenous hydration and nasogastric feeding may be required for some patients. The nasogastric tube may stimulate the cough reflex in some infants; however, nasogastric feedings should be attempted before parenteral nutrition for infants who are unable to gain weight because of severe coughing paroxysms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Adjunctive treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive treatments, including bronchodilators, corticosteroids, and antitussive agents have not been proven to be beneficial in patients with pertussis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/6\">",
"     6",
"    </a>",
"    ]. Because of an association between extreme leukocytosis and severe and fatal pertussis, extracorporeal membrane oxygenation with leukodepletion or double-exchange transfusion have been tried as rescue measures for infants with severe respiratory failure and pulmonary hypertension due to pertussis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/7-10\">",
"     7-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Bronchodilators",
"      </strong>",
"      &ndash; In two small trials including a total of 34 patients, pertussis-associated cough did not improve with inhaled beta-agonists [",
"      <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Nevertheless, based upon anecdotal experience, some clinicians may attempt a therapeutic trial of inhaled beta-agonists for infants with compromised respiratory status. Enhanced risks of beta-agonists in patients with pertussis have not been reported.",
"     </li>",
"     <li>",
"      <strong>",
"       Corticosteroids",
"      </strong>",
"      &ndash; Anecdotal reports have suggested a clinical benefit of steroid therapy; however, no clear benefits of steroid treatment were observed in small clinical trials [",
"      <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. There are no prospective, well-controlled trials evaluating steroid therapy for pertussis patients, and their use is not routinely recommended.",
"     </li>",
"     <li>",
"      <strong>",
"       Antitussives",
"      </strong>",
"      &ndash; The use of antitussives and opioid cough suppressants such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32230?source=see_link\">",
"       codeine",
"      </a>",
"      should be discouraged. There is no therapeutic benefit, and the sedation associated with these medications may have an adverse effect, especially in young infants.",
"     </li>",
"     <li>",
"      <strong>",
"       B. pertussis immunoglobulin",
"      </strong>",
"      &ndash; In a multicenter, prospective, blinded trial, children who were treated with immunoglobulin (Ig) enriched for",
"      <em>",
"       B. pertussis",
"      </em>",
"      toxin antibodies (BPIG) showed an improvement in frequency of whoops compared with controls [",
"      <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/15\">",
"       15",
"      </a>",
"      ]. However, further development of BPIG has not been pursued, and it is not currently available for routine patient care. Commercially available IVIG preparations have not been evaluated, nor are they routinely screened for pertussis antibodies, and thus are not likely to offer significant benefit to pertussis patients.",
"     </li>",
"     <li>",
"      <strong>",
"       Extracorporeal membrane oxygenation",
"      </strong>",
"      &ndash; Infants with severe respiratory failure and pulmonary hypertension secondary to pertussis have been treated with extracorporeal membrane oxygenation (ECMO). In a review of 23,970 patients in an international database of children and adults treated with ECMO, 61 children with pertussis were identified [",
"      <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/16\">",
"       16",
"      </a>",
"      ]. The mortality rate was 70.5 percent.",
"     </li>",
"     <li>",
"      <strong>",
"       Leukodepletion",
"      </strong>",
"      &ndash; The use of ECMO with a leukocyte filter or double-exchange transfusion for infants with extreme leukocytosis has been reported in a few case reports and a single series. In the case reports, infants with pertussis and extreme leukocytosis, severe respiratory failure, and pulmonary hypertension improved after leukodepletion. In the report of a series of 10 patients, double-exchange transfusion or ECMO with a leukocyte filter had a greater-than-expected survival rate compared with historical controls [",
"      <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/7-10\">",
"       7-10",
"      </a>",
"      ]. Given the sparsity of the data, use of this modality in infants with severe leukocytosis and respiratory failure should be considered investigational.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial therapy for pertussis, when administered early in the course, may shorten the duration of symptoms and decrease transmission to susceptible contacts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/17\">",
"     17",
"    </a>",
"    ]. We recommend treatment for all children with clinical pertussis (with or without laboratory confirmation). We also recommend treatment for children with culture- or polymerase chain reaction (PCR)-confirmed pertussis, even if they are asymptomatic at the time of confirmation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical features and diagnosis of Bordetella pertussis infection in infants and children\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obtaining laboratory confirmation of pertussis may take several days to weeks, depending on the laboratory facilities and methods that are available. Consequently, antimicrobial therapy should be initiated based upon a high degree of clinical suspicion. The laboratory diagnosis of pertussis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13911?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of",
"    <em>",
"     B. pertussis",
"    </em>",
"    infection has two goals: decreased severity of symptoms in the index case and decreased spread of infection to close contacts.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early treatment (eg, during the first seven days of symptoms) may decrease the severity of symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/18\">",
"       18",
"      </a>",
"      ]. Unfortunately, most patients do not come to medical attention until the paroxysmal phase, which occurs one to two weeks after illness onset. Clinical trials and observational studies of treatment during the paroxysmal stage have yielded inconsistent results regarding the ability of treatment to alter the clinical course [",
"      <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/19-22\">",
"       19-22",
"      </a>",
"      ]. A systematic review of randomized and quasi-randomized trials of antibiotics for the treatment of pertussis concluded that antibiotic treatment does not alter the clinical course [",
"      <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/23\">",
"       23",
"      </a>",
"      ]. However, in many of the studies that were included, treatment was initiated after the paroxysmal phase.",
"     </li>",
"     <li>",
"      Patients are most contagious during the catarrhal stage and during the first two weeks after onset of coughing [",
"      <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/24\">",
"       24",
"      </a>",
"      ]. The systematic review described above concluded that antibiotic treatment is effective in eradicating pertussis from the nasopharynx, thereby eliminating the risk of transmission [",
"      <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment indications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend antimicrobial treatment for all individuals who have",
"      <em>",
"       B. pertussis",
"      </em>",
"      isolated from pertussis cultures or positive polymerase chain reaction (PCR), regardless of their age or whether they continue to have symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      We also recommend treatment for patients with a clinical diagnosis of pertussis who have had symptoms for less than 21 days. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=see_link&amp;anchor=H22#H22\">",
"       \"Clinical features and diagnosis of Bordetella pertussis infection in infants and children\", section on 'Clinical diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antimicrobial therapy also may be indicated for patients who have had more than 21 days of symptoms, particularly those who are likely to be in contact with high-risk individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/26,27\">",
"       26,27",
"      </a>",
"      ], although the utility of therapy in such patients is less clear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Choice of agent",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Children &ge;6 months",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antimicrobials of choice are macrolide antibiotics, including",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    and new-generation preparations, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     clarithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"     azithromycin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef75339 \" href=\"UTD.htm?24/3/24636\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/20,28\">",
"     20,28",
"    </a>",
"    ]. Erythromycin-resistant",
"    <em>",
"     B. pertussis",
"    </em>",
"    rarely has been reported; however, macrolide sensitivity testing using standard methods should be performed.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     Clarithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"     azithromycin",
"    </a>",
"    may be better tolerated than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    . These drugs have excellent in vitro activity and have been evaluated in several clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. In the largest of these, 477 children with confirmed or suspected pertussis were randomly assigned to treatment with erythromycin or azithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/32\">",
"     32",
"    </a>",
"    ]. Pertussis was eradicated from the nasopharynx of children who had positive cultures (24 percent of the total), regardless of which antibiotic they received. However, 90 percent of children who took azithromycin completed therapy, compared with 55 percent who took erythromycin.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) may be an alternative for patients who have a contraindication to or cannot tolerate macrolide agents [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/24\">",
"     24",
"    </a>",
"    ]. TMP-SMX should not be used in pregnant or nursing women because of the potential risk of kernicterus related to bilirubin displacement in the fetus or infant, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other agents, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/38/28262?source=see_link\">",
"     tetracycline",
"    </a>",
"    , cephalosporins, and fluoroquinolones have not been demonstrated to be efficacious in the treatment of pertussis. Beta-lactam antibiotics (ampicillin, amoxicillin, cephalosporins) have variable activity against",
"    <em>",
"     B. pertussis",
"    </em>",
"    and are not recommended. Ampicillin and amoxicillin do not eradicate",
"    <em>",
"     B. pertussis",
"    </em>",
"    from the nasopharynx [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/33\">",
"     33",
"    </a>",
"    ]. Neither",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/54/12136?source=see_link\">",
"     doxycycline",
"    </a>",
"    nor the fluoroquinolones are recommended for use in young children because of potential adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Infants &lt;6 months",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is particularly important for infants younger than six months because they are at increased risk for complications. In addition, if not treated, they remain culture positive for longer periods than do older children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H968412571\">",
"    <span class=\"h4\">",
"     Infants &lt;1 month of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2012 Report of the American Academy of Pediatrics (AAP) Committee on Infectious Diseases and CDC prefer the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"     azithromycin",
"    </a>",
"    for infants younger than one month of age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/24,28\">",
"     24,28",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     Erythromycin",
"    </a>",
"    is an alternative;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     clarithromycin",
"    </a>",
"    is not recommended . TMP-SMX should not be used in infants younger than two months of age because of the potential risk of kernicterus related to bilirubin displacement. For the same reason, it should not be used in pregnant or nursing women.",
"   </p>",
"   <p>",
"    Infants younger than one month are at increased risk for severe pertussis and life-threatening complications. Data regarding the effectiveness of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"     azithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     clarithromycin",
"    </a>",
"    in children younger than one month are lacking. Abstracts and unpublished case series suggest azithromycin has fewer adverse effects than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/37\">",
"     37",
"    </a>",
"    ], which has been associated with the development of infantile hypertrophic pyloric stenosis (IHPS) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/38\">",
"     38",
"    </a>",
"    ]. There has been one report of IHPS following use of azithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/39\">",
"     39",
"    </a>",
"    ]. IHPS should be considered in young infants who develop vomiting within one month of therapy with a macrolide antibiotic given in the first month of life. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H968412582\">",
"    <span class=\"h4\">",
"     Infants 1 to 5 months of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2005 CDC guidelines and the 2012 Report of the AAP Committee on Infectious Diseases suggest that infants between one and five months of age may be treated with any of the macrolide antibiotics (",
"    <a class=\"graphic graphic_table graphicRef75339 \" href=\"UTD.htm?24/3/24636\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/24,28\">",
"     24,28",
"    </a>",
"    ]. However, neither",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"     azithromycin",
"    </a>",
"    nor",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     clarithromycin",
"    </a>",
"    is licensed by the United States Food and Drug Administration for use in infants younger than six months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The limited available data regarding the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"     azithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     clarithromycin",
"    </a>",
"    in this age group suggest the microbiologic effectiveness is similar to that in older children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/28\">",
"     28",
"    </a>",
"    ]. Although the newer macrolides have a more convenient dosing schedule than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    , erythromycin is less expensive.",
"   </p>",
"   <p>",
"    For infants who are &ge;2 months, TMP-SMX is an alternative to macrolide antibiotics. TMP-SMX should not be used in younger infants because of the risks of bilirubin displacement and kernicterus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dose and duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended doses for the antimicrobial agents used to treat pertussis are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef75339 \" href=\"UTD.htm?24/3/24636\">",
"     table 1",
"    </a>",
"    ). The duration of therapy varies as follows, depending upon the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/24,28\">",
"     24,28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"       Erythromycin",
"      </a>",
"      should be administered for 14 days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      should be administered for 7 days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"       Azithromycin",
"      </a>",
"      should be administered for 5 days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      should be administered for 14 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis evaluated randomized and quasi-randomized controlled trials of antibiotics for the treatment of pertussis that compared short-term (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"     azithromycin",
"    </a>",
"    for three days,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     clarithromycin",
"    </a>",
"    for seven days, or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    estolate for seven days) and long-term macrolide therapy (erythromycin estolate or erythromycin for 14 days) for the eradication of",
"    <em>",
"     B. pertussis",
"    </em>",
"    from the nasopharynx [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/23\">",
"     23",
"    </a>",
"    ]. The report concluded that short-term therapy was as effective and associated with significantly fewer side effects.",
"   </p>",
"   <p>",
"    However, we continue to recommend a 14-day course of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    , because relapses have been reported after courses of 7 to 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/40\">",
"     40",
"    </a>",
"    ]. We also continue to recommend a five-day course of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"     azithromycin",
"    </a>",
"    , because the number of subjects treated with the shorter duration of azithromycin in the above study was small (&lt;20 subjects) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"     azithromycin",
"    </a>",
"    to young infants for postexposure prophylaxis or treatment of pertussis has been associated with infantile hypertrophic pyloric stenosis (IHPS) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/38,39,41\">",
"     38,39,41",
"    </a>",
"    ]. The greatest risk appears to occur in infants given the medication within the first two weeks of life [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. It is not known if",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     clarithromycin",
"    </a>",
"    poses the same risks for IHPS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/29/3545?source=see_link\">",
"     \"Infantile hypertrophic pyloric stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H543437300\">",
"    <span class=\"h1\">",
"     IMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Well-documented pertussis infection (eg, a positive culture for",
"    <em>",
"     B. pertussis",
"    </em>",
"    or an epidemiologic link to a culture-positive case) is likely to confer immunity against pertussis. However, the duration of immunity is unknown, and pertussis infection can reoccur as immunity wanes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/24\">",
"     24",
"    </a>",
"    ]. The American Academy of Pediatrics recommends that young children who have had pertussis disease complete the primary diphtheria-tetanus-pertussis vaccine series with pertussis containing vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Vaccination'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initiation of postexposure prophylaxis in asymptomatic contacts within 21 days of the onset of cough in the index case can prevent the development of symptoms. The utility of postexposure prophylaxis after 21 days of onset of cough in the index case is unclear. We suggest antimicrobial prophylaxis for close contacts of the index case and for exposed individuals at high risk for severe or complicated pertussis, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective epidemiologic studies have suggested that early chemoprophylaxis is useful in diminishing the risk of transmission of pertussis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/24,44-46\">",
"     24,44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the only prospective randomized trial,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    prophylaxis was 68 percent efficacious in preventing culture-confirmed pertussis in household contacts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/47\">",
"     47",
"    </a>",
"    ]. However, there was no difference in duration of respiratory symptoms between the treatment and placebo groups. Of note, 20 percent of household contacts in both groups had symptoms consistent with pertussis before treatment was initiated. A post-hoc analysis excluding these subjects demonstrated no difference in the secondary attack rate between treatment and placebo groups, but the sample size may have been too small to detect a significant difference. Therefore, antimicrobial prophylaxis continues to be recommended for close contacts of patients with pertussis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Prophylaxis indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that must be considered in the decision include the contagiousness of the patient, the intensity of the exposure, the potential for consequences of severe pertussis in the contact, and the possibility for secondary exposure of persons at high risk of severe infection from the contact [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/28\">",
"     28",
"    </a>",
"    ]. The benefits of prophylaxis must be weighed against the potential adverse effects of therapy.",
"   </p>",
"   <p>",
"    We suggest antimicrobial prophylaxis for close contacts of the index case and for exposed individuals at high risk for severe or complicated pertussis, as discussed below.",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics (AAP) recommends antimicrobial prophylaxis for all close contacts, such as child care workers or household members, regardless of their immunization status [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/24\">",
"     24",
"    </a>",
"    ]. The AAP generally does not recommend extensive prophylaxis for entire classrooms or schools; local public health officials should be consulted for recommendations regarding control of pertussis in schools [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antimicrobial prophylaxis in conjunction with therapy of infected patients has been shown to be effective for the termination of nosocomial outbreaks of pertussis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/48\">",
"     48",
"    </a>",
"    ]. Thus, prophylaxis should be given to exposed healthcare workers and patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Close contacts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Close contacts are defined by [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Face-to-face exposure within three feet of a symptomatic patient",
"     </li>",
"     <li>",
"      Direct contact with respiratory, oral, or nasal secretions from a symptomatic patient",
"     </li>",
"     <li>",
"      Sharing the same confined space in close proximity with a symptomatic patient for &ge;1 hour",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persons at high risk for severe or complicated pertussis include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infants younger than one year, particularly those younger than four months",
"     </li>",
"     <li>",
"      Persons with immunodeficiency",
"     </li>",
"     <li>",
"      Persons with underlying medical conditions (chronic lung disease, respiratory insufficiency, cystic fibrosis)",
"     </li>",
"     <li>",
"      Because of the risk of severe disease in infants younger than one year of age, especially those younger than four months of age, women in the third trimester of pregnancy should be given postexposure prophylaxis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Choice of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike most prophylaxis regimens, chemoprophylaxis for pertussis consists of full dosing of antimicrobial therapy (",
"    <a class=\"graphic graphic_table graphicRef75339 \" href=\"UTD.htm?24/3/24636\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/24,28,44,45\">",
"     24,28,44,45",
"    </a>",
"    ]. Antimicrobial prophylaxis for contacts is probably most effective when initiated within 21 days of the onset of cough in the index patient [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Adverse reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adverse effects of antimicrobial prophylaxis of",
"    <em>",
"     B. pertussis",
"    </em>",
"    infection are the same as those of antimicrobial treatment. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Adverse effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     OTHER PREVENTION MEASURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Isolation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard precautions, as well as droplet precautions (mask within three feet), are recommended for children with pertussis who are admitted to the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/24\">",
"     24",
"    </a>",
"    ]. These precautions should be in effect until five days of effective therapy have been administered or three weeks after the onset of symptoms in untreated patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link&amp;anchor=H12#H12\">",
"     \"General principles of infection control\", section on 'Droplet precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization against pertussis has dramatically reduced the burden of disease from the prevaccination era. Initial vaccines used killed whole-cell pertussis in combination with tetanus toxoid and diphtheria toxoid. However, due to reports of adverse events that were associated with whole-cell pertussis, acellular pertussis vaccines (which contain purified pertussis antigens only) were developed and are currently the only pertussis vaccines in use in the United States. These vaccines are available in combination with tetanus toxoid and diphtheria toxoid.",
"   </p>",
"   <p>",
"    For children &le;6 years of age, the dosages of diphtheria toxoid and pertussis antigens are higher than in the adolescent and adult formulation. Consequently, the notations of these vaccines are different. For children &le;6 years of age, the combined diphtheria and tetanus toxoid and acellular pertussis is notated as DTaP, whereas for adolescents and adults, the combined diphtheria and tetanus toxoid and acellular pertussis vaccine is notated as Tdap. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5722?source=see_link&amp;anchor=H3#H3\">",
"     \"Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age\", section on 'Vaccines'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34233?source=see_link&amp;anchor=H3#H3\">",
"     \"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age\", section on 'Vaccines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Routine immunization",
"      </strong>",
"      &mdash; Routine vaccination of children, adolescents, and adults (including pregnant women) is the most important preventive strategy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/28\">",
"       28",
"      </a>",
"      ]. Routine vaccination against pertussis is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5722?source=see_link\">",
"       \"Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34233?source=see_link\">",
"       \"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link&amp;anchor=H17#H17\">",
"       \"Immunizations during pregnancy\", section on 'Tetanus, diphtheria, pertussis (Tdap)'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=see_link&amp;anchor=H12882667#H12882667\">",
"       \"Treatment and prevention of Bordetella pertussis infection in adolescents and adults\", section on 'Vaccination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Immunization of contacts",
"      </strong>",
"      &ndash; Close contacts of the index case who are younger than seven years of age and who are unimmunized or underimmunized should have pertussis immunization initiated or continued according to the recommended schedule [",
"      <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34233?source=see_link\">",
"       \"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5722?source=see_link&amp;anchor=H3#H3\">",
"       \"Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age\", section on 'Vaccines'",
"      </a>",
"      .)",
"      <br/>",
"     </li>",
"     <li>",
"      <strong>",
"       Immunization after pertussis infection",
"      </strong>",
"      &ndash; Well-documented pertussis infection (eg, a positive culture for",
"      <em>",
"       B. pertussis",
"      </em>",
"      or an epidemiologic link to a culture-positive case) is likely to confer immunity against pertussis. However, the duration of immunity is unknown. The AAP recommends that children who have had well-documented pertussis disease complete the primary diphtheria-tetanus-pertussis vaccine series with diphtheria-tetanus-acellular pertussis vaccine (DTaP) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Neonatal immunization",
"      </strong>",
"      &ndash; Early neonatal immunization is a strategy that is being studied [",
"      <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/49-51\">",
"       49-51",
"      </a>",
"      ], but is not yet recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     School or day care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the high risk of transmission, infected children should be excluded from school or day care until they have completed five days of effective antimicrobial therapy, or, if they are not treated, 21 days after the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25833/abstract/24\">",
"     24",
"    </a>",
"    ]. Contacts of an infected child should be closely observed for development of respiratory symptoms for at least 21 days after the last contact with the infected individual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/38/36450?source=see_link\">",
"       \"Patient information: Whooping cough (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=see_link\">",
"       \"Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/18/37156?source=see_link\">",
"       \"Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supportive care is the mainstay of treatment for pertussis in infants and children. Particular attention must be paid to the child's fluid and nutritional status. Indications for hospitalization include increased work of breathing, inability to feed, cyanosis, apnea, seizures, or concerns for rapid deterioration. For infants &lt;3 months, hospitalization at a major medical center with a pediatric intensive care unit may be desirable because clinical decline may occur rapidly and without warning. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adjunctive treatments including bronchodilators, corticosteroids, and antitussive agents have not been proven to be beneficial in patients with pertussis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Adjunctive treatments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When administered early in the course, antimicrobial therapy can shorten the duration of symptoms and decrease transmission to close contacts. Early initiation of antimicrobial therapy entails a high degree of clinical suspicion, since laboratory confirmation of the diagnosis can take several days to weeks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=see_link&amp;anchor=H21#H21\">",
"       \"Clinical features and diagnosis of Bordetella pertussis infection in infants and children\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Given the ability of antibiotics to eradicate pertussis from the nasopharynx, we recommend antimicrobial treatment for infants and children who have",
"      <em>",
"       Bordetella pertussis",
"      </em>",
"      isolated from cultures or have positive polymerase chain reaction for pertussis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment indications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=see_link&amp;anchor=H21#H21\">",
"       \"Clinical features and diagnosis of Bordetella pertussis infection in infants and children\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We also recommend antimicrobial treatment for patients with a clinical diagnosis of pertussis who have had symptoms for less than 21 days. (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment indications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=see_link&amp;anchor=H21#H21\">",
"       \"Clinical features and diagnosis of Bordetella pertussis infection in infants and children\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend macrolide antibiotics for the treatment and prophylaxis of pertussis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX) may be an alternative for patients who have a contraindication to or cannot tolerate macrolide agents (",
"      <a class=\"graphic graphic_table graphicRef75339 \" href=\"UTD.htm?24/3/24636\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Choice of agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infantile hypertrophic pyloric stenosis should be considered in young infants who develop vomiting within one month of therapy with a macrolide antibiotic given in the first month of life. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Adverse effects'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/29/3545?source=see_link\">",
"       \"Infantile hypertrophic pyloric stenosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest antimicrobial prophylaxis for close contacts of the index case and for individuals at high risk for severe or complicated pertussis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Prophylaxis indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The regimen for antimicrobial prophylaxis is the same as that for treatment (",
"      <a class=\"graphic graphic_table graphicRef75339 \" href=\"UTD.htm?24/3/24636\">",
"       table 1",
"      </a>",
"      ). Antimicrobial prophylaxis should be initiated within 21 days of onset of cough in the index case. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Choice of regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In countries where the diphtheria-tetanus-acellular pertussis (DTaP) vaccine is available, we suggest that incompletely immunized children (&lt;7 years of age) with well-documented pertussis infection complete immunization with DTaP rather than with diphtheria-tetanus vaccine (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Vaccination'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5722?source=see_link\">",
"       \"Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with pertussis or suspected pertussis may return to school or day care after they have completed five days of effective antimicrobial therapy or, if they are not treated, 21 days after the onset of symptoms. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'School or day care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/1\">",
"      Halperin SA, Wang EE, Law B, et al. Epidemiological features of pertussis in hospitalized patients in Canada, 1991-1997: report of the Immunization Monitoring Program--Active (IMPACT). Clin Infect Dis 1999; 28:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Pertussis--United States, 2001-2003. MMWR Morb Mortal Wkly Rep 2005; 54:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/3\">",
"      Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005; 18:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/4\">",
"      Paddock CD, Sanden GN, Cherry JD, et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis 2008; 47:328.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Pertussis in young infants. www.aap-ca.org/clinical/pertussis/pertussis_in_young_infants.html (Accessed on February 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/6\">",
"      Pillay V, Swingler G. Symptomatic treatment of the cough in whooping cough. Cochrane Database Syst Rev 2003; :CD003257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/7\">",
"      Rowlands HE, Goldman AP, Harrington K, et al. Impact of rapid leukodepletion on the outcome of severe clinical pertussis in young infants. Pediatrics 2010; 126:e816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/8\">",
"      Romano MJ, Weber MD, Weisse ME, Siu BL. Pertussis pneumonia, hypoxemia, hyperleukocytosis, and pulmonary hypertension: improvement in oxygenation after a double volume exchange transfusion. Pediatrics 2004; 114:e264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/9\">",
"      Grzeszczak MJ, Churchwell KB, Edwards KM, Pietsch J. Leukopheresis therapy for severe infantile pertussis with myocardial and pulmonary failure. Pediatr Crit Care Med 2006; 7:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/10\">",
"      Donoso AF, Cruces PI, Camacho JF, et al. Exchange transfusion to reverse severe pertussis-induced cardiogenic shock. Pediatr Infect Dis J 2006; 25:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/11\">",
"      Mertsola J, Viljanen MK, Ruuskanen O. Salbutamol in the treatment of whooping cough. Scand J Infect Dis 1986; 18:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/12\">",
"      Krantz I, Norrby SR, Trollfors B. Salbutamol vs. placebo for treatment of pertussis. Pediatr Infect Dis 1985; 4:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/13\">",
"      Roberts I, Gavin R, Lennon D. Randomized controlled trial of steroids in pertussis. Pediatr Infect Dis J 1992; 11:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/14\">",
"      Zoumboulakis D, Anagnostakis D, Albanis V, Matsaniotis N. Steroids in treatment of pertussis. A controlled clinical trial. Arch Dis Child 1973; 48:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/15\">",
"      Granstr&ouml;m M, Olinder-Nielsen AM, Holmblad P, et al. Specific immunoglobulin for treatment of whooping cough. Lancet 1991; 338:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/16\">",
"      Halasa NB, Barr FE, Johnson JE, Edwards KM. Fatal pulmonary hypertension associated with pertussis in infants: does extracorporeal membrane oxygenation have a role? Pediatrics 2003; 112:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/17\">",
"      Bortolussi R, Miller B, Ledwith M, Halperin S. Clinical course of pertussis in immunized children. Pediatr Infect Dis J 1995; 14:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/18\">",
"      Bass JW. Pertussis: current status of prevention and treatment. Pediatr Infect Dis 1985; 4:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/19\">",
"      Hoppe JE. Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis. The Erythromycin Study Group. Pediatr Infect Dis J 1992; 11:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/20\">",
"      Bass JW, Klenk EL, Kotheimer JB, et al. Antimicrobial treatment of pertussis. J Pediatr 1969; 75:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/21\">",
"      Steketee RW, Wassilak SG, Adkins WN Jr, et al. Evidence for a high attack rate and efficacy of erythromycin prophylaxis in a pertussis outbreak in a facility for the developmentally disabled. J Infect Dis 1988; 157:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/22\">",
"      Bergquist SO, Bernander S, Dahnsj&ouml; H, Sundel&ouml;f B. Erythromycin in the treatment of pertussis: a study of bacteriologic and clinical effects. Pediatr Infect Dis J 1987; 6:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/23\">",
"      Altunaiji S, Kukuruzovic R, Curtis N, Massie J. Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev 2007; :CD004404.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Pertussis (whooping cough). In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.553.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/25\">",
"      Centers for Disease Control and Prevention (CDC). Pertussis--United States, 1997-2000. MMWR Morb Mortal Wkly Rep 2002; 51:73.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Guidelines for the control of pertussis outbreaks. file://www.cdc.gov/vaccines/pubs/pertussis-guide/guide.htm (Accessed on August 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/27\">",
"      Hewlett EL, Edwards KM. Clinical practice. Pertussis--not just for kids. N Engl J Med 2005; 352:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/28\">",
"      Tiwari T, Murphy TV, Moran J, National Immunization Program, CDC. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/29\">",
"      Lebel MH, Mehra S. Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: a prospective, randomized, single blind trial. Pediatr Infect Dis J 2001; 20:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/30\">",
"      Aoyama T, Sunakawa K, Iwata S, et al. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. J Pediatr 1996; 129:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/31\">",
"      Bae A, Zrni T, Begovac J, et al. Short-term treatment of pertussis with azithromycin in infants and young children. Eur J Clin Microbiol Infect Dis 1999; 18:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/32\">",
"      Langley JM, Halperin SA, Boucher FD, et al. Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. Pediatrics 2004; 114:e96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/33\">",
"      Trollfors B. Effect of erythromycin and amoxycillin on Bordetella pertussis in the nasopharynx. Infection 1978; 6:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/34\">",
"      Kwantes W, Joynson DH, Williams WO. Bordetella pertussis isolation in general practice: 1977-79 whooping cough epidemic in West Glamorgan. J Hyg (Lond) 1983; 90:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/35\">",
"      Henry R, Dorman D, Skinner J, Mellis C. Limitations of erythromycin in whooping cough. Med J Aust 1981; 2:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/36\">",
"      Riitta H. The effect of early erythromycin treatment on the infectiousness of whooping cough patients. Acta Paediatr Scand 1982; 298:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/37\">",
"      Friedman DS, Curtis CR, Schauer SL, et al. Surveillance for transmission and antibiotic adverse events among neonates and adults exposed to a healthcare worker with pertussis. Infect Control Hosp Epidemiol 2004; 25:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/38\">",
"      Honein MA, Paulozzi LJ, Himelright IM, et al. Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromcyin: a case review and cohort study. Lancet 1999; 354:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/39\">",
"      Centers for Disease Control and Prevention (CDC). Hypertrophic pyloric stenosis in infants following pertussis prophylaxis with erythromycin--Knoxville, Tennessee, 1999. MMWR Morb Mortal Wkly Rep 1999; 48:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/40\">",
"      Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory committee (ACIP). MMWR Recomm Rep 1991; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/41\">",
"      Morrison W. Infantile hypertrophic pyloric stenosis in infants treated with azithromycin. Pediatr Infect Dis J 2007; 26:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/42\">",
"      Mahon BE, Rosenman MB, Kleiman MB. Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J Pediatr 2001; 139:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/43\">",
"      Cooper WO, Griffin MR, Arbogast P, et al. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med 2002; 156:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/44\">",
"      Dodhia H, Miller E. Review of the evidence for the use of erythromycin in the management of persons exposed to pertussis. Epidemiol Infect 1998; 120:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/45\">",
"      De Serres G, Boulianne N, Duval B. Field effectiveness of erythromycin prophylaxis to prevent pertussis within families. Pediatr Infect Dis J 1995; 14:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/46\">",
"      Yeh SH. Pertussis: persistent pathogen, imperfect vaccines. Expert Rev Vaccines 2003; 2:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/47\">",
"      Halperin SA, Bortolussi R, Langley JM, et al. A randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive bordetella pertussis infection. Pediatrics 1999; 104:e42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/48\">",
"      Cherry JD. Pertussis in adults. Ann Intern Med 1998; 128:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/49\">",
"      Knuf M, Schmitt HJ, Wolter J, et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr 2008; 152:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/50\">",
"      Belloni C, De Silvestri A, Tinelli C, et al. Immunogenicity of a three-component acellular pertussis vaccine administered at birth. Pediatrics 2003; 111:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25833/abstract/51\">",
"      Halasa NB, O'Shea A, Shi JR, et al. Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. J Pediatr 2008; 153:327.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5997 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-2AD339225F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_14_25833=[""].join("\n");
var outline_f25_14_25833=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hospitalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fluids and nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Adjunctive treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ANTIMICROBIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Rationale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Children &ge;6 months",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Infants &lt;6 months",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H968412571\">",
"      Infants &lt;1 month of age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H968412582\">",
"      Infants 1 to 5 months of age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dose and duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H543437300\">",
"      IMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ANTIMICROBIAL PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Prophylaxis indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Close contacts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Choice of regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Adverse reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      OTHER PREVENTION MEASURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Isolation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      School or day care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5997\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5997|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/3/24636\" title=\"table 1\">",
"      Pertussis Rx and prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=related_link\">",
"      Clinical features and diagnosis of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=related_link\">",
"      Clinical features and diagnosis of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13911?source=related_link\">",
"      Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34233?source=related_link\">",
"      Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5722?source=related_link\">",
"      Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/29/3545?source=related_link\">",
"      Infantile hypertrophic pyloric stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/18/37156?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=related_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/38/36450?source=related_link\">",
"      Patient information: Whooping cough (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=related_link\">",
"      Treatment of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_14_25834="Fertility, pregnancy, and nursing in inflammatory bowel disease";
var content_f25_14_25834=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fertility, pregnancy, and nursing in inflammatory bowel disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/14/25834/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/14/25834/contributors\">",
"     Mark A Peppercorn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/14/25834/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/14/25834/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/14/25834/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/14/25834/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/14/25834/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/14/25834/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory bowel disease (IBD) can affect women in their childbearing years and therefore has implications on fertility, pregnancy, and nursing.",
"   </p>",
"   <p>",
"    This topic will review issues related to fertility in patients with IBD and the diagnosis and management of IBD in pregnant and nursing women. The medical management of IBD in the general population is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link\">",
"     \"Management of mild to moderate ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"     \"Management of severe ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link\">",
"     \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=see_link\">",
"     \"Overview of the medical management of mild to moderate Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H692771488\">",
"    <span class=\"h1\">",
"     FERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with quiescent inflammatory bowel disease (IBD) do not have decreased fertility as compared with the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Low birth rates among women with IBD are more likely due to patient choice than disease-related infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17287?source=see_link\">",
"     \"Overview of infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, IBD can cause infertility in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Active inflammation in women with Crohn&rsquo;s disease may result in infertility due to inflammation involving the fallopian tubes and ovaries [",
"      <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/4\">",
"       4",
"      </a>",
"      ]. Perianal disease can also cause dyspareunia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3367?source=see_link&amp;anchor=H5#H5\">",
"       \"Causes of female infertility\", section on 'Fallopian tube abnormalities/pelvic adhesions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medications may decrease fertility in men. As examples,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      can cause reversible oligospermia. In addition, sulfasalazine is also associated with reduced sperm motility and abnormal sperm morphology [",
"      <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/5-7\">",
"       5-7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Surgery may impact fertility in patients with IBD. Proctocolectomy in men may lead to impotence or ejaculatory difficulties [",
"      <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/8\">",
"       8",
"      </a>",
"      ]. Restorative proctocolectomy with ileoanal anastomosis has been associated with dyspareunia and a reduction in fertility due to scarring and formation of adnexal adhesions [",
"      <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/2,9-12\">",
"       2,9-12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link&amp;anchor=H165136853#H165136853\">",
"       \"Surgical management of ulcerative colitis\", section on 'Types of surgical procedures based upon clinical setting'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/29/38361?source=see_link&amp;anchor=H3886063#H3886063\">",
"       \"Operative management of Crohn's disease of the small bowel and colon\", section on 'Operative management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H692770159\">",
"    <span class=\"h1\">",
"     PRECONCEPTION COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preconception counseling offers an opportunity for the clinician to address specific patient concerns regarding the risk of transmission of inflammatory bowel disease (IBD) to their offspring, to optimize control of disease activity and nutritional status, and discontinue medications that may adversely affect pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/25/16794?source=see_link\">",
"     \"Preconception evaluation and counseling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H692770651\">",
"    <span class=\"h2\">",
"     Heredity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although IBD follows a non-Mendelian pattern of inheritance, genetically determined factors contribute to IBD susceptibility. First-degree relatives of patients with IBD are approximately 3 to 20 times more likely to develop IBD as compared with the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/13-18\">",
"     13-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical features of the disease also demonstrate a heritable pattern with concordance in disease location (eg, ileal versus colonic Crohn&rsquo;s disease) and type (eg, fibrostenotic Crohn&rsquo;s disease, fistulas) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/19-24\">",
"     19-24",
"    </a>",
"    ]. Subsequent generations may demonstrate \"genetic anticipation\" with the development of earlier onset of IBD and more severe disease as compared with their parents [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/18,25\">",
"     18,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of genetic factors that increase susceptibility to IBD and genetic syndromes associated with IBD is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44455?source=see_link\">",
"     \"Genetic factors in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H521044030\">",
"    <span class=\"h2\">",
"     Disease control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with IBD should attempt conception at a time when the disease is in remission. The course of IBD during pregnancy appears to be determined in part by the activity of the disease at conception. Patients in remission at the time of conception are likely to remain in remission during pregnancy. In contrast, two-thirds of patients with active disease at conception will have active disease during the pregnancy and, of these, two-thirds will have a disease flare with worsening symptoms during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H692771764\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications that may affect fertility or adversely affect pregnancy should be discontinued, when possible, in women planning pregnancy. The risks and benefits of fetal drug exposure versus discontinuation of medications should be specifically discussed. These risks and benefits are discussed in detail below (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Medications during pregnancy and lactation'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    causes reversible oligospermia that resolves within discontinuation of therapy. Oligospermia is not associated with 5-aminosalicylic acid (5-ASA) medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    ). Men on sulfasalazine should therefore be transitioned to 5-ASAs three months prior to conception (",
"    <a class=\"graphic graphic_table graphicRef86818 \" href=\"UTD.htm?2/28/2509\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H451430319\">",
"     'Sulfasalazine and 5-aminosalicylic acid'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is associated with oligospermia and is an abortifacient and potent teratogen. Men should discontinue methotrexate and use contraception for at least three months prior to conception. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H17#H17\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Methotrexate'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H12\">",
"     'Medications during pregnancy and lactation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    does not appear to reduce male fertility or to have a demonstrable effect on sperm. However, given the paucity of data related to male-mediated teratogenicity and the potential for unknown effects on offspring, men on cyclosporine should discontinue the medication for three months prior to conception. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H12#H12\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Cyclosporine'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H18\">",
"     'Cyclosporine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Data on the risk of fetal teratogenicity with paternal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    use are limited and studies have had variable results [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/30-35\">",
"     30-35",
"    </a>",
"    ]. In a 2012 meta-analysis, exposure to thiopurines in men at the time of conception was not associated with congenital abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/36\">",
"     36",
"    </a>",
"    ]. We therefore do not routinely recommend that men on azathioprine and mercaptopurine discontinue treatment unless the couple has a history of infertility or miscarriages. In such cases, we advise the prospective father to discontinue",
"    <span class=\"nowrap\">",
"     azathioprine/mercaptopurine",
"    </span>",
"    three months prior to conception. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21592?source=see_link\">",
"     \"Azathioprine and 6-mercaptopurine in inflammatory bowel disease\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H521045305\">",
"     'Azathioprine and mercaptopurine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H805110346\">",
"    <span class=\"h2\">",
"     Nutrition and supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consultation with a nutritionist should be considered to offer advice on eating a well-balanced, healthy diet.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    is important for neural tube development during pregnancy. Folate supplementation (2 mg daily) should be recommended in patients with IBD on low residue diets, with ileal involvement, and patients on medications that interfere with folic acid metabolism (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/4,37\">",
"     4,37",
"    </a>",
"    ]). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5081?source=see_link\">",
"     \"Folic acid for prevention of neural tube defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with IBD are at risk for iron and vitamin B12 deficiency. Furthermore, iron requirements increase during pregnancy. Iron and B12 levels should therefore be checked in the first trimester and supplementation should be provided as needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=see_link\">",
"     \"Nutrient deficiencies in inflammatory bowel disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=see_link&amp;anchor=H16#H16\">",
"     \"Nutrition in pregnancy\", section on 'Iron'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREGNANCY AND LACTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy, through its effect on the immune system, may confer a small protective effect on inflammatory bowel disease (IBD) activity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/38\">",
"     38",
"    </a>",
"    ]. However, women with IBD are at an increased risk for worse obstetric and medical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Effect of pregnancy on IBD",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with quiescent IBD at conception, the course of IBD is approximately the same as in nonpregnant patients. Furthermore, some studies suggest that the course of Crohn&rsquo;s disease may in fact be slightly milder during pregnancy. In one observational study, Crohn&rsquo;s disease activity was lower during pregnancy in women with Crohn&rsquo;s disease as compared with the years preceding and following pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/42\">",
"     42",
"    </a>",
"    ]. However, it is unclear if this reduction in disease activity was due to the effect of pregnancy on the immune system or due to smoking cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately one-third of women with quiescent disease at conception relapse during the pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/43\">",
"     43",
"    </a>",
"    ]. Relapses are more common during the first trimester. However, remission achieved during pregnancy is likely to be sustained throughout the remainder of the pregnancy.",
"   </p>",
"   <p>",
"    In contrast, approximately 70 percent of patients with active disease at conception are likely to have continued or worsening symptoms during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Complications occurring during pregnancy in women whose disease is active are similar to those in nonpregnant patients with ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link&amp;anchor=H25425471#H25425471\">",
"     \"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults\", section on 'Acute complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The events occurring during one pregnancy do not correlate with the course in subsequent pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/45\">",
"     45",
"    </a>",
"    ]. However, pregnancy may be protective in the long term, as suggested by lower relapse rates up to ten years following pregnancy as compared with rates prior to pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. As parity increases, the risk for surgery to treat IBD also decreases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Effect of IBD on pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women with IBD may be at increased risk for antepartum hemorrhage, low birth weight infants, and premature delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/39,41,48,49\">",
"     39,41,48,49",
"    </a>",
"    ]. However, the risk of congenital abnormalities does not appear to be increased [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/39,50,51\">",
"     39,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree of disease activity may account, in part, for the poor pregnancy-related outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/50,52\">",
"     50,52",
"    </a>",
"    ]. The risk of poor pregnancy outcomes in women with IBD is greatest in those who have active disease at the time of conception, and in whom remission may be difficult to achieve during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/3,50,52-56\">",
"     3,50,52-56",
"    </a>",
"    ]. As an example, in a Danish cohort study, the risk of preterm birth increased if the mother was hospitalized during pregnancy (odds ratio [OR] 1.4), and if the first hospitalization for ulcerative colitis occurred during pregnancy (OR 3.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with IBD should be followed closely, particularly in the third trimester, and if the disease is active. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link&amp;anchor=H16043308#H16043308\">",
"     \"Risk factors for preterm labor and delivery\", section on 'Chronic maternal medical disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30121?source=see_link\">",
"     \"Overview of fetal assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H805115129\">",
"    <span class=\"h2\">",
"     Effect of lactation on IBD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breastfeeding does not independently affect the course of disease in IBD after adjusting for an increase in disease activity due to cessation of IBD medications. However, 56 percent of women with IBD do not breastfeed their children either because of a clinician recommendation, fear of medication interactions, or personal choice [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/57\">",
"     57",
"    </a>",
"    ]. It is therefore important to discuss the benefits of breastfeeding as well as the compatibility of several antiinflammatory and immunosuppressive medications with breastfeeding as discussed below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"     \"Infant benefits of breastfeeding\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H12\">",
"     'Medications during pregnancy and lactation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=see_link\">",
"     \"Principles of medication use during lactation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42616?source=see_link\">",
"     \"Breastfeeding: Parental education and support\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SAFETY OF DIAGNOSTIC EVALUATION DURING PREGNANCY AND LACTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopy or imaging studies may be indicated during pregnancy for the diagnosis of suspected inflammatory bowel disease (IBD) or for the assessment of disease severity, or diagnosis and management of complications in patients with established IBD. However, it is important to consider the risks, benefits, and optimal timing of such a diagnostic evaluation in pregnant or nursing women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link&amp;anchor=H25426526#H25426526\">",
"     \"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link&amp;anchor=H12689148#H12689148\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link&amp;anchor=H1133540027#H1133540027\">",
"     \"Management of severe ulcerative colitis\", section on 'Pretreatment evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The safety and efficacy of endoscopic procedures during pregnancy have not been extensively studied. Endoscopy should be performed during pregnancy only if there is a strong indication (eg, significant bleeding) or if the information is critical for making treatment decisions (eg, obtaining colon biopsies to exclude CMV colitis and establish the diagnosis of IBD in a pregnant patient with chronic diarrhea). When possible, endoscopy should be postponed until the second trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/58\">",
"     58",
"    </a>",
"    ]. Flexible sigmoidoscopy may be safe during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/59\">",
"     59",
"    </a>",
"    ]. While there are several reports of colonoscopies being performed during pregnancy without complications, experience is relatively limited compared with sigmoidoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Obstetrical staff should be closely involved and the degree of maternal and fetal monitoring should be individualized. Recommendations for procedural sedation for endoscopy in pregnant and nursing women are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of procedural sedation for gastrointestinal endoscopy\", section on 'Pregnancy and lactation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiographic studies involving ionizing radiation (eg, computed tomography (CT) enterography, abdominal x-rays, small bowel follow-through) should be avoided in pregnancy if possible. These studies can be performed if they are necessary for maternal management and if there is no alternative imaging modality available. Several techniques can be used to minimize fetal radiation exposure. Magnetic resonance (MR) enterography is the preferred diagnostic modality because it provides better images than ultrasonography, while avoiding the ionizing radiation of computed tomography. When possible, MR imaging should be avoided in the first trimester, since there is limited experience assessing safety during organogenesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MEDICATIONS DURING PREGNANCY AND LACTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of antiinflammatory and immunosuppressive used during pregnancy and lactation should be based upon their relative safety and indications as well as the risk of relapse of inflammatory bowel disease (IBD) if the medications are discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=see_link\">",
"     \"Principles of medication use during lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Active IBD itself is associated with poor pregnancy outcomes and therefore the risks associated with discontinuing some medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , anti-TNFs) is higher in patients with IBD than those with other inflammatory disorders (eg, rheumatoid arthritis) that are treated with the same medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , are frequently used in the management of patients with inflammatory bowel disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/34/20008?source=see_link\">",
"     \"Antibiotics for treatment of inflammatory bowel diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=see_link&amp;anchor=H12#H12\">",
"     \"Principles of medication use during lactation\", section on 'Antimicrobials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    should be limited to short courses. A number of studies have suggested that metronidazole is not associated with an increased risk of birth defects or cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. However, long-term use in pregnancy remains controversial because it is carcinogenic in rodents and mutagenic in bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. In one study, metronidazole was associated with prematurity in high risk women, but it is unclear if these results are generalizable [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    is excreted into breast milk. The American Academy of Pediatrics classifies metronidazole as a drug for which the effect on nursing infants is unknown, but may be of concern [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=see_link&amp;anchor=H396541156#H396541156\">",
"     \"Principles of medication use during lactation\", section on 'Metronidazole and tinidazole'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     Ciprofloxacin",
"    </a>",
"    is not recommended in pregnant women and in children under age 18 as it affects growing cartilage and can cause arthropathy. However, among 200 pregnancies exposed to fluoroquinolones (including ciprofloxacin), the incidence of adverse events were similar to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     Ciprofloxacin",
"    </a>",
"    is excreted into breast milk, but short courses of ciprofloxacin are probably safe during breastfeeding due to the low concentration in breast milk. The American Academy of Pediatrics classifies ciprofloxacin as compatible with breastfeeding [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H451430319\">",
"    <span class=\"h2\">",
"     Sulfasalazine and 5-aminosalicylic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    and 5-aminosalicylic acid (5-ASA) drugs can be used during pregnancy and lactation.",
"   </p>",
"   <p>",
"    The incidence of decreased birth weight, prematurity, spontaneous abortion, stillbirths, or birth defects is similar in children born to mothers taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    as compared with the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/68\">",
"     68",
"    </a>",
"    ]. Sulfasalazine and its sulfapyridine metabolite can be found in umbilical cord blood at similar concentrations to maternal blood. However, these concentrations do",
"    <strong>",
"     not",
"    </strong>",
"    cause significant displacement of bilirubin from albumin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. As a result, sulfasalazine does not have to be discontinued during pregnancy.",
"   </p>",
"   <p>",
"    Folate supplementation (2 mg daily) should be recommended in patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    as it interferes with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H805110346\">",
"     'Nutrition and supplements'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Experience with the 5-ASA agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    during pregnancy is more limited as compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , but studies suggest that 5-ASA agents by themselves are safe during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/71-74\">",
"     71-74",
"    </a>",
"    ]. Enteric coating of mesalamine with dibutyl phthalate (DBP) has been associated with skeletal malformations and adverse effects on the male reproductive system in fetal animal models exposed to high doses of DBP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/75\">",
"     75",
"    </a>",
"    ]",
"    <em>",
"     .",
"    </em>",
"    Patients on enteric coated mesalamine should therefore be switched to a non-enteric coated 5-ASA (",
"    <a class=\"graphic graphic_table graphicRef86818 \" href=\"UTD.htm?2/28/2509\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link\">",
"     \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    and 5-ASAs are excreted in breast milk in low concentrations. Infants whose mothers are on sulfasalazine and 5-ASAs should be monitored for the development of diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/66,76,77\">",
"     66,76,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are considered low risk in pregnancy and should be administered for the same indications as a nonpregnant patient with IBD. The lowest possible dose of systemic glucocorticoids should be used and, if possible, their use should be avoided in the first trimester due to the risk of oral clefts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H8#H8\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Glucocorticoids'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link\">",
"     \"Risk factors for preterm labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although studies have demonstrated a threefold increase in the risk of cleft palate after maternal exposure to glucocorticoids, the absolute risk is low (0.2 to 0.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/78\">",
"     78",
"    </a>",
"    ]. In addition, as palatal closure is usually complete by the 12",
"    <sup>",
"     th",
"    </sup>",
"    week of pregnancy, the risk is limited to administration during the first trimester. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/44/20169?source=see_link\">",
"     \"Etiology, prenatal diagnosis, obstetrical management, and recurrence of orofacial clefts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fetal adrenal insufficiency and low birth weight have also been associated with glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/79\">",
"     79",
"    </a>",
"    ]. However, adrenal insufficiency of the fetus following maternal administration of glucocorticoids is rare as rapid maternal metabolism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    , binding to serum proteins, and conversion to inactive metabolites by placental 11 beta-hydroxysteroid dehydrogenase results in relatively low fetal concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. However, long-term administration of high doses of glucocorticoids (&gt;20 mg) is associated with adrenal insufficiency and warrants close neonatal monitoring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30121?source=see_link\">",
"     \"Overview of fetal assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glucocorticoids have the potential for exacerbating pregnancy-induced hypertension, gestational diabetes, and preterm delivery from premature rupture of membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/82\">",
"     82",
"    </a>",
"    ]. Therefore, pregnant women on glucocorticoids should be appropriately monitored for these complications [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/78,83\">",
"     78,83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29383?source=see_link\">",
"     \"Gestational hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37866?source=see_link\">",
"     \"Medical management and follow-up of gestational diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4313?source=see_link\">",
"     \"Obstetrical management of pregnancies complicated by gestational diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link\">",
"     \"Preterm premature rupture of membranes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although low levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and its metabolite,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    , can be measured in breast milk, these are unlikely to be clinically significant. In one study, following a dose of prednisolone 50 mg IV, an average of 0.025 percent was recovered from breast milk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H521045305\">",
"    <span class=\"h2\">",
"     Azathioprine and mercaptopurine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiopurines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    , should be continued during pregnancy if the IBD cannot be managed with other medications [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/30,85\">",
"     30,85",
"    </a>",
"    ]. Azathioprine and mercaptopurine have been classified as pregnancy category D medications by the US Food and Drug Administration (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 2",
"    </a>",
"    ). However, in a 2012 meta-analysis of 3045 women with IBD, thiopurine exposure was associated with preterm birth (odds ratio [OR] 1.7, 95% CI 1.3-2.2), but not with congenital abnormalities or low birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, discontinuing azathioprine and mercaptopurine is associated with a high rate of relapse and active IBD is itself associated with an increased risk of low birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/30,86-92\">",
"     30,86-92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    are detectable in breast milk but studies have demonstrated that levels in breast milk are low and metabolites are undetectable in breastfed neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. Although data are limited, these studies suggest that breastfeeding is safe. Breastfeeding can be continued while on azathioprine and mercaptopurine after a detailed discussion of the risks and benefits of breastfeeding [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H9#H9\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Azathioprine and 6-MP'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is effective at inducing remission in patients with severe steroid refractory ulcerative colitis during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/52\">",
"     52",
"    </a>",
"    ]. When the administration of cyclosporine&nbsp;is necessary during pregnancy, the minimum dose should be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link&amp;anchor=H12#H12\">",
"     \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\", section on 'Cyclosporine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a meta-analysis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    &nbsp;was not associated with an increase in risk of congenital malformations but was associated with increased rates of prematurity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/95\">",
"     95",
"    </a>",
"    ]. A higher incidence of small for gestational age infants has also been reported. However, it is unclear if fetal growth restriction and prematurity were due to cyclosporine or due to the mother&rsquo;s underlying disease.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    &nbsp;should not be administered in breastfeeding women. Cyclosporine is excreted in breast milk, and therapeutic levels have been reported in breastfed infants [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H12#H12\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Cyclosporine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is contraindicated in pregnancy as it is a potent abortifacient, and its use during pregnancy is associated with multiple skeletal abnormalities. Women who plan to conceive should therefore discontinue methotrexate and use contraception for at least three months prior to conception.",
"   </p>",
"   <p>",
"    The rate of congenital malformations due to maternal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    use is estimated to be 9 to 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. The risk of methotrexate-induced developmental toxicity is highest at 8 to 10 weeks of gestation and with doses &ge;10",
"    <span class=\"nowrap\">",
"     mg/week.",
"    </span>",
"   </p>",
"   <p>",
"    Breastfeeding is contraindicated in women on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    as it is excreted into breast milk and can accumulate in neonatal tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/4,100\">",
"     4,100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H17#H17\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Anti-tumor necrosis factor agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with anti-tumor necrosis factor (anti-TNF) therapy agents used to treat IBD during pregnancy is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/101,102\">",
"     101,102",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , and certolizumab are classified as pregnancy category B medications and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    is classified as pregnancy category C by the US Food and Drug Administration (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26647?source=see_link\">",
"     \"Anti-tumor necrosis factor therapy in ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"     \"Infliximab in Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H805105456\">",
"    <span class=\"h3\">",
"     Infliximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    is compatible with use during conception in men and women and during pregnancy in at least the first two trimesters [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rates of live births, miscarriages, and therapeutic terminations do not appear to be significantly different in women exposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    during pregnancy as compared with the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/103-105\">",
"     103-105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    crosses the placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/106\">",
"     106",
"    </a>",
"    ]. The exact timing is unclear but in general, maternal antibodies are transported across the placenta beginning in the early to mid second trimester, with the highest fetal concentration in the third trimester near term. High levels of infliximab have been detected in the cord blood of newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. The clinical significance of this is unclear but it raises concern about an increased risk of infection and a suboptimal response to vaccinations in the newborn [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/109\">",
"     109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link\">",
"     \"Standard immunizations for children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Discontinuing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    early in the third trimester or at the end of the second trimester may help to reduce infliximab transport across the placenta and lower levels of serum infliximab in the newborn. Discontinuation of anti-TNF therapy also appears to be safe for pregnant women with quiescent IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/108\">",
"     108",
"    </a>",
"    ]. We therefore suggest discontinuing infliximab 8 to 10 weeks before the estimated date of delivery in women with quiescent IBD. Infliximab can then be resumed immediately after delivery. IBD flares following discontinuation of infliximab can be treated with resumption of infliximab, unless birth is imminent, or glucocorticoids for the remainder of the pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    is considered compatible with breastfeeding as it is excreted in trace amounts in human milk and is poorly absorbed orally, thus reducing the potential for systemic adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/4,110\">",
"     4,110",
"    </a>",
"    ]. While it is important to note that there are limited safety data and local immune suppression in the gastrointestinal tract is possible, the decision to discontinue infliximab should take into account the importance of the drug to the control of IBD activity in the mother [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/110,111\">",
"     110,111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H805105475\">",
"    <span class=\"h3\">",
"     Adalimumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     Adalimumab",
"    </a>",
"    is considered compatible with use during conception and pregnancy in at least the first two trimesters. In small observational studies, the incidence of congenital malformations, spontaneous abortion, stillbirth, and preterm delivery was not increased in pregnant women exposed to adalimumab. Adalimumab crosses the placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/106\">",
"     106",
"    </a>",
"    ]. We therefore suggest discontinuing adalimumab 8 to 10 weeks before the estimated date of delivery in women with quiescent IBD, as is done with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited evidence suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    is compatible with breastfeeding. While it can be detected in breast milk, levels are low and it has not been demonstrated to adversely affect the nursing infant [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/112\">",
"     112",
"    </a>",
"    ]. As with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , the decision to discontinue the use of adalimumab during nursing should take into account the role of adalimumab in controlling IBD disease activity in the mother.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H805105487\">",
"    <span class=\"h3\">",
"     Certolizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certolizumab is a PEGylated Fab fragment of a humanized anti-TNF-alpha monoclonal antibody. Unlike",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    which are actively transferred across the placenta in the third trimester, there is minimal placental transfer of certolizumab to the infant during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certolizumab can therefore be used through conception and continued throughout pregnancy until delivery. Although there are limited data,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    may also be compatible with breastfeeding as it is minimally excreted into breast milk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H805114179\">",
"    <span class=\"h3\">",
"     Natalizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited safety data on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    during pregnancy and lactation. The risk of congenital malformations was not increased in 164 pregnancies in patients with Crohn&rsquo;s disease or multiple sclerosis on natalizumab during the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Antidiarrheal drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidiarrheal drugs should be avoided, especially early in pregnancy. Antidiarrheals should only be used for severe diarrhea that cannot be controlled with dietary manipulation and bulking agents (eg,",
"    <span class=\"nowrap\">",
"     kaolin/pectin,",
"    </span>",
"    Metamucil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/26/8614?source=see_link\">",
"     psyllium",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Diphenoxylate with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    are not teratogenic in animal studies but there are no controlled studies in humans. Case reports have reported fetal malformations in infants exposed to diphenoxylate with atropine during the first trimester, but it is unclear if this was causal [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/114,115\">",
"     114,115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"     Loperamide",
"    </a>",
"    is compatible with nursing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/66\">",
"     66",
"    </a>",
"    ]. However, there are no data for diphenoxylate.",
"    <span class=\"nowrap\">",
"     Diphenoxylate/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"      atropine",
"     </a>",
"    </span>",
"    should therefore be used only in short, infrequent courses, at low doses while breastfeeding an older infant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications associated with IBD that warrant surgery in a pregnant patient include acute refractory colitis, perforation, abscesses, severe hemorrhage, and obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/4\">",
"     4",
"    </a>",
"    ]. There are limited data pertaining to the risk of surgery in pregnant patients with inflammatory bowel disease (IBD) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/116,117\">",
"     116,117",
"    </a>",
"    ]. However, surgery has been associated with preterm labor and spontaneous abortions, possibly related to inadvertent uterine manipulation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/4,118\">",
"     4,118",
"    </a>",
"    ]. Therefore, when possible, medical treatment should be intensified prior to considering surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/119\">",
"     119",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link&amp;anchor=H25425471#H25425471\">",
"     \"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults\", section on 'Acute complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/29/38361?source=see_link\">",
"     \"Operative management of Crohn's disease of the small bowel and colon\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H692770870\">",
"    <span class=\"h1\">",
"     MODE OF DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with perineal disease or rectal involvement with Crohn&rsquo;s disease should undergo cesarean delivery in order to avoid perineal trauma from vaginal birth that can trigger or worsen existing perineal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/120\">",
"     120",
"    </a>",
"    ]. The mode of delivery in all other patients with inflammatory bowel disease should be dictated by obstetric necessity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=see_link\">",
"     \"Perianal complications of Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vaginal delivery can be attempted in women with a colostomy, ileostomy, or continent ileostomy and has not been associated with an increased risk of ostomy complications [",
"    <a class=\"abstract\" href=\"UTD.htm?25/14/25834/abstract/4,121\">",
"     4,121",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=see_link&amp;anchor=H24#H24\">",
"     \"Management of patients with a colostomy or ileostomy\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/20/5443?source=see_link\">",
"       \"Patient information: Inflammatory bowel disease and pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5611899\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammatory bowel disease (IBD) can affect women in their childbearing years and therefore has implications on fertility, pregnancy, and nursing. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with quiescent IBD disease do not have decreased fertility compared with the general population. However, fertility in patients with IBD may be affected by active inflammation, medications, and prior surgery. (See",
"      <a class=\"local\" href=\"#H692771488\">",
"       'Fertility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The course of IBD during pregnancy is determined in part by the activity of the disease at conception. Patients in remission at the time of conception are likely to remain in remission during pregnancy. In contrast, approximately 70 percent of patients with active disease at conception are likely to have continued or worsening symptoms during pregnancy. (See",
"      <a class=\"local\" href=\"#H521044030\">",
"       'Disease control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnancy, through its effect on the immune system, may confer a small protective effect on IBD activity. However, women with IBD are at an increased risk for worse obstetric and pregnancy related outcomes. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pregnancy and lactation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endoscopy should be performed during pregnancy only if there is a strong indication or if the information is critical for making treatment decisions. When possible, endoscopy should be postponed until the second trimester. Magnetic resonance enterography is the preferred diagnostic modality in pregnant patients with IBD. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Safety of diagnostic evaluation during pregnancy and lactation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of antiinflammatory and immunosuppressive medications during pregnancy and lactation should be based upon their relative safety and indications as well as the risk of relapse of IBD if the medications are discontinued. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Medications during pregnancy and lactation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with perineal disease or rectal involvement with Crohn&rsquo;s disease should undergo a Cesarean section. The mode of delivery in all other patients with IBD should be dictated by obstetric necessity. (See",
"      <a class=\"local\" href=\"#H692770870\">",
"       'Mode of delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications associated with IBD that warrant surgery in a pregnant patient include acute refractory colitis, perforation, abscesses, severe hemorrhage, and obstruction. Although data are limited, surgery is associated with premature labor or spontaneous abortion, possibly related to inadvertent uterine manipulation. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/1\">",
"      Baird DD, Narendranathan M, Sandler RS. Increased risk of preterm birth for women with inflammatory bowel disease. Gastroenterology 1990; 99:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/2\">",
"      Hudson M, Flett G, Sinclair TS, et al. Fertility and pregnancy in inflammatory bowel disease. Int J Gynaecol Obstet 1997; 58:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/3\">",
"      Woolfson K, Cohen Z, McLeod RS. Crohn's disease and pregnancy. Dis Colon Rectum 1990; 33:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/4\">",
"      Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis 2010; 4:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/5\">",
"      Birnie GG, McLeod TI, Watkinson G. Incidence of sulphasalazine-induced male infertility. Gut 1981; 22:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/6\">",
"      O'Mor&aacute;in C, Smethurst P, Dor&eacute; CJ, Levi AJ. Reversible male infertility due to sulphasalazine: studies in man and rat. Gut 1984; 25:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/7\">",
"      Toovey S, Hudson E, Hendry WF, Levi AJ. Sulphasalazine and male infertility: reversibility and possible mechanism. Gut 1981; 22:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/8\">",
"      Narendranathan M, Sandler RS, Suchindran CM, Savitz DA. Male infertility in inflammatory bowel disease. J Clin Gastroenterol 1989; 11:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/9\">",
"      Weber AM, Ziegler C, Belinson JL, et al. Gynecologic history of women with inflammatory bowel disease. Obstet Gynecol 1995; 86:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/10\">",
"      &Oslash;rding Olsen K, Juul S, Berndtsson I, et al. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology 2002; 122:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/11\">",
"      Tiainen J, Matikainen M, Hiltunen KM. Ileal J-pouch--anal anastomosis, sexual dysfunction, and fertility. Scand J Gastroenterol 1999; 34:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/12\">",
"      Wikland M, Jansson I, Aszt&eacute;ly M, et al. Gynaecological problems related to anatomical changes after conventional proctocolectomy and ileostomy. Int J Colorectal Dis 1990; 5:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/13\">",
"      Laharie D, Debeugny S, Peeters M, et al. Inflammatory bowel disease in spouses and their offspring. Gastroenterology 2001; 120:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/14\">",
"      Roth MP, Petersen GM, McElree C, et al. Familial empiric risk estimates of inflammatory bowel disease in Ashkenazi Jews. Gastroenterology 1989; 96:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/15\">",
"      Mons&eacute;n U, Brostr&ouml;m O, Nordenvall B, et al. Prevalence of inflammatory bowel disease among relatives of patients with ulcerative colitis. Scand J Gastroenterol 1987; 22:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/16\">",
"      Fielding JF. The relative risk of inflammatory bowel disease among parents and siblings of Crohn's disease patients. J Clin Gastroenterol 1986; 8:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/17\">",
"      Yang H, McElree C, Roth MP, et al. Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut 1993; 34:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/18\">",
"      Satsangi J, Grootscholten C, Holt H, Jewell DP. Clinical patterns of familial inflammatory bowel disease. Gut 1996; 38:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/19\">",
"      Bayless TM, Tokayer AZ, Polito JM 2nd, et al. Crohn's disease: concordance for site and clinical type in affected family members--potential hereditary influences. Gastroenterology 1996; 111:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/20\">",
"      Colombel JF, Grandbastien B, Gower-Rousseau C, et al. Clinical characteristics of Crohn's disease in 72 families. Gastroenterology 1996; 111:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/21\">",
"      Polito JM 2nd, Childs B, Mellits ED, et al. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology 1996; 111:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/22\">",
"      Peeters M, Nevens H, Baert F, et al. Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology 1996; 111:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/23\">",
"      Henckaerts L, Van Steen K, Verstreken I, et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol 2009; 7:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/24\">",
"      Annese V, Andreoli A, Astegiano M, et al. Clinical features in familial cases of Crohn's disease and ulcerative colitis in Italy: a GISC study. Italian Study Group for the Disease of Colon and Rectum. Am J Gastroenterol 2001; 96:2939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/25\">",
"      Grandbastien B, Peeters M, Franchimont D, et al. Anticipation in familial Crohn's disease. Gut 1998; 42:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/26\">",
"      Hanan IM, Kirsner JB. Inflammatory bowel disease in the pregnant woman. Clin Perinatol 1985; 12:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/27\">",
"      Rogers RG, Katz VL. Course of Crohn's disease during pregnancy and its effect on pregnancy outcome: a retrospective review. Am J Perinatol 1995; 12:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/28\">",
"      Shaffer JL, Kershaw A, Berrisford MH. Sulphasalazine-induced infertility reversed on transfer to 5-aminosalicylic acid. Lancet 1984; 1:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/29\">",
"      Wu FC, Aitken RJ, Ferguson A. Inflammatory bowel disease and male infertility: effects of sulfasalazine and 5-aminosalicylic acid on sperm-fertilizing capacity and reactive oxygen species generation. Fertil Steril 1989; 52:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/30\">",
"      Francella A, Dyan A, Bodian C, et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003; 124:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/31\">",
"      Rajapakse RO, Korelitz BI, Zlatanic J, et al. Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 2000; 95:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/32\">",
"      Kane SV. What's good for the goose should be good for the gander--6-MP use in fathers with inflammatory bowel disease. Am J Gastroenterol 2000; 95:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/33\">",
"      N&oslash;rg&aring;rd B, Pedersen L, Jacobsen J, et al. The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception. Aliment Pharmacol Ther 2004; 19:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/34\">",
"      Dejaco C, Mittermaier C, Reinisch W, et al. Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology 2001; 121:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/35\">",
"      Teruel C, L&oacute;pez-San Rom&aacute;n A, Bermejo F, et al. Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines. Am J Gastroenterol 2010; 105:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/36\">",
"      Akbari M, Shah S, Velayos FS, et al. Systematic Review and Meta-analysis on the Effects of Thiopurines on Birth Outcomes from Female and Male Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2013; 19:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/37\">",
"      Mullin GE. Micronutrients and inflammatory bowel disease. Nutr Clin Pract 2012; 27:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/38\">",
"      Buyon JP. The effects of pregnancy on autoimmune diseases. J Leukoc Biol 1998; 63:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/39\">",
"      Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007; 56:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/40\">",
"      Mahadevan U, Sandborn WJ, Li DK, et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 2007; 133:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/41\">",
"      Nguyen GC, Boudreau H, Harris ML, Maxwell CV. Outcomes of obstetric hospitalizations among women with inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol 2009; 7:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/42\">",
"      Agret F, Cosnes J, Hassani Z, et al. Impact of pregnancy on the clinical activity of Crohn's disease. Aliment Pharmacol Ther 2005; 21:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/43\">",
"      Nielsen OH, Andreasson B, Bondesen S, Jarnum S. Pregnancy in ulcerative colitis. Scand J Gastroenterol 1983; 18:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/44\">",
"      Smink M, Lotgering FK, Albers L, de Jong DJ. Effect of childbirth on the course of Crohn's disease; results from a retrospective cohort study in the Netherlands. BMC Gastroenterol 2011; 11:6.",
"     </a>",
"    </li>",
"    <li>",
"     Korelitz BI. Pregnancy. In: Seminars in Colon and Rectal Surgery, Peppercorn MA (Ed), WB Saunders, 1993. p.48.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/46\">",
"      Castiglione F, Pignata S, Morace F, et al. Effect of pregnancy on the clinical course of a cohort of women with inflammatory bowel disease. Ital J Gastroenterol 1996; 28:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/47\">",
"      Riis L, Vind I, Politi P, et al. Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel disease. Am J Gastroenterol 2006; 101:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/48\">",
"      Br&ouml;ms G, Granath F, Linder M, et al. Complications from inflammatory bowel disease during pregnancy and delivery. Clin Gastroenterol Hepatol 2012; 10:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/49\">",
"      Bortoli A, Pedersen N, Duricova D, et al. Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. Aliment Pharmacol Ther 2011; 34:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/50\">",
"      N&oslash;rg&aring;rd B, Fonager K, S&oslash;rensen HT, Olsen J. Birth outcomes of women with ulcerative colitis: a nationwide Danish cohort study. Am J Gastroenterol 2000; 95:3165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/51\">",
"      Stephansson O, Larsson H, Pedersen L, et al. Crohn's disease is a risk factor for preterm birth. Clin Gastroenterol Hepatol 2010; 8:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/52\">",
"      Reddy D, Murphy SJ, Kane SV, et al. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol 2008; 103:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/53\">",
"      Baiocco PJ, Korelitz BI. The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. J Clin Gastroenterol 1984; 6:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/54\">",
"      Khosla R, Willoughby CP, Jewell DP. Crohn's disease and pregnancy. Gut 1984; 25:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/55\">",
"      Mayberry JF, Weterman IT. European survey of fertility and pregnancy in women with Crohn's disease: a case control study by European collaborative group. Gut 1986; 27:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/56\">",
"      Fedorkow DM, Persaud D, Nimrod CA. Inflammatory bowel disease: a controlled study of late pregnancy outcome. Am J Obstet Gynecol 1989; 160:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/57\">",
"      Kane S, Lemieux N. The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease. Am J Gastroenterol 2005; 100:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/58\">",
"      ASGE Standard of Practice Committee, Shergill AK, Ben-Menachem T, et al. Guidelines for endoscopy in pregnant and lactating women. Gastrointest Endosc 2012; 76:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/59\">",
"      Cappell MS, Colon VJ, Sidhom OA. A study at 10 medical centers of the safety and efficacy of 48 flexible sigmoidoscopies and 8 colonoscopies during pregnancy with follow-up of fetal outcome and with comparison to control groups. Dig Dis Sci 1996; 41:2353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/60\">",
"      Homan WP, Thorbjarnarson B. Crohn disease and pregnancy. Arch Surg 1976; 111:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/61\">",
"      Czeizel AE, Rockenbauer M. A population based case-control teratologic study of oral metronidazole treatment during pregnancy. Br J Obstet Gynaecol 1998; 105:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/62\">",
"      Caro-Pat&oacute;n T, Carvajal A, Martin de Diego I, et al. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 1997; 44:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/63\">",
"      Beard CM, Noller KL, O'Fallon WM, et al. Cancer after exposure to metronidazole. Mayo Clin Proc 1988; 63:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/64\">",
"      Falagas ME, Walker AM, Jick H, et al. Late incidence of cancer after metronidazole use: a matched metronidazole user/nonuser study. Clin Infect Dis 1998; 26:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/65\">",
"      Shennan A, Crawshaw S, Briley A, et al. A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study. BJOG 2006; 113:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/66\">",
"      American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/67\">",
"      Loebstein R, Addis A, Ho E, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother 1998; 42:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/68\">",
"      Mogadam M, Dobbins WO 3rd, Korelitz BI, Ahmed SW. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 1981; 80:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/69\">",
"      J&auml;rnerot G, Into-Malmberg MB, Esbj&ouml;rner E. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites. Scand J Gastroenterol 1981; 16:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/70\">",
"      J&auml;rnerot G, Andersen S, Esbj&ouml;rner E, et al. Albumin reserve for binding of bilirubin in maternal and cord serum under treatment with sulphasalazine. Scand J Gastroenterol 1981; 16:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/71\">",
"      Habal FM, Hui G, Greenberg GR. Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course. Gastroenterology 1993; 105:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/72\">",
"      Bell CM, Habal FM. Safety of topical 5-aminosalicylic acid in pregnancy. Am J Gastroenterol 1997; 92:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/73\">",
"      Trallori G, d'Albasio G, Bardazzi G, et al. 5-Aminosalicylic acid in pregnancy: clinical report. Ital J Gastroenterol 1994; 26:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/74\">",
"      Diav-Citrin O, Park YH, Veerasuntharam G, et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 1998; 114:23.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Asacol (mesalamine) delayed release tablets -- Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER), May 2010. Available at: file://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm215476.htm (Accessed on December 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/76\">",
"      Berlin CM Jr, Yaffe SJ. Disposition of salicylazosulfapyridine (Azulfidine) and metabolites in human breast milk. Dev Pharmacol Ther 1980; 1:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/77\">",
"      Nelis GF. Diarrhoea due to 5-aminosalicylic acid in breast milk. Lancet 1989; 1:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/78\">",
"      Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/79\">",
"      Reinisch JM, Simon NG, Karow WG, Gandelman R. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science 1978; 202:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/80\">",
"      Yang K. Placental 11 beta-hydroxysteroid dehydrogenase: barrier to maternal glucocorticoids. Rev Reprod 1997; 2:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/81\">",
"      Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. JAMA 1995; 273:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/82\">",
"      Cowchock FS, Reece EA, Balaban D, et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992; 166:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/83\">",
"      Gur C, Diav-Citrin O, Shechtman S, et al. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol 2004; 18:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/84\">",
"      Greenberger PA, Odeh YK, Frederiksen MC, Atkinson AJ Jr. Pharmacokinetics of prednisolone transfer to breast milk. Clin Pharmacol Ther 1993; 53:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/85\">",
"      Alstead EM, Ritchie JK, Lennard-Jones JE, et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990; 99:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/86\">",
"      van Dieren JM, Kuipers EJ, Samsom JN, et al. Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflamm Bowel Dis 2006; 12:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/87\">",
"      Baumgart DC, Pintoffl JP, Sturm A, et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. Am J Gastroenterol 2006; 101:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/88\">",
"      Ierardi E, Principi M, Francavilla R, et al. Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. Aliment Pharmacol Ther 2001; 15:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/89\">",
"      Ng SC, Arebi N, Kamm MA. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis 2007; 13:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/90\">",
"      Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis 2008; 14:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/91\">",
"      N&oslash;rg&aring;rd B, Pedersen L, Christensen LA, S&oslash;rensen HT. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol 2007; 102:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/92\">",
"      Coelho J, Beaugerie L, Colombel JF, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 2011; 60:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/93\">",
"      Christensen LA, Dahlerup JF, Nielsen MJ, et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther 2008; 28:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/94\">",
"      Sau A, Clarke S, Bass J, et al. Azathioprine and breastfeeding: is it safe? BJOG 2007; 114:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/95\">",
"      Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001; 71:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/96\">",
"      Petri M. Immunosuppressive drug use in pregnancy. Autoimmunity 2003; 36:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/97\">",
"      Treacy G. Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFalpha monoclonal antibody. Hum Exp Toxicol 2000; 19:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/98\">",
"      &Oslash;stensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006; 8:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/99\">",
"      Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 2003; 30:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/100\">",
"      Johns DG, Rutherford LD, Leighton PC, Vogel CL. Secretion of methotrexate into human milk. Am J Obstet Gynecol 1972; 112:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/101\">",
"      O'Donnell S, O'Morain C. Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. Aliment Pharmacol Ther 2008; 27:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/102\">",
"      Mahadevan U, Cucchiara S, Hyams JS, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol 2011; 106:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/103\">",
"      Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004; 99:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/104\">",
"      Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/105\">",
"      Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011; 17:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/106\">",
"      Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/107\">",
"      Vasiliauskas EA, Church JA, Silverman N, et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006; 4:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/108\">",
"      Zelinkova Z, van der Ent C, Bruin KF, et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol 2013; 11:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/109\">",
"      Cheent K, Nolan J, Shariq S, et al. Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010; 4:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/110\">",
"      Ben-Horin S, Yavzori M, Kopylov U, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis 2011; 5:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/111\">",
"      Miehsler W, Novacek G, Wenzl H, et al. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis 2010; 4:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/112\">",
"      Ben-Horin S, Yavzori M, Katz L, et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol 2010; 8:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/113\">",
"      Nazareth M, Cristiano L, Kooijmans M. Natalizumab use during pregnancy. Am J Gastroenterol 2008; 104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/114\">",
"      Lewis JH, Weingold AB. The use of gastrointestinal drugs during pregnancy and lactation. Am J Gastroenterol 1985; 80:912.",
"     </a>",
"    </li>",
"    <li>",
"     Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation, 8th ed, Lippincott Williams &amp; Wilkins, Philadelphia, PA 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/116\">",
"      Boulton R, Hamilton M, Lewis A, et al. Fulminant ulcerative colitis in pregnancy. Am J Gastroenterol 1994; 89:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/117\">",
"      Watson WJ, Gaines TE. Third-trimester colectomy for severe ulcerative colitis. A case report. J Reprod Med 1987; 32:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/118\">",
"      Anderson JB, Turner GM, Williamson RC. Fulminant ulcerative colitis in late pregnancy and the puerperium. J R Soc Med 1987; 80:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/119\">",
"      Dubinsky M, Abraham B, Mahadevan U. Management of the pregnant IBD patient. Inflamm Bowel Dis 2008; 14:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/120\">",
"      Ilnyckyji A, Blanchard JF, Rawsthorne P, Bernstein CN. Perianal Crohn's disease and pregnancy: role of the mode of delivery. Am J Gastroenterol 1999; 94:3274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/14/25834/abstract/121\">",
"      Van Horn C, Barrett P. Pregnancy, delivery, and postpartum experiences of fifty-four women with ostomies. J Wound Ostomy Continence Nurs 1997; 24:151.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4083 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-B60670ABF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_14_25834=[""].join("\n");
var outline_f25_14_25834=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5611899\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H692771488\">",
"      FERTILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H692770159\">",
"      PRECONCEPTION COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H692770651\">",
"      Heredity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H521044030\">",
"      Disease control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H692771764\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H805110346\">",
"      Nutrition and supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREGNANCY AND LACTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Effect of pregnancy on IBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Effect of IBD on pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H805115129\">",
"      Effect of lactation on IBD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SAFETY OF DIAGNOSTIC EVALUATION DURING PREGNANCY AND LACTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MEDICATIONS DURING PREGNANCY AND LACTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H451430319\">",
"      Sulfasalazine and 5-aminosalicylic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H521045305\">",
"      Azathioprine and mercaptopurine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Anti-tumor necrosis factor agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H805105456\">",
"      - Infliximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H805105475\">",
"      - Adalimumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H805105487\">",
"      - Certolizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H805114179\">",
"      - Natalizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Antidiarrheal drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H692770870\">",
"      MODE OF DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5611899\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4083\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4083|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/28/2509\" title=\"table 1\">",
"      Sulfasalazine and 5-ASA formulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 2\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26647?source=related_link\">",
"      Anti-tumor necrosis factor therapy in ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/34/20008?source=related_link\">",
"      Antibiotics for treatment of inflammatory bowel diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=related_link\">",
"      Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21592?source=related_link\">",
"      Azathioprine and 6-mercaptopurine in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42616?source=related_link\">",
"      Breastfeeding: Parental education and support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3367?source=related_link\">",
"      Causes of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=related_link\">",
"      Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/44/20169?source=related_link\">",
"      Etiology, prenatal diagnosis, obstetrical management, and recurrence of orofacial clefts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5081?source=related_link\">",
"      Folic acid for prevention of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44455?source=related_link\">",
"      Genetic factors in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29383?source=related_link\">",
"      Gestational hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=related_link\">",
"      Infliximab in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=related_link\">",
"      Management of mild to moderate ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=related_link\">",
"      Management of patients with a colostomy or ileostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=related_link\">",
"      Management of severe ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37866?source=related_link\">",
"      Medical management and follow-up of gestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=related_link\">",
"      Nutrient deficiencies in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=related_link\">",
"      Nutrition in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4313?source=related_link\">",
"      Obstetrical management of pregnancies complicated by gestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/29/38361?source=related_link\">",
"      Operative management of Crohn's disease of the small bowel and colon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30121?source=related_link\">",
"      Overview of fetal assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17287?source=related_link\">",
"      Overview of infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=related_link\">",
"      Overview of procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=related_link\">",
"      Overview of the medical management of mild to moderate Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/20/5443?source=related_link\">",
"      Patient information: Inflammatory bowel disease and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=related_link\">",
"      Perianal complications of Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/25/16794?source=related_link\">",
"      Preconception evaluation and counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=related_link\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=related_link\">",
"      Risk factors for preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=related_link\">",
"      Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=related_link\">",
"      Surgical management of ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_14_25835="Maternal blood lead follow-up testing during lactation";
var content_f25_14_25835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of maternal blood lead follow-up testing during lactation to assess risk for infant lead exposure from maternal breast milk*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Initial venous blood lead level",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"        (BLL; &micro;g/dL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Perform follow-up blood lead test(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-19",
"       </td>",
"       <td>",
"        Every 3 months, unless infant blood lead levels are rising or fail to decline.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20-39",
"       </td>",
"       <td>",
"        2 weeks postpartum and then at 1- to 3-month intervals depending on direction/magnitude of trend in infant BLLs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;40",
"       </td>",
"       <td>",
"        Within 24 hours postpartum and then at frequent intervals depending on clinical interventions and trend in BLLs. Consultation with a clinician experienced in the management of lead poisoning is advised.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * If a woman becomes pregnant while lactating, she should be followed according to the schedule for pregnancy.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Last blood lead level measured in pregnancy or at delivery (maternal or cord BLL).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Ettinger AS, Wengrovitz AG. Guidelines for the Identification and Management of Lead Exposure in Pregnant and Lactating Women. Centers for Disease Control and Prevention. November 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_14_25835=[""].join("\n");
var outline_f25_14_25835=null;
var title_f25_14_25836="Therapy for different types of acute HAE attacks";
var content_f25_14_25836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F69098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F69098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of acute episodes of hereditary angioedema (HAE)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Laryngeal attack",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Abdominal attack",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Cutaneous attack",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Extremities, trunk",
"       </td>",
"       <td class=\"subtitle2\">",
"        Face, neck",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C1-INH concentrate (plasma-derived or recombinant)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Usually not needed",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ecallantide (United States only)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Usually not needed",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Icatibant",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Usually not needed",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasma (solvent/detergent treated or fresh frozen)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes if severe",
"       </td>",
"       <td>",
"        Usually not needed",
"       </td>",
"       <td>",
"        Yes if near upper airway",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intubation*, transfer to ICU, rarely emergent tracheotomy",
"       </td>",
"       <td>",
"        Yes (consider early intubation if above agents are not available)",
"       </td>",
"       <td>",
"        Not appropriate",
"       </td>",
"       <td>",
"        Not appropriate",
"       </td>",
"       <td>",
"        May be necessary if attack spreads to involve upper airway",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wait and see (spontaneous resolution)",
"       </td>",
"       <td>",
"        Not sufficient",
"       </td>",
"       <td>",
"        Acceptable if others not available",
"       </td>",
"       <td>",
"        Acceptable",
"       </td>",
"       <td>",
"        Not sufficient (because angioedema can spread to involve airway)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    All acute attacks should be treated as early as possible, at first sign of prodromal symptoms and before the attack becomes fully established.",
"    <div class=\"footnotes\">",
"     ICU: intensive care unit.",
"     <br/>",
"     * Consider intubation early in setting of progressive laryngeal edema or if C1 inhibitor preparations, ecallantide, or icatibant are not available.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Bowen T, Cicardi M, Farkas H, et al. 2010 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Allergy, Asthma, and Clinical Immunology; 2010; 6:24. Copyright &copy; 2010 BioMed Central Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_14_25836=[""].join("\n");
var outline_f25_14_25836=null;
var title_f25_14_25837="Symptoms of odontogenic infx";
var content_f25_14_25837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of odontogenic orofacial and peripharyngeal \"space\" infections",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Space",
"infections",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Usual",
"site of origin",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\" rowspan=\"1\">",
"        Clinical",
"features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Pain",
"       </td>",
"       <td class=\"subtitle2\">",
"        Trismus",
"       </td>",
"       <td class=\"subtitle2\">",
"        Swelling",
"       </td>",
"       <td class=\"subtitle2\">",
"        Dysphagia",
"       </td>",
"       <td class=\"subtitle2\">",
"        Dyspnea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"7\" rowspan=\"1\">",
"        Masticator",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Masseteric and pterygoid",
"       </td>",
"       <td class=\"sublist_other\">",
"        Molars (especially 3rd)",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td class=\"sublist_other\">",
"        +++",
"       </td>",
"       <td class=\"sublist_other\">",
"        May not be evident (deep)",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Temporal",
"       </td>",
"       <td class=\"sublist_other\">",
"        Post. maxillary molars",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        Face, orbit (late)",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Buccal",
"       </td>",
"       <td>",
"        Bicuspids, molars",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        Cheek (marked)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Canine",
"       </td>",
"       <td>",
"        Maxillary canines, incisors",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Upper lip, canine fossa",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infratemporal",
"       </td>",
"       <td>",
"        Post. maxillary molars",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Face, orbit (late)",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Submental parotid",
"       </td>",
"       <td>",
"        Mandibular incisors",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Chin (firm)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Submandibular",
"       </td>",
"       <td>",
"        Masseteric spaces",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Angle of jaw (marked)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sublingual",
"       </td>",
"       <td>",
"        2nd, 3rd mandibular molars",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        Submandibular (brawny)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"7\" rowspan=\"1\">",
"        Lateral pharyngeal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anterior",
"       </td>",
"       <td class=\"sublist_other\">",
"        Mandibular incisors",
"       </td>",
"       <td class=\"sublist_other\">",
"        +&nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &plusmn;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;Floor of mouth (tender)",
"       </td>",
"       <td class=\"sublist_other\">",
"        + (if bilateral)&nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        + (if bilateral)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Posterior",
"       </td>",
"       <td class=\"sublist_other\">",
"        Masticator spaces",
"       </td>",
"       <td class=\"sublist_other\">",
"        +++",
"       </td>",
"       <td class=\"sublist_other\">",
"        +++",
"       </td>",
"       <td class=\"sublist_other\">",
"        Angle of jaw",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td class=\"sublist_other\">",
"        &plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Retropharyngeal (and \"danger\")",
"       </td>",
"       <td>",
"        Masticator spaces",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        Post. pharynx",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lateral pharyngeal space, distant via lymphatics",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        Post. pharynx (midline)",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pretracheal",
"       </td>",
"       <td>",
"        Retropharyngeal space, anterior esophagus",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Hypopharynx",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     &plusmn;: minimal or occasional; +: present; ++: moderate; +++: prominent or severe.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_14_25837=[""].join("\n");
var outline_f25_14_25837=null;
var title_f25_14_25838="Survival MUD transplant CML";
var content_f25_14_25838=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Survival in chronic myeloid leukemia after matched unrelated donor transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 290px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This graph shows the probability of survival versus years after matched unrelated donor (MUD) hematopoietic cell transplantation for patients transplanted within the first year after diagnosis of chronic myelogenous leukemia (CML). Survival data is shown in red for those &lt;21 years of age at the time of transplant, in blue for those 21 to 36, in green for those 37 to 50, and in red for those &gt;50.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Hansen, JA, et al. N Engl J Med 1998; 338:962.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_14_25838=[""].join("\n");
var outline_f25_14_25838=null;
var title_f25_14_25839="Functional mobility scale";
var content_f25_14_25839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The Functional Mobility Scale (FMS) for evaluating mobility in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 417px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kerr GH, Harvey A, Rodda J, et al. The functional mobility score. J Pediatr Orthop 2004; 24:514. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_14_25839=[""].join("\n");
var outline_f25_14_25839=null;
